

Ms Fuller

Access DB# 85483

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BEN SACKY Examiner #: 73489 Date: 1/29/03  
Art Unit: 1676 Phone Number: 305 6889 Serial Number: 10/681,025  
Mail Box and Bldg/Room Location: CM I 3E11 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

MEJ


Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Subst. Acid deriv. useful as antidiabetic and antiobesity agents

Inventors (please provide full names): Cheng et al.

Earliest Priority Filing Date: 9/22/99

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



A method of lowering blood glucose levels or treating diabetes or for treating a premalignant disease, an early malignant disease, a malignant disease, or a dysplastic disease comprising the administration of compounds wherein X is 1, 2, 3, or 4; m is 1 or 2; n is 1 or 2

- Q is -C- or -N-;
- A is -O- or -S-;
- Z is a bond, or -O-
- R' is -H- or lower alkyl
- X is -CH-
- R<sup>2</sup> is H, alkyl, alkoxy, halogen, amino, or subst. amino
- R<sup>2a</sup>, R<sup>2b</sup> and R<sup>2c</sup> are selected from H, alkyl, alkoxy, halogen, amino or subst. amino.

RECEIVED  
JAN 29 2003  
FEDERAL BUREAU OF INVESTIGATION  
(STIC)

## STAFF USE ONLY

Searcher: <u>K. Fuller</u>	Type of Search	Vendors and cost where applicable
Searcher Phone #: _____	NA: Sequence (#) _____	STN <u>✓</u>
Searcher Location: _____	AA Sequence (#) _____	Dialog _____
Date Searcher Picked Up: _____	Structure (#) <u>1</u>	Questel/Orbit _____
Date Completed: <u>1/29/02</u>	Bibliographic _____	Dr.Link _____
Searcher Prep & Review Time: <u>20</u>	Litigation _____	Lexis/Nexis _____
Clerical Prep Time: _____	Fulltext _____	Sequence Systems _____
Online Time: <u>20</u>	Patent Family _____	WWW/Internet _____
	Other _____	Other (specify) _____

=> file reg

FILE 'REGISTRY' ENTERED AT 16:46:52 ON 29 JAN 2003  
USE IS ~~SUBJECT~~ TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5  
DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> file hcaplus

FILE 'HCAPLUS' ENTERED AT 16:46:57 ON 29 JAN 2003  
USE IS ~~SUBJECT~~ TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)



Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
the American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 29 Jan 2003 VOL 138 ISS 5  
FILE LAST UPDATED: 28 Jan 2003 (20030128/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d que

L3 STR



O~Cb~Ak~N~Ak  
@21 22 23 24 25

Cb~Ak~N~Ak  
@27 28 29 30

1,599 structures

VAR G1=O/S  
VAR G2=8/9/10  
VAR G3=C/N  
VAR G4=21/27  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC I  
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE  
L5 1599 SEA FILE=REGISTRY SSS FUL L3  
L6 50 SEA FILE=HCAPLUS ABB=ON L5  
L7 28 SEA FILE=HCAPLUS ABB=ON L6(L)THU/RL

=> sel hit rn 17 1-28  
E# OR SYSTEM LIMIT REACHED WHILE PROCESSING ANSWER 5  
E1 THROUGH E999 ASSIGNED



=> d 17 all 1-28 fhitstr

L7 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2003 ACS  
AN 2002:964190 HCAPLUS  
DN 138:39272  
TI Preparation of 3-(oxazolylalkoxyphenyl)propionic acids and analogs as  
modulators of peroxisome proliferator activated receptors for treatment of  
diabetes and related conditions  
IN Gossett, Lynn Stacy; Green, Jonathan Edward; Henry, James Robert; Jones,  
Winton Dennis, Jr.; Matthews, Donald Paul; Shen, Quan Rong; Smith, Daryl  
Lynn; Vance, Jennifer Ann; Warshawsky, Alan M.  
PA Eli Lilly and Company, USA  
SO PCT Int. Appl., 438 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K031-42  
ICS C07D263-32; A61P003-10; C07D231-12; A61K031-422; A61K031-426;  
A61K031-427; C07D233-58; C07D277-24; C07D277-24; C07D277-38;  
C07C271-24; C07C271-22; C07C233-87; C07C233-63; C07D413-12;  
C07D417-12; C07D413-14; C07D413-04; C07D413-10  
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1

Too many hit registry  
numbers to print  
them all. Printed 1  
structure/RN per  
record

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100403	A1	20021219	WO 2002-US15143	20020524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-296701P	P	20010607		
OS	MARPAT 138:39272				
GI					



AB Title compds. I [wherein n = 2-5; V = a bond or O; X = CH<sub>2</sub> or O; p = 0 or 1; m = 1-4; Y<sub>1</sub> = (un)substituted (hetero)aryl; Y<sub>2</sub> and Y<sub>3</sub> = independently H, alkyl, or alkoxy; Y<sub>4</sub> = (un)substituted alk(en/yn)ylaminoalkyl, carboxyaminoalkyl, (thio)ureidoalkyl, carbamoylalkyl, aminoalkyl, alkoxyalkyl, alkylthioalkyl, or CN; R<sub>5</sub> = H or alkyl; and pharmaceutically acceptable salts, solvates, hydrates, or stereoisomers thereof] were prepd. as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, 3-[2-(1,3-dioxo-1,3-dihydroisindolo-2-ylmethyl)-4-hydroxyphenyl]propionic acid tert-Bu ester was coupled with toluene-4-sulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester in the presence of Cs<sub>2</sub>CO<sub>3</sub> in DMF. Deprotection of the amine using NaBH<sub>4</sub> in isopropanol followed by conversion to the carbamate and deesterification gave II. I are useful for the treatment of Syndrome X, Type II diabetes,

hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X, as well as cardiovascular diseases (no data).

ST oxazolylalkoxyphenyl propionic acid prepn peroxisome proliferator activated receptor modulator; antidiabetic cardiovascular agent  
oxazolylalkoxyphenyl propionic acid prepn PPAR modulator

IT Appetite  
(bulimia; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Anticholesteremic agents  
Antiobesity agents  
Hypolipemic agents  
(compn. component; compns. of (isoxazolylalkoxyphenyl)propionic acid PPAR modulators with known therapeutic agents for treatment of diabetes and related conditions)

IT Sulfonylureas  
Vitamins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(compn. component; compns. of (isoxazolylalkoxyphenyl)propionic acid PPAR modulators with known therapeutic agents for treatment of diabetes and related conditions)

IT Cardiovascular system  
(disease; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Lipids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(dyslipidemia; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Heart, disease  
(failure; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Lipoproteins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(high-d., enhancers, compn. component; compns. of (isoxazolylalkoxyphenyl)propionic acid PPAR modulators with known therapeutic agents for treatment of diabetes and related conditions)

IT Lipids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyperlipidemia; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Diabetes mellitus  
(insulin-dependent; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Diabetes mellitus  
(non-insulin-dependent; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Anorexia  
Anticholesteremic agents  
Antidiabetic agents  
Antihypertensives  
Antiobesity agents  
Cardiovascular agents  
Human  
Hypercholesterolemia  
Hyperglycemia  
Hypertension

Hypertriglyceridemia  
 Hypolipemic agents  
 Obesity

(prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Disease, animal

(syndrome X; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Peroxisome proliferator-activated receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(.alpha.; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT Peroxisome proliferator-activated receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(.delta.; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT **478535-83-0P**, 3-[2-[[[(Phenylmethoxy)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-84-1P**, 3-[2-[[[3-Phenylpropanoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-85-2P**, 3-[2-[[[(Phenylmethyl)amino]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-86-3P**, 3-[2-[[[(Phenylmethyl)sulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-87-4P**, 3-[2-[[[Butylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-88-5P**, 3-[2-[[[Octylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-89-6P**, 3-[2-[[[(Cyclohexylacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-90-9P**, 3-[2-[[[(Cyclopentylacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-91-0P**, 3-[2-[[[(5-Methylhexanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-92-1P**, 3-[2-[[[Isobutanoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-93-2P**, 3-[2-[[[Butanoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-94-3P**, 3-[2-[[[(Cyclobutylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-95-4P**, 3-[2-[[[(3-Cyclopentylpropanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-96-5P**, 3-[2-[[[(2,6-Difluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-97-6P**, 3-[2-[[[(Phenylthio)acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-98-7P**, 3-[2-[[[(Diphenylacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478535-99-8P**, 3-[2-[[[(3,5-Bis(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478536-00-4P**, 3-[2-[[[(2,5-Dichloro-3-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478536-01-5P**, 3-[2-[[[(4-(Methoxycarbonyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478536-02-6P**, 3-[2-[[[(4-Pentylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478536-03-7P**, 3-[2-[[[(3-Chloro-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478536-04-8P**, 3-[2-[[[(3-Ethoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-

yl)ethoxy]phenyl]propionic acid 478536-05-9P,  
3-[2-[[[(Phenoxyacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-06-0P,  
3-[2-[[[(3-Cyanobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-07-1P,  
3-[2-[[[(2-Phenoxybutanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-08-2P,  
3-[2-[[[(2,4,5-Trifluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-10-6P,  
3-[2-[[[(4-Hexylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-11-7P,  
3-[2-[[[(2-Fluoro-4-(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-12-8P,  
3-[2-[[[(2,3-Dimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-14-0P,  
3-[2-[[[(2-(Benzoyloxymethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-15-1P,  
3-[2-[[[(2,4,6-Trifluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-16-2P,  
3-[2-[[[(1-Adamantylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-18-4P,  
3-[2-[[[(4-Fluoro-2-(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-20-8P,  
3-[2-[[[(2,4,6-Trichlorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-23-1P,  
3-[2-[[[(2-(4-Chlorophenoxy)-2-methylpropanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-25-3P,  
3-[2-[[[(2-Phenoxypropanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-27-5P,  
3-[2-[[[(2-(2-Thienyl)acetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-29-7P,  
3-[2-[[[(5-Chloro-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-31-1P,  
3-[2-[[[(Cyclopropylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-33-3P,  
3-[2-[[[(2-Thienylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-35-5P,  
3-[2-[[[(4-Methoxy-3-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-37-7P,  
3-[2-[[[(5-Methyl-3-furyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-39-9P,  
3-[2-[[[Benzoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-41-3P,  
3-[2-[[[2-(3-Thienyl)acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-43-5P,  
3-[2-[[[(5-Methyl-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-45-7P,  
3-[2-[[[(3-Methyl-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-47-9P,  
3-[2-[[[(3-Thienylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-49-1P,  
3-[2-[[[(3-Bromo-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-51-5P,  
3-[2-[[[(3-Benzoyloxy-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-53-7P,  
3-[2-[[[(4-Methyl-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-55-9P,  
3-[2-[[[(Phenylacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-57-1P,  
3-[2-[[[4-(2-Thienyl)butanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-

4-yl)ethoxy]phenyl]propionic acid 478536-59-3P,  
3-[2-[[[5-(2-Thienyl)pentanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-61-7P,  
3-[2-[[[4-(2-Thienyl)-4-oxobutanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-63-9P,  
3-[2-[[[2,3,4-Trimethoxybenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-65-1P,  
3-[2-[[[2,4,5-Trimethoxybenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-67-3P,  
3-[2-[[[4-Phenoxyphenyl]acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-69-5P,  
3-[2-[[[3,5-Difluorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-70-8P,  
3-[2-[[[2-Phenoxyphenyl]acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-72-0P,  
3-[2-[[[Cyclopentylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-74-2P,  
3-[2-[[[2,2-Dimethylpropanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-76-4P,  
3-[2-[[[Cyclohexylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-78-6P,  
3-[2-[[[3-Cyclohexylpropanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-82-2P,  
3-[2-[[[3-Methyl-2-phenylbutanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-85-5P,  
3-[2-[[[Heptanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-87-7P,  
3-[2-[[[5-Phenylpentanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-88-8P,  
3-[2-[[[2,4-Dichlorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-90-2P,  
3-[2-[[[Octanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-93-5P,  
3-[2-[[[4-Phenylbutanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-95-7P,  
3-[2-[[[Cyclopropylacetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478536-98-0P,  
3-[2-[[[3,4-Difluorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-01-8P,  
3-[2-[[[2,6-Dichlorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-03-0P,  
3-[2-[[[2-Chlorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-06-3P,  
3-[2-[[[2,4-Dimethoxybenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-09-6P,  
3-[2-[[[4-Fluorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-12-1P,  
3-[2-[[[3,4-Dichlorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-15-4P,  
3-[2-[[[2-Fluorobenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-18-7P,  
3-[2-[[[3-(Trifluoromethyl)benzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-22-3P,  
3-[2-[[[2,5-Dimethoxybenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-25-6P,  
3-[2-[[[4-Methylbenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-28-9P,  
3-[2-[[[3-Methoxybenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-31-4P,  
3-[2-[[[3,5-Dimethoxybenzoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-

yl)ethoxy]phenyl]propionic acid 478537-35-8P,  
3-[2-[[[(3,5-Dichlorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-39-2P,  
3-[2-[[[(2-Methoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-43-8P,  
3-[2-[[[(2,5-Dichlorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-46-1P,  
3-[2-[[[(2,3-Dichlorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-49-4P,  
3-[2-[[[(4-Bromo-2-chlorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-52-9P,  
3-[2-[[[(3-Methylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-54-1P,  
3-[2-[[[(6-Phenylhexanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-56-3P,  
3-[2-[[[(Methoxy)(phenyl)acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-58-5P,  
3-[2-[[[(3-Methylbutanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-60-9P,  
3-[2-[[[(4-Cyclohexylbutanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-62-1P,  
3-[2-[[[(Pentanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-65-4P,  
3-[2-[[[(2-Chloro-6-fluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-67-6P,  
3-[2-[[[(2-Methylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-69-8P,  
3-[2-[[[(4-Methylpentanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-71-2P,  
3-[2-[[[(2,4-Difluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-73-4P,  
3-[2-[[[(2-Chloro-4-fluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-75-6P,  
3-[2-[[[(2,3-Difluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-77-8P,  
3-[2-[[[(2-(Trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-79-0P,  
3-[2-[[[(3-Chloro-4-fluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-81-4P,  
3-[2-[[[(2,4-Dimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-83-6P,  
3-[2-[[[(2,5-Dimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-85-8P,  
3-[2-[[[(3-Fluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-87-0P,  
3-[2-[[[(2,4,6-Trimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-89-2P,  
3-[2-[[[(3,4-Dimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-91-6P,  
3-[2-[[[(4-Ethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-93-8P,  
3-[2-[[[(3,5-Dimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-95-0P,  
3-[2-[[[(2,5-Difluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-97-2P,  
3-[2-[[[(2,6-Dimethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478537-99-4P,  
3-[2-[[[(7,7-Dimethyloctanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478538-01-1P,  
3-[2-[[[(2,6-Dimethoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-

yl)ethoxy]phenyl]propionic acid **478538-03-3P**,  
 3-[2-[[[(3,4-Dimethoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-05-5P**,  
 3-[2-[[[(2-(Phenylmethyl)propanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-07-7P**,  
 3-[2-[[[(2,3,4,5,6-Pentamethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-09-9P**,  
 3-[2-[[[(2,3,5,6-Tetramethylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-11-3P**,  
 3-[2-[[[(4-Chloro-2-fluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-13-5P**,  
 3-[2-[[[(2-Bromobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-15-7P**,  
 3-[2-[[[(4-Phenoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-17-9P**,  
 3-[2-[[[(4-(Trifluoromethoxy)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-19-1P**,  
 3-[2-[[[(4-Bromobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-21-5P**,  
 3-[2-[[[(3,4,5-Trimethoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-23-7P**,  
 3-[2-[[[(9-Oxo-9H-fluoren-4-yl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-25-9P**,  
 3-[2-[[[(9-Oxo-9H-fluoren-2-yl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-27-1P**,  
 3-[2-[[[(4-Benzylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-29-3P**,  
 3-[2-[[[(3,3,3-Trifluoropropanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-31-7P**,  
 3-[2-[[[(3-Bromobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-33-9P**,  
 3-[2-[[[(3-Chloro-2-fluorobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-35-1P**,  
 3-[2-[[[[1-(4-Chlorophenyl)cyclopropyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-37-3P**,  
 3-[2-[[[(2,4,6-Trimethoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-39-5P**,  
 3-[2-[[[(2,5-Bis(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-40-8P**,  
 3-[2-[[[(2-Methyl-2-phenylpropanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-41-9P**,  
 3-[2-[[[(3-(Trifluoromethoxy)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-42-0P**,  
 3-[2-[[[(4-Fluoro-3-(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-44-2P**,  
 3-[2-[[[(3-Fluoro-4-(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-46-4P**,  
 3-[2-[[[(3,5-Bis(tert-butyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-48-6P**,  
 3-[2-[[[(2-(Trifluoromethoxy)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-50-0P**,  
 3-[2-[[[(2,4-Bis(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-52-2P**,  
 3-[2-[[[(3-Fluoro-5-(trifluoromethyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-53-3P**,  
 3-[2-[[[(3-(4-Chlorophenylthio)butanoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-55-5P**,  
 3-[2-[[[(5-Isoxazolylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-57-7P**,  
 3-[2-[[[[2-(4-Chlorophenyl)-4-methylthiazol-5-

yl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-59-9P**,  
 3-[2-[[[(3-Aminobenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-61-3P**,  
 3-[2-[[[(Methylthio)acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-63-5P**,  
 3-[2-[[[(2-Phenylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-65-7P**,  
 3-[2-[[[(3-Phenyl-2-propynoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-67-9P**,  
 3-[2-[[[(4-Methoxycyclohexylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-69-1P**,  
 3-[2-[[[(2-Phenoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-71-5P**,  
 3-[2-[[[(3-(Benzoyl)benzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-72-6P**,  
 3-[2-[[[(trans-4-Pentylcyclohexyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-74-8P**,  
 , 3-[2-[[[(3-(2-Naphthylthio)propanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-75-9P**,  
 3-[2-[[[(2-(4-Chlorophenyl)-3-methylbutanoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-77-1P**,  
 3-[2-[[[(4-(Trifluoromethyl)phenyl)thio)acetyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-79-3P**,  
 3-[2-[[[(5-Methyl-3-phenylisoxazol-4-yl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-81-7P**,  
 3-[2-[[[(4-(4-Chlorophenyl)-2-methyl-3-furyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-83-9P**,  
 3-[2-[[[(5-(Trifluoromethyl)-2-furyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-85-1P**,  
 3-[2-[[[(2-[4-(Trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-86-2P**,  
 3-[2-[[[(5-[3-(Trifluoromethyl)phenyl]-2-furyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-87-3P**,  
 3-[2-[[[(3-(4-Fluorophenylmethoxy)-2-thienyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-88-4P**,  
 3-[2-[[[Propanoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-89-5P**,  
 3-[2-[[[(5-Bromo-2-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-91-9P**,  
 3-[2-[[[(2,5-Dichloro-3-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-(biphenyl-4-yl)oxazol-4-yl)ethoxy]phenyl]propionic acid **478538-93-1P**,  
 3-[2-[[[(Cyclopentyloxy)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-95-3P**,  
 3-[2-[[[(2-Methoxyethoxy)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-97-5P**,  
 3-[2-[[[(2-Naphthyloxycarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478538-99-7P**,  
 3-[2-[[[(Isopropoxycarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-01-4P**,  
 3-[2-[[[(Butoxycarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-02-5P**,  
 3-[2-[[[(Phenoxy)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-03-6P**,  
 3-[2-[[[(Methoxycarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-04-7P**,

3-[2-[[[Isobutoxycarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-05-8P**,  
 3-[2-[[[Ethoxycarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-06-9P**,  
 3-[2-[[[Decyloxycarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-07-0P**,  
 3-[2-[[[2-Naphthoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-08-1P**,  
 3-[2-[[[2-Furylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-09-2P**,  
 3-[2-[[[2-Quinolinylnylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-10-5P**,  
 3-[2-[[[1H-Indol-2-yl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-11-6P**,  
 3-[2-[[[2-Pyrazinylnylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-12-7P**,  
 3-[2-[[[2-Tetrahydrofuran-2-yl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-13-8P**,  
 3-[2-[[[2-Pyridylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-14-9P**,  
 3-[2-[[[3-Pyridylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-15-0P**,  
 3-[2-[[[1H-Pyrrol-2-yl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid hydrochloride **478539-16-1P**,  
 3-[2-[[[4-Pyridylcarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid hydrochloride **478539-17-2P**,  
 3-[2-[[[3-(3-Pyridyl)-2-propenoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-18-3P**,  
 3-[2-[[[3-(4-Pyridyl)-2-propenoyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-19-4P**,  
 3-[2-[[[5-(2-Pyridyl)-2-thienyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-20-7P**,  
 3-[2-[[[3-(1H-Pyrrol-1-yl)-2-thienyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-21-8P**,  
 3-[2-[[[5-Methylthio-2-thienyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-23-0P**,  
 3-[2-[[[2-(2-Thienyl)-4-thiazolyl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-24-1P**,  
 3-[2-[[[1,3-Dimethyl-1H-thieno[2,3-c]pyrazol-5-yl]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-25-2P**,  
 3-[2-[[[Isopropylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-26-3P**,  
 3-[2-[[[Ethylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-27-4P**,  
 3-[2-[[[Propylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-28-5P**,  
 3-[2-[[[Phenylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-29-6P**,  
 3-[2-[[[2-Thienylsulfonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-30-9P**,  
 3-[2-[[[Isopropylamino]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-31-0P**,  
 3-[2-[[[2-Phenylethyl]amino]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-32-1P**,  
 3-[2-[[[2-(2-Thienyl)ethyl]amino]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-33-2P**,  
 3-[2-[[[Butylamino]carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-34-3P**,  
 3-[2-[[[4-

Methylphenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-35-4P, 3-[2-[[[(2,3,4,5,6-Pentafluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-36-5P, 3-[2-[[[(4-Fluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-37-6P, 3-[2-[[[(3-Fluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-38-7P, 3-[2-[[[(2,4-Difluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-39-8P, 3-[2-[[[(3,4-Difluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-40-1P, 3-[2-[[[(Phenylamino)carbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-41-2P, 3-[2-[[[(1-Naphthylaminocarbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-42-3P, 3-[2-[[[(4-Phenoxyphenyl)amino)carbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-43-4P, 3-[2-[[[(Phenylaminocarbothioyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-44-5P, 3-[2-[[[(2,3,4-Trifluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-45-6P, 3-[2-[[[(2-Fluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-46-7P, 3-[2-[[[(2-(Carboxy)benzoyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-47-8P, 3-[2-[[[(Propoxycarbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-48-9P, 3-[2-[[[(2,2-Dimethylpropoxy)carbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-49-0P, 3-[2-[[[Bis(2-naphthylsulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-50-3P, 3-[2-[[[Bis(phenylsulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR modulator; prepn. of (oxazolylalkoxyphenyl)propionic acid and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 478539-51-4P, 3-[2-[[[(Methylsulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-52-5P, 3-[2-[[[(N-(4-Tosyl)-D-phenylalanyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-53-6P, 3-[2-[[[Acetyl]amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-54-7P, 3-[2-[[[[5-(Methylsulfonyl)-2-thienyl]carbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-55-8P, 3-[2-[[[(Heptylaminocarbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-56-9P, 3-[2-[[[(tert-Butyl)amino)carbonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-57-0P, 3-[2-[[[Bis((4-nitrophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-58-1P, 3-[2-[[[Bis((4-(trifluoromethoxy)phenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-59-2P, 3-[2-[[[(4-(Trifluoromethyl)phenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-60-5P, 3-[2-[[[Bis((3-fluorophenyl)sulfonyl)amino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-61-6P,

3-[2-[[Bis((2,4-difluorophenyl)sulfonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-62-7P,  
 3-[2-[[Bis((2,6-difluorophenyl)sulfonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-63-8P,  
 3-[2-[[Bis((3,4-difluorophenyl)sulfonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478539-64-9P**,  
 3-[2-[[Morpholinocarbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478539-65-0P, 3-[4-[2-(2-(Phenylmethyl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-66-1P, 3-[4-[2-(2-(Phenylmethyl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-67-2P, 3-[4-[2-(2-(2-Phenylethyl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-68-3P,  
 3-[4-[2-(2-(2-Phenylethyl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-69-4P,  
 3-[4-[2-(2-(2H-Tetrahydropyran-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-70-7P,  
 3-[4-[2-(2-(2H-Tetrahydropyran-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-71-8P,  
 3-[4-[2-(2-(Benzothien-2-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-72-9P,  
 3-[4-[2-(2-(Benzothien-2-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-73-0P,  
 3-[4-[2-(2-(2-Methoxyethyl)amino)-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-74-1P,  
 3-[4-[2-(2-(2-Methoxyethyl)amino)-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid **478539-75-2P**,  
 3-[4-[2-(2-(4-Pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid **478539-76-3P**,  
 3-[4-[2-(2-(4-Pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-77-4P,  
 3-[4-[2-(2-(4-Methyl-1-piperazinyl)-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-78-5P,  
 3-[4-[2-(2-(4-Phenyl-1-piperazinyl)-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-79-6P,  
 3-[4-[2-(2-(4-Phenyl-1-piperazinyl)-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-80-9P,  
 3-[4-[2-(2-(4-Methyl-1-piperazinyl)-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid **478539-81-0P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid **478539-82-1P**, 3-[4-[2-(2-Phenyl-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid 478539-83-2P,  
 3-[4-[2-(2-(1-Methylcyclohexyl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid **478539-84-3P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid **478539-85-4P**, 3-[4-[2-(2-Phenyl-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-86-5P,  
 3-[4-[2-(2-(1-Methylcyclohexyl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid 478539-87-6P,  
 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-indol-2-yl)methyl]phenyl]propionic acid 478539-88-7P,  
 3-[4-[2-(2-(3-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-indol-2-yl)methyl]phenyl]propionic acid **478539-89-8P**, 3-[4-[2-(2-(3-Bromophenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid **478539-90-1P**, 3-[4-[2-(2-(4-Bromophenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl]amino]methyl]phenyl]propionic acid **478539-91-2P**, 3-[4-[2-(2-(4-(Trifluoromethyl)phenyl)-5-

methyloxazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478539-92-3P**, 3-[4-[2-(2-(6-Phenyl-3-pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478539-93-4P**, 3-[4-[2-(2-(6-Phenyl-3-pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[ (2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478539-94-5P**, 3-[4-[2-(2-(3-Pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid hydrochloride **478539-95-6P**, 3-[4-[2-(2-(4-Butoxyphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478539-96-7P**, 3-[4-[2-(2-(2-Pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid hydrochloride **478539-97-8P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (cyclopentylcarbonyl)amino]methyl]phenyl]propionic acid **478539-98-9P**, 3-[4-[2-(2-(5-Phenyl-3-pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478539-99-0P**, 3-[4-[2-(2-(6-Phenoxy-3-pyridyl)-5-methylthiazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478540-00-0P**, 3-[4-[2-(2-(4-(Phenylamino)phenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478540-01-1P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (isobutoxycarbonyl)amino]methyl]phenyl]propionic acid **478540-02-2P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (isopropylamino)carbonyl]amino]methyl]phenyl]propionic acid **478540-03-3P**, 3-[4-[2-(2-Phenyl-5-methyloxazol-4-yl)ethoxy]-2-[[ (tert-butoxy)carbonyl]amino]methyl]phenyl]propionic acid **478540-04-4P**, 3-[4-[2-(2-(3-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478540-05-5P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (benzoylamino)amino]methyl]phenyl]propionic acid **478540-06-6P**, 3-[4-[2-(2-(3-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (benzoylamino)amino]methyl]phenyl]propionic acid **478540-07-7P**, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[[ (benzoylamino)amino]methyl]phenyl]propionic acid **478540-08-8P**, 3-[4-[2-(2-(2-Thienyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (benzoylamino)amino]methyl]phenyl]propionic acid **478540-09-9P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (cyclobutylcarbonyl)amino]methyl]phenyl]propionic acid **478540-10-2P**, 3-[4-[2-(2-(3-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (cyclobutylcarbonyl)amino]methyl]phenyl]propionic acid **478540-11-3P**, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[[ (cyclobutylcarbonyl)amino]methyl]phenyl]propionic acid **478540-12-4P**, 3-[4-[2-(2-(2-Thienyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (cyclobutylcarbonyl)amino]methyl]phenyl]propionic acid **478540-13-5P**, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[ (cyclobutylcarbonyl)amino]methyl]phenyl]propionic acid **478540-14-6P**, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478540-15-7P**, 3-[4-[2-(2-(2-Thienyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478540-16-8P**, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478540-17-9P**, 3-[4-[2-(2-(3-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478540-18-0P**, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[[ (2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478540-19-1P**, 3-[4-[2-(2-(2-Thienyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478540-20-4P**, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[ (2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478540-21-5P**, 3-[4-[2-(2-(3-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[ (2,5-

dichloro-3-thienyl)carbonyl)]amino)methyl]phenyl]propionic acid  
 478540-22-6P, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[[[(2,5-dichloro-3-thienyl)carbonyl)]amino)methyl]phenyl]propionic acid  
 478540-23-7P, 3-[4-[2-(2-(2-Thienyl)-5-methyloxazol-4-yl)ethoxy]-2-[[[(2,5-dichloro-3-thienyl)carbonyl)]amino)methyl]phenyl]propionic acid  
 478540-24-8P, 3-[4-[2-(2-Phenyl-5-methyloxazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]propionic acid  
 478540-25-9P, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]propionic acid  
 478540-26-0P, 3-[4-[2-(2-(2-Thienyl)-5-methyloxazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]propionic acid  
 478540-27-1P, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]propionic acid  
 478540-28-2P, 3-[4-[2-(2-(1-Methylcyclohexyl)-5-methyloxazol-4-yl)ethoxy]-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]propionic acid  
 478540-29-3P, 3-[4-[2-(2-(4-(Methyl)(phenyl)amino)phenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-30-6P, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[3-methylbutanoylamino)methyl]phenyl]propionic acid 478540-31-7P, 3-[4-[2-(2-Phenyl-5-methoxyoxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-32-8P, 3-[4-[2-(2-Phenyl-5-methoxyoxazol-4-yl)ethoxy]-2-[[2-pyridylcarbonyl)amino)methyl]phenyl]propionic acid 478540-33-9P, 3-[4-[2-(2-(4-Butoxyphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[[(cyclopropylmethoxy)carbonyl)amino)methyl]phenyl]propionic acid 478540-34-0P, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[[(cyclopropylmethoxy)carbonyl)amino)methyl]phenyl]propionic acid 478540-35-1P, 3-[4-[2-(2-(4-Morpholinophenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[3-methylbutanoylamino)methyl]phenyl]propionic acid 478540-36-2P, 3-[4-[2-(2-(4-(Phenylamino)phenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[3-methylbutanoylamino)methyl]phenyl]propionic acid 478540-37-3P, 3-[4-[2-(2-(4-Phenoxyphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[3-methylbutanoylamino)methyl]phenyl]propionic acid 478540-38-4P, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[3-methylbutanoylamino)methyl]phenyl]propionic acid 478540-39-5P, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[[(cyclobutoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-40-8P, 3-[4-[2-(2-(4-Phenoxyphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[[(cyclobutoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-41-9P, 3-[4-[2-(2-(4-(Phenylmethoxy)phenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[[(cyclobutoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-42-0P, 3-[4-[2-(2-(4-Butoxyphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[[(cyclobutoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-43-1P, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[[(cyclobutoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-44-2P, 3-[4-[2-(2-(4-Phenylphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyrazinylcarbonyl)amino)methyl]phenyl]propionic acid 478540-45-3P, 3-[4-[2-(2-(4-Phenoxyphenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyrazinylcarbonyl)amino)methyl]phenyl]propionic acid 478540-46-4P, 3-[4-[2-(2-(4-Morpholinophenyl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyrazinylcarbonyl)amino)methyl]phenyl]propionic acid 478540-47-5P, 3-[4-[2-(2-(Tetrahydro-4H-pyran-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[2-pyrazinylcarbonyl)amino)methyl]phenyl]propionic acid 478540-48-6P, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[2-pyrazinylcarbonyl)amino)methyl]phenyl]propionic acid 478540-49-7P, 3-[4-[2-(2-Morpholino-5-methylthiazol-4-yl)ethoxy]-2-[[isobutoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-50-0P, 3-[4-[2-(2-[[4-(tert-Butoxycarbonyl)piperazin-1-yl]]-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl)amino)methyl]phenyl]propionic acid 478540-51-1P, 3-[3-[[Butanoylamino)methyl]-4-[2-(5-methyl-2-

phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-52-2P**,  
 3-[3-[[[(Cyclobutylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-53-3P**,  
 3-[3-[[[(2,5-Dichloro-3-thienyl)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-54-4P**,  
 3-[3-[[[3-Phenylpropanoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-55-5P**,  
 3-[3-[[[(Phenylacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-56-6P**,  
 3-[3-[[[Benzoylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-57-7P**,  
 3-[3-[[[(Phenoxyacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-58-8P**,  
 3-[3-[[[(Isopropoxycarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-59-9P**,  
 3-[3-[[[(Cyclopentyloxy)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-60-2P**,  
 3-[3-[[[(2-Pyridylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-61-3P**,  
 3-[3-[[[(2-Pyrazinylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-62-4P**,  
 3-[3-[[[(2-Furylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-63-5P**,  
 3-[3-[[[(2-Naphthoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-64-6P**,  
 3-[3-[[[(2-Quinolinylnylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-65-7P**,  
 3-[3-[[[(4-Methylbenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-66-8P**,  
 3-[3-[[[(2-Methoxybenzoyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-67-9P**,  
 3-[3-[[[(Cyclopentylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-68-0P**,  
 3-[3-[[[(Cyclopropylacetyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-69-1P**,  
 3-[3-[[[[[5-(Trifluoromethyl)-2-furyl]carbonyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-70-4P**,  
 3-[3-[[[[[2-(2-Thienyl)acetyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-71-5P**,  
 3-[3-[[[[[5-Chloro-2-thienyl]carbonyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-72-6P**,  
 3-[3-[[[(2-Thienylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-73-7P**,  
 3-[3-[[[[[5-(2-Thienyl)pentanoyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-74-8P**,  
 3-[3-[[[[[4-Methoxy-3-thienyl]carbonyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-75-9P**,  
 3-[3-[[[[[2-(3-Thienyl)acetyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-76-0P**,  
 3-[3-[[[[[4-Oxo-4-(2-thienyl)butanoyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-77-1P**,  
 3-[3-[[[[[5-Methyl-2-thienyl]carbonyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-78-2P**,  
 3-[3-[[[[[3-Methyl-2-thienyl]carbonyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-79-3P**,  
 3-[3-[[[(3-Thienylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-80-6P**,  
 3-[3-[[[[[4-Methyl-2-thienyl]carbonyl]]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478540-81-7P**,  
 3-[3-[[[[[3-Chloro-2-thienyl]carbonyl]]amino]methyl]-

4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid  
 478540-82-8P, 3-[3-[[[(Phenylsulfonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478540-83-9P,  
 3-[3-[[[(2-Thienylsulfonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR modulator; prepn. of (oxazolylalkoxyphenyl)propionic acid and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 478545-29-8P, 3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester  
 478545-43-6P, 3-[4-[2-[2-(4-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-[[[cyclohexylcarbamoyl]oxy]methyl]phenyl]propionic acid tert-butyl ester  
 478545-44-7P, 3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-[5-methyl-2-(4-morpholinyl)oxazol-4-yl]ethoxy]phenyl]propionic acid

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(PPAR modulator; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 403610-63-9P, 2-[2-Methoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-64-0P,  
 2-[2-Benzylloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-65-1P, 2-[2-Cyclohexylcarbamoyloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid  
 403610-66-2P, 2-[2-Isopropylcarbamoyloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-67-3P,  
 2-[2-Benzylcarbamoyloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-68-4P,  
 2-[2-(4-Fluorobenzylcarbamoyloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-69-5P,  
 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-m-tolyloxymethylphenoxy]propionic acid 403610-70-8P, 2-[2-(4-Fluorophenoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-71-9P, 2-[2-(3-Fluorophenoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid  
 403610-72-0P, 2-[2-(2-Fluorophenoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-73-1P,  
 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-p-tolyloxymethylphenoxy]propionic acid 403610-74-2P, 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-o-tolyloxymethylphenoxy]propionic acid 403610-75-3P, 2-[2-(4-Methoxyphenoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-76-4P,  
 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenoxy]propionic acid 403610-77-5P,  
 2-[2-(Biphenyl-2-yloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 403610-78-6P,  
 2-[2-(Biphenyl-4-yloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid **478541-68-3P**,  
 3-[4-[2-[5-Methyl-2-(4-phenylphenyl)oxazol-4-yl]ethoxy]-2-[(isopropoxycarbonylamino)methyl]phenyl]propionic acid 478541-70-7P,  
 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478541-73-0P,  
 3-[2-(2-Isopropoxycarbonylethyl)-4-[2-[5-methyl-2-(6-phenoxy-pyridin-3-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478541-75-2P,  
 3-[4-[2-(3-(Biphenyl-4-yl)-5-methylpyrazol-1-yl)ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478541-76-3P,

3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-(5-methyl-3-phenylpyrazol-1-yl)ethoxy]phenyl]propionic acid 478541-78-5P, 3-[4-[2-(3-(Biphenyl-4-yl)-5-methylpyrazol-1-yl)ethoxy]-2-[[2-(pyridylcarbonyl)amino]methyl]phenyl]propionic acid trifluoroacetate 478541-79-6P, 3-[4-[2-(5-(Biphenyl-4-yl)-3-methylpyrazol-1-yl)ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478541-80-9P, 3-[4-[2-[3-(4-Bromophenyl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid tert-butyl ester 478541-81-0P, 3-[4-[2-[3-(4-Bromo-phenyl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478541-82-1P, 3-[4-[2-(5-Methyl-3-(naphthalen-2-yl)pyrazol-1-yl)ethoxy]-2-[[2-(pyridylcarbonyl)amino]methyl]phenyl]propionic acid hydrochloride 478541-83-2P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-(5-methyl-3-(naphthalen-2-yl)pyrazol-1-yl)ethoxy]phenyl]propionic acid 478541-84-3P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-(5-methyl-3-(naphthalen-1-yl)pyrazol-1-yl)ethoxy]phenyl]propionic acid 478541-85-4P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-(5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)ethoxy]phenyl]propionic acid 478541-86-5P, 3-[4-[2-(3-(Biphenyl-4-yl)-5-methylpyrazol-1-yl)ethoxy]-2-[[2-(isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid 478541-87-6P, 3-[4-[2-[3-(4-Bromophenyl)-5-methylpyrazol-1-yl]ethoxy]-2-[[2-(isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid 478541-88-7P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethoxy]phenyl]propionic acid 478541-91-2P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-3-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid hydrochloride 478541-93-4P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-3-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478541-94-5P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478541-95-6P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[3-(pyridin-3-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478541-96-7P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[3-(pyridin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478541-97-8P, 3-[4-[2-[2-(4'-Fluorobiphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478541-98-9P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(4'-trifluoromethylbiphenyl-4-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478541-99-0P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(2'-trifluoromethylbiphenyl-4-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478542-00-6P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-(4'-methoxybiphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid 478542-01-7P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-(3'-methoxybiphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid 478542-02-8P, 3-[4-[2-[2-(4'-Fluorobiphenyl-3-yl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478542-03-9P, 3-[4-[2-[2-(3'-Fluorobiphenyl-3-yl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478542-04-0P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(4'-trifluoromethylbiphenyl-3-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478542-05-1P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(3'-trifluoromethylbiphenyl-3-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478542-06-2P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(2'-trifluoromethylbiphenyl-3-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478542-07-3P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-(3'-methoxybiphenyl-3-yl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid 478542-08-4P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-(2'-methoxybiphenyl-3-yl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid 478542-09-5P, 3-[4-[2-[2-(3'-Fluorobiphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]-2-

(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-10-8P**, 3-[4-[2-[2-(2'-Fluorobiphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-11-9P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(3'-trifluoromethylbiphenyl-4-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-12-0P**, 3-[4-[2-[2-(Biphenyl-2-yl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-13-1P**, 4'-[4-[2-[4-(2-Carboxyethyl)-3-(isopropoxycarbonylaminomethyl)phenoxy]ethyl]-5-methyloxazol-2-yl]biphenyl-3-carboxylic acid **478542-14-2P**, 4'-[4-[2-[4-(2-Carboxyethyl)-3-(isopropoxycarbonylaminomethyl)phenoxy]ethyl]-5-methyloxazol-2-yl]biphenyl-4-carboxylic acid **478542-15-3P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-3-[4-(pyridin-4-yl)phenyl]pyrazol-1-yl]ethoxy]phenyl]propionic acid hydrochloride **478542-16-4P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-3-[4-(pyridin-3-yl)phenyl]pyrazol-1-yl]ethoxy]phenyl]propionic acid hydrochloride **478542-17-5P**, 3-[4-[2-[3-(4'-Fluorobiphenyl-4-yl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-18-6P**, 3-[4-[2-[3-(4'-Methoxybiphenyl-4-yl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-19-7P**, 3-[4-[2-[3-(3'-Methoxybiphenyl-4-yl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-20-0P**, 3-[4-[2-[3-(2'-Fluorobiphenyl-4-yl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-21-1P**, 3-[4-[2-[3-(2'-Methylbiphenyl-4-yl)-5-methylpyrazol-1-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-22-2P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyrazin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-24-4P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-25-5P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(5-methylpyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-26-6P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(3-methylpyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-27-7P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(6-methylpyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-28-8P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(4-methylpyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-29-9P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(4-trifluoromethylpyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-30-2P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(5-trifluoromethylpyridin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-31-3P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-[4-(6-methoxypyridin-3-yl)phenyl]-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-32-4P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-[4-(6-methoxypyridin-2-yl)phenyl]-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-33-5P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(quinolin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-34-6P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-[4-(4-methoxypyridin-2-yl)phenyl]-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-35-7P**, 3-[4-[2-[2-[4-(5-Cyanopyridin-2-yl)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-36-8P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyrimidin-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-37-9P**, 3-[4-[2-[2-[4-(4-Fluorophenylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478542-39-1P**, 3-[4-[2-[2-[4-(4-Cyanophenylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid

c acid **478542-40-4P**, 3-[4-[2-[2-[4-(3,5-Difluorophenylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-41-5P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(4-p-tolylaminophenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-42-6P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[2-[4-(4-methoxyphenylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-43-7P**, 3-[4-[2-[2-(3-Benzylaminophenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid hydrochloride **478542-45-9P**, 3-[4-[2-[2-(4-Diethylaminophenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-46-0P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[4-(morpholin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-47-1P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[3-(morpholin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-48-2P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[4-(piperidin-1-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-49-3P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[3-(piperidin-1-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-51-7P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[4-(morpholin-4-ylamino)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-53-9P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-56-2P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(3-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-57-3P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(2-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-58-4P**, 3-[4-[2-[2-[4-(4-Cyanophenoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-59-5P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[4-(4-trifluoromethylphenoxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-60-8P**, 3-[4-[2-[2-[4-(4-Fluorophenoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-61-9P**, 3-[4-[2-[2-[4-(3,4-Difluorophenoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-62-0P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(4-m-tolylloxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-63-1P**, 3-[4-[2-[2-[4-(4-Acetylphenoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-66-4P**, 3-[4-[2-[2-(3-Hydroxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid tert-butyl ester **478542-67-5P**, 3-[4-[2-[2-(4-Hydroxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-68-6P**, 3-[4-[2-[2-(3-Hydroxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-69-7P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-71-1P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(4-propoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478542-72-2P**, 3-[4-[2-[2-(4-Ethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-73-3P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-74-4P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[2-(3-methoxyphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478542-75-5P**, 3-[4-[2-[2-(3-Ethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478542-76-6P**, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[2-(3-isopropoxyphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid

478542-77-7P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(3-propoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-78-8P, 3-[4-[2-[2-(3-Butoxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-79-9P, 3-[4-[2-[2-(3-Cyclopentyloxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-80-2P, 3-[4-[2-[2-(3-Cyclohexyloxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-81-3P, 3-[4-[2-[2-(4-Cyclopentyloxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-82-4P, 3-[4-[2-[2-(4-Cyclohexyloxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-83-5P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(tetrahydropyran-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-84-6P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(1-methylpiperidin-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-85-7P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[3-(tetrahydropyran-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-86-8P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[3-(1-methylpiperidin-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-87-9P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[3-(piperidin-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-88-0P, 3-[4-[2-[2-[3-(3-Dimethylaminopropoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-89-1P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(piperidin-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-90-4P, 3-[4-[2-[2-[4-(2-Dimethylaminoethoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-91-5P, 3-[4-[2-[2-[4-(3-Dimethylaminopropoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478542-92-6P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-2-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-93-7P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-4-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-94-8P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-3-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-95-9P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyrimidin-2-yloxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-96-0P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(4-methylcarbamoylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid  
478542-99-3P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(3-methylcarbamoylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid  
478543-00-9P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(3-propylcarbamoylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid  
478543-01-0P, 3-[4-[2-[2-[3-(Cyclobutylcarbamoyl)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478543-02-1P, 3-[4-[2-[2-(3-Isobutylcarbamoylphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478543-03-2P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(3-phenylcarbamoylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid  
478543-04-3P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[3-(morpholine-4-carbonyl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid  
478543-05-4P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(4-propylcarbamoylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid  
478543-06-5P, 3-[4-[2-[2-[4-(Cyclobutylcarbamoyl)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid  
478543-07-6P, 3-[4-[2-[2-[4-(Cyclohexylcarbamoyl)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid

5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-08-7P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(4-phenylcarbamoylethoxy)phenyl]propionic acid **478543-09-8P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(pyridin-3-ylcarbamoylethoxy)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478543-10-1P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-[4-(1-pyrrolidinylcarbonyl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478543-11-2P**, 4-[4-[2-[4-(2-Carboxyethyl)-3-(isopropoxycarbonylaminomethyl)phenoxy]ethyl]-5-methyloxazol-2-yl]benzoic acid **478543-12-3P**, 3-[4-[2-[4-(2-Carboxyethyl)-3-(isopropoxycarbonylaminomethyl)phenoxy]ethyl]-5-methyloxazol-2-yl]benzoic acid **478543-13-4P**, 3-[4-[2-[2-[3-(Cyclohexylcarbamoylethoxy)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-15-6P**, 3-[4-[2-[2-[4-(3-Fluorobenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-17-8P**, 3-[4-[2-[2-[4-(4-Fluorobenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-18-9P**, 3-[4-[2-[2-[4-(3,5-Difluorobenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-19-0P**, 3-[4-[2-[2-[4-(3,4-Difluorobenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-20-3P**, 3-[4-[2-[2-(4-Acetylaminophenyl)-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-21-4P**, 3-[4-[2-[2-(4-Aminophenyl)-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-22-5P**, 3-[4-[2-[2-(4-Isobutoxycarbonylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-23-6P**, 3-[4-[2-[2-(4-Aminophenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-24-7P**, 3-[4-[2-[2-(4-Benzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-25-8P**, 3-[4-[2-[2-(4-Benzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-26-9P**, 3-[4-[2-[2-[4-(4-Methoxybenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-27-0P**, 3-[4-[2-[5-Methyl-2-[4-[(3-pyridylcarbonyl)amino]phenyl]oxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-28-1P**, 3-[4-[2-[2-[4-[(2,5-Dichloro-3-thienylcarbonyl)amino]phenyl]-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-29-2P**, 3-[4-[2-[2-[4-[N,N-Bis(butylsulfonyl)amino]phenyl]-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-30-5P**, 3-[4-[2-[2-[4-(Butylsulfonylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-31-6P**, 3-[4-[2-[2-(4-Acetylaminophenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-32-7P**, 3-[4-[2-[2-(4-Butyrylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-33-8P**, 3-[4-[2-[2-[4-(Cyclobutylcarbonylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-34-9P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[2-[4-(4-methoxybenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid **478543-35-0P**, 3-[4-[2-[2-[4-(3,5-Dimethoxybenzoylamino)phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid **478543-36-1P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-

2-[4-[(3-pyridylcarbonyl)amino]phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478543-37-2P**, 3-[4-[2-[2-[4-[(2,5-Dichloro-3-thienylcarbonyl)amino]phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478543-38-3P**, 3-[2-(Isopropoxycarbonylamino)methyl]-4-[2-[5-methyl-2-[4-[(2-pyridylcarbonyl)amino]phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid **478543-39-4P**, 3-[4-[2-[2-[4-[(Furan-2-carbonyl)amino]phenyl]-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478543-40-7P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[[pyrimidin-2-yl)amino]methyl]phenyl]propionic acid **478543-41-8P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(2-methylsulfanylpirimidin-4-ylamino)methyl]phenyl]propionic acid **478543-42-9P**, 3-[2-(Benzothiazol-2-ylamino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-44-1P**, 3-[2-[(2-Benzoylphenylamino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-45-2P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(4-trifluoromethylphenylamino)methyl]phenyl]propionic acid **478543-47-4P**, 3-[2-[(4-Methanesulfonylphenylamino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-48-5P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(4-propionylphenylamino)methyl]phenyl]propionic acid **478543-49-6P**, 3-[2-[[Bis(4-methoxyphenyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-50-9P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(pyridin-2-yl)amino]methyl]phenyl]propionic acid **478543-51-0P**, 3-[2-[[2,5-Dichloro-3-thienylcarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-56-5P**, 3-[2-[(Butyrylmethylamino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-57-6P**, 3-[2-[[Cyclobutylcarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-58-7P**, 3-[2-[[Benzyloxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-59-8P**, 3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid **478543-60-1P**, 3-[4-[2-[2-(3-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-[[isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid **478543-61-2P**, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid **478543-62-3P**, 3-[2-[[Isopropoxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid **478543-63-4P**, 3-[4-[2-[2-(4-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-[[isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid **478543-64-5P**, 3-[2-[[Isopropoxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-phenylthiazol-4-yl)ethoxy]phenyl]propionic acid **478543-65-6P**, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methylthiazol-4-yl)ethoxy]-2-[[isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid **478543-66-7P**, 3-[2-[[Isopropoxycarbonyl)methylamino]methyl]-4-[2-[5-methyl-2-(1-methylcyclohexyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478543-67-8P**, 3-[2-[[Isopropoxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-phenethyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-68-9P**, 3-[2-[[Isopropoxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478543-69-0P**, 3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[methyl(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid **478543-70-3P**, 3-[4-[2-[2-(2-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid **478543-71-4P**, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[ethyl(isopropoxycarbonyl)amino]methyl]phenyl]propionic acid **478543-72-5P**, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-

yl)ethoxy]-2-[[ (isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid 478543-73-6P, 3-[2-[[ (Isopropoxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-3-phenylpyrazol-1-yl)ethoxy]phenyl]propionic acid 478543-74-7P, 3-[2-[[ (Isopropoxycarbonyl)methylamino]methyl]-4-[2-[5-methyl-2-[3-(pyridin-3-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478543-76-9P, 3-[2-[[ (Isopropoxycarbonyl)methylamino]methyl]-4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478543-77-0P, 3-[4-[2-[2-(4-Butoxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-[[ (isopropoxycarbonyl)methylamino]methyl]phenyl]propionic acid 478543-78-1P, 3-[2-[[ (Isopropoxycarbonyl)methylamino]methyl]-4-[2-(5-methyl-2-(pyridin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478543-87-2P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478543-95-2P, 3-[2-[2-(Butylsulfonylamino)ethyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478543-96-3P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[2-[(2-pyridylcarbonyl)amino]ethyl]phenyl]propionic acid 478543-97-4P, 3-[2-[2-[(2,5-Dichloro-3-thienylcarbonyl)amino]ethyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478543-98-5P 478543-99-6P, 3-[2-[2-(Cyclobutylcarbonylamino)ethyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-00-2P, 3-[2-(2-Benzoylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-01-3P, 3-[2-(2-Isobutoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR modulator; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 478544-02-4P, 3-[2-(2-Benzylloxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-03-5P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-[4-(morpholin-4-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478544-05-7P, 3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-[2-(isopropoxycarbonylamino)ethyl]phenyl]propionic acid 478544-06-8P, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(2-isopropoxycarbonylaminoethyl)phenyl]propionic acid 478544-07-9P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478544-08-0P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-(pyridin-2-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478544-09-1P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-3-phenylpyrazol-1-yl)ethoxy]phenyl]propionic acid 478544-10-4P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-(4-phenylaminophenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478544-11-5P, 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-[4-(methylphenylamino)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid 478544-12-6P, 2-[2-(tert-Butoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 478544-20-6P, [2-(tert-Butoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid 478544-21-7P, 2-[2-(Ethoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid 478544-28-4P, [2-(Benzylloxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid 478544-30-8P, [2-[[ (2,5-Dichloro-3-thienylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid 478544-33-1P, [2-

[(Cyclobutylcarbonylamino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]acetic acid **478544-34-2P**, 2-[2-(Butyrylaminomethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid **478544-36-4P**, 2-[2-[(2,5-Dichloro-3-thienylcarbonyl)amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid **478544-37-5P**, 2-[2-[(Cyclobutylcarbonylamino)methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid **478544-38-6P**, 3-[2-Cyano-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478544-42-2P**, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-cyanophenyl]propionic acid **478544-43-3P**, 3-[4-[3-(Biphenyl-4-yl)oxy]propoxy]-2-cyanophenyl]propionic acid **478544-44-4P**, 3-[4-[2-[2-(4-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-cyanophenyl]propionic acid **478544-45-5P**, 3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-cyanophenyl]propionic acid **478544-46-6P**, 3-[2-Cyano-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid **478544-47-7P**, 3-[2-Cyano-4-[2-(5-methyl-3-phenylpyrazol-1-yl)ethoxy]phenyl]propionic acid **478544-48-8P**, 3-[4-[2-[2-(4-Butoxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-cyanophenyl]propionic acid **478544-49-9P**, 3-[2-Cyano-4-[2-[5-methyl-2-(6-phenylpyridin-3-yl)thiazol-4-yl]ethoxy]phenyl]propionic acid **478544-50-2P**, 3-[2-Cyano-4-[2-(5-methyl-2-phenylthiazol-4-yl)ethoxy]phenyl]propionic acid **478544-51-3P**, 3-[2-Benzylcarbamoyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-58-0P**, 3-[2-Benzylcarbamoyl-4-[2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-61-5P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-phenylcarbamoylphenyl]propionic acid **478544-62-6P**, 3-[2-(3,4-Dichlorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-63-7P**, 3-[2-(4-Methoxybenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-64-8P**, 3-[2-[(Biphenyl-3-yl)methyl]carbamoyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-65-9P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-phenethylcarbamoylphenyl]propionic acid **478544-66-0P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(3-phenylpropylcarbamoyl)phenyl]propionic acid **478544-67-1P**, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(thiophen-2-yl)methyl]carbamoyl]phenyl]propionic acid **478544-68-2P**, 3-[2-(Hexylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-69-3P**, 3-[2-Methylcarbamoyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-70-6P**, 3-[2-(Butylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-71-7P**, 3-[2-(Isopropylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-72-8P**, 3-[2-(Cyclohexylmethylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-73-9P**, 3-[2-(tert-Butylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-74-0P**, 3-[2-Carbamoyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-75-1P**, 3-[2-(2-Fluorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-76-2P**, 3-[2-(2-Chlorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-77-3P**, 3-[2-(2,4-Dichlorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-78-4P**, 3-[2-(2-Methoxybenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid **478544-79-5P**

yl)ethoxy]phenyl]propionic acid 478544-79-5P, 3-[2-(Indan-1-ylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-80-8P, 3-[2-(3-Fluorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-81-9P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylbenzylcarbamoyl)phenyl]propionic acid 478544-82-0P, 3-[2-(3-Methylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-83-1P, 3-[2-(4-Fluorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-84-2P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(naphthalen-1-ylmethyl)carbamoyl]phenyl]propionic acid 478544-85-3P, 3-[2-(4-Methanesulfonylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-86-4P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(2-trifluoromethylbenzylcarbamoyl)phenyl]propionic acid 478544-87-5P, 3-[2-(4-Nitrobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-88-6P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(4-sulfamoylbenzylcarbamoyl)phenyl]propionic acid 478544-89-7P, 3-[2-(3,5-Dimethylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-90-0P, 3-[2-(4-tert-Butylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-91-1P, 3-[2-(2-Methylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-92-2P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-[(pyridin-4-ylmethyl)carbamoyl]phenyl]propionic acid 478544-93-3P, 3-[2-(3-Methoxybenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-94-4P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(3-trifluoromethylbenzylcarbamoyl)phenyl]propionic acid 478544-95-5P, 3-[2-(3,5-Bis-trifluoromethylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-96-6P, 3-[2-(3-Chlorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-97-7P, 3-[2-(3-Fluoro-5-trifluoromethylbenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-98-8P, 3-[2-(3,5-Difluorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478544-99-9P, 3-[2-(3,5-Dichlorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-00-5P, (R)-3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(1-phenylethylcarbamoyl)phenyl]propionic acid 478545-01-6P 478545-02-7P 478545-03-8P, (S)-3-[2-[(Carboxyphenylmethyl)carbamoyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-04-9P, (S)-3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(1-phenylethylcarbamoyl)phenyl]propionic acid 478545-05-0P, 3-[2-Benzylcarbamoyl-4-[2-(2-(biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-06-1P, 3-[2-Benzylcarbamoyl-4-[2-(2-cyclohexyl-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-07-2P, 3-(2-Benzylcarbamoyl-4-[2-[5-methyl-2-(1-methylcyclohexyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478545-08-3P, 3-[2-Benzylcarbamoyl-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478545-09-4P, (R)-3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(1-phenylethylcarbamoyl)phenyl]propionic acid 478545-10-7P, (R)-3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)-ethoxy]-2-(1-phenylethylcarbamoyl)phenyl]propionic acid 478545-11-8P,

(R)-3-[4-[2-(5-Methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]-2-(1-phenylethylcarbamoyl)phenyl]propionic acid 478545-12-9P,  
3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(3,5-difluorobenzylcarbamoyl)phenyl]propionic acid 478545-13-0P,  
3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-(3,5-difluorobenzylcarbamoyl)phenyl]propionic acid 478545-14-1P,  
3-[2-(3,5-Difluorobenzylcarbamoyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478545-15-2P,  
3-[2-(3,5-Difluorobenzylcarbamoyl)-4-[2-(5-methyl-2-phenylthiazol-4-yl)ethoxy]phenyl]propionic acid 478545-16-3P,  
3-(2-Benzylcarbamoyl-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl)propionic acid 478545-17-4P,  
3-[2-Benzylcarbamoyl-4-(2-[5-methyl-2-[4-(methylphenylamino)phenyl]oxazol-4-yl]ethoxy)phenyl]propionic acid 478545-18-5P,  
3-(2-Benzylcarbamoyl-4-[2-[5-methyl-2-(4-phenylaminophenyl)oxazol-4-yl]ethoxy]phenyl)propionic acid 478545-19-6P 478545-24-3P,  
3-[2-[[[Isopropylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-25-4P,  
3-[2-[[[Isopropylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-26-5P, 3-[2-[[[Benzylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-27-6P,  
3-[2-[[[Benzylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-28-7P, Morpholine-4-carboxylic acid 2-(2-carboxyethyl)-5-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl ester 478545-30-1P, 3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-35-6P,  
3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[[cyclohexylcarbamoyl]oxy]methyl]phenyl]propionic acid tert-butyl ester 478545-36-7P, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[[cyclohexylcarbamoyl]oxy]methyl]phenyl]propionic acid 478545-37-8P,  
3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[[cyclohexylcarbamoyl]oxy]methyl]phenyl]propionic acid tert-butyl ester 478545-38-9P, 3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-[[[cyclohexylcarbamoyl]oxy]methyl]phenyl]propionic acid 478545-39-0P,  
3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-40-3P, 3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478545-41-4P,  
3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid tert-butyl ester 478545-42-5P, 3-[2-[[[Cyclohexylcarbamoyl]oxy]methyl]-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478545-46-9P,  
3-[2-Cyclohexylcarbamoyloxymethyl-4-[2-[5-methyl-2-(4-phenylaminophenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478545-47-0P, 3-[2-Cyclohexylcarbamoyloxymethyl-4-[2-[5-methyl-2-(4-(methylphenylamino)phenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478545-48-1P, 3-[2-Methoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-50-5P, 3-[2-Benzyloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-51-6P, 3-[2-Benzyloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-52-7P, 3-[2-Ethoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-54-9P, 3-[2-Ethoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-56-1P, 3-[2-(4-tert-Butylbenzyloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-58-3P, 3-[2-(4-tert-Butylbenzyloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-60-7P, 3-[2-(Biphenyl-4-ylmethoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-

yl)ethoxy]phenyl]propionic acid tert-butyl ester 478545-62-9P,  
 3-[2-(Biphenyl-4-ylmethoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-64-1P, 3-[2-sec-Butoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-68-5P,  
 3-[2-Isopropoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-70-9P, 3-[2-Cyclohexyloxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-72-1P, 3-[2-Isobutoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-74-3P, 3-[2-Cyclohexylmethoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-76-5P, 3-[2-(Biphenyl-4-yloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-77-6P, 3-[2-(3-Methylbutoxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-78-7P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-79-8P, 3-[2-(4-Fluorophenoxy)methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-80-1P, 3-[2-(3-Fluorophenoxy)methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-81-2P, 3-[2-(2-Fluorophenoxy)methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-82-3P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-p-tolyloxymethylphenyl]propionic acid 478545-83-4P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-m-tolyloxymethylphenyl]propionic acid 478545-84-5P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-o-tolyloxymethylphenyl]propionic acid 478545-85-6P, 3-[2-(4-Methoxyphenoxy)methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-86-7P, 3-[2-(Biphenyl-2-yloxymethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-87-8P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-phenylsulfanylmethylphenyl]propionic acid 478545-88-9P, 3-[2-Benzenesulfonylmethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 478545-89-0P, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-94-7P, 3-[4-[2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-95-8P, 3-[4-[2-(5-Methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-96-9P, 3-[4-[2-(2-(Biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-97-0P, 3-[4-[2-[5-Methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-98-1P, 3-[4-[4-Methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethoxy]-2-(4-trifluoromethylphenoxy)methyl]phenyl]propionic acid 478545-99-2P, 3-[2-Benzyloxymethyl-4-[2-(2-cyclohexyl-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid 478546-03-1P,  
 , 3-[2-Benzyloxymethyl-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid 478546-04-2P, 3-[2-Benzyloxymethyl-4-[2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid 478546-05-3P, 3-[2-Benzyloxymethyl-4-[2-(2-(biphenyl-3-yl)-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid 478546-06-4P, 3-[2-Benzyloxymethyl-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478546-07-5P, 3-[2-Benzyloxymethyl-4-[2-[2-(4-butoxyphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]propionic acid 478546-08-6P, 3-[2-Benzyloxymethyl-4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]phenyl]propionic acid 478546-09-7P 478546-11-1P 478546-14-4P, 3-[2-(Benzoylaminomethyl)-4-[3-(biphenyl-4-yloxy)propoxy]phenyl]propionic acid 478546-16-6P, 3-[2-(Benzoylaminomethyl)-4-[2-(4-phenoxyphenoxy)ethoxy]phenyl]propionic acid 478546-17-7P, 3-[2-(Benzoylaminomethyl)-4-[2-(3-phenylbenzofuran-6-

yloxy)ethoxy]phenyl]propionic acid 478546-18-8P, 3-[2-(Benzoylaminomethyl)-4-[2-(6-methoxynaphthalen-2-yloxy)ethoxy]phenyl]propionic acid 478546-19-9P, 3-[2-[(Cyclobutanecarbonylamino)methyl]-4-[2-(4-phenoxyphenoxy)ethoxy]phenyl]propionic acid 478546-20-2P, 3-[4-[2-(Biphenyl-4-yloxy)ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478546-21-3P, 3-[4-[2-(Biphenyl-4-yloxy)ethoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-22-4P, 3-[4-[2-(Biphenyl-3-yloxy)ethoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-23-5P, 3-[4-[2-(4-Phenoxyphenoxy)ethoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-24-6P, 3-[4-[2-(3-Phenylbenzofuran-6-yloxy)ethoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-25-7P, 3-[4-[2-(6-Methoxynaphthalen-2-yloxy)ethoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-26-8P, 3-[2-(Benzoylaminomethyl)-4-[4-(biphenyl-4-yloxy)butoxy]phenyl]propionic acid 478546-27-9P, 3-[2-(Benzoylaminomethyl)-4-[4-(biphenyl-3-yloxy)butoxy]phenyl]propionic acid 478546-28-0P, 3-[2-(Benzoylaminomethyl)-4-[4-(4-phenoxyphenoxy)butoxy]phenyl]propionic acid 478546-29-1P, 3-[2-(Benzoylaminomethyl)-4-[4-(3-phenylbenzofuran-6-yloxy)butoxy]phenyl]propionic acid 478546-30-4P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[4-(4-phenoxyphenoxy)butoxy]phenyl]propionic acid 478546-31-5P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[4-(3-phenylbenzofuran-6-yloxy)butoxy]phenyl]propionic acid 478546-32-6P, 3-[4-[4-(Biphenyl-3-yloxy)butoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-33-7P, 3-[4-[4-(4-Phenoxyphenoxy)butoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-34-8P, 3-[4-[4-(3-Phenylbenzofuran-6-yloxy)butoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-35-9P, 3-[4-[4-(6-Methoxynaphthalen-2-yloxy)butoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-36-0P, 3-[4-[4-(Biphenyl-3-yloxy)butoxy]-2-[[2,5-dichloro-3-thienylcarbonyl)amino]methyl]phenyl]propionic acid 478546-37-1P, 3-[2-(Benzoylaminomethyl)-4-[3-(biphenyl-3-yloxy)propoxy]phenyl]propionic acid 478546-38-2P, 3-[4-[3-(Biphenyl-3-yloxy)propoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478546-39-3P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-40-6P, 3-[4-[3-(Biphenyl-3-yloxy)propoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-41-7P, 3-[4-[3-(6-Methoxynaphthalen-2-yloxy)propoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-42-8P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-[[2,5-dichloro-3-thienylcarbonyl)amino]methyl]phenyl]propionic acid 478546-43-9P, 3-[2-[[2,5-Dichloro-3-thienylcarbonyl)amino]methyl]-4-[3-(3-phenylbenzofuran-6-yloxy)propoxy]phenyl]propionic acid 478546-44-0P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-(1,3-dioxo-1,3-dihydroisoindol-2-ylmethyl)phenyl]propionic acid 478546-45-1P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid 478546-46-2P, 3-[2-(Benzoylaminomethyl)-4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propionic acid 478546-47-3P, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propionic acid 478546-48-4P, 3-[4-[3-(4-Phenoxyphenoxy)propoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-49-5P, (2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)acetic acid methyl ester **478546-52-0P**, 3-[4-[2-[5-Methyl-2-(6-phenylpyridin-3-yl)thiazol-4-yl]ethoxy]-2-[[2-(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid hydrochloride **478546-53-1P**, 3-[2-(Isopropoxycarbonylaminomethyl)-4-[2-[5-methyl-2-(6-phenoxyphenyl-3-yl)oxazol-4-yl]ethoxy]phenyl]propionic acid **478546-54-2P**, 3-[4-[2-[2-(Biphenyl-4-yl)-5-methyloxazol-4-yl]ethoxy]-2-(cyclopropylmethoxycarbonylaminomethyl)phenyl]propionic acid

478546-55-3P, 3-[2-(Cyclopropylmethoxycarbonylaminomethyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid hydrochloride  
**478546-56-4P**, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(cyclobutoxycarbonylaminomethyl)phenyl]propionic acid hydrochloride  
 478546-57-5P, 3-[2-(Cyclobutoxycarbonylaminomethyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethoxy]phenyl]propionic acid hydrochloride  
**478546-58-6P**, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methoxyoxazol-4-yl)ethoxy]-2-(isopropoxycarbonylaminomethyl)phenyl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR modulator; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 50-99-7, D-Glucose, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (blood; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 50-78-2, Aspirin 56-03-1D, Biguanide, derivs. 943-45-3D, Fibrin acid, derivs. 2295-31-0D, Thiazolidinedione, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compn. component; compns. of (isoxazolylalkoxyphenyl)propionic acid PPAR modulators with known therapeutic agents for treatment of diabetes and related conditions)

IT 9001-42-7, .alpha.-Glucosidase 9027-63-8, Acyl-CoA:cholesterol acyltransferase 9028-35-7, Hydroxymethylglutaryl coenzyme A reductase

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibitors, compn. component; compns. of (isoxazolylalkoxyphenyl)propionic acid PPAR modulators with known therapeutic agents for treatment of diabetes and related conditions)

IT 2973-80-0P, 2-Bromo-5-hydroxybenzaldehyde 3347-62-4P 3351-60-8P, 4-(2-Bromoethoxy)biphenyl 36157-41-2P, 2,5-Dichlorothiophene-3-carboxylic acid 39065-54-8P, 2-Phenyl-5-cyanopyridine 53669-78-6P, 4-(4-Bromobutoxy)biphenyl 63457-51-2P, 4-(3-Bromopropoxy)-1-phenoxybenzene 85604-06-4P, 5-Benzyloxy-2-bromobenzaldehyde 86555-45-5P 87545-48-0P, 4-(2-Bromoethoxy)-1-phenoxybenzene 105983-77-5P, 4-Bromo-3-oxopentanoic acid methyl ester 113795-28-1P, 4-(3-Bromopropoxy)biphenyl 119454-89-6P, 4-(4-Bromobutoxy)-1-phenoxybenzene 132646-47-0P, 2-(2-Cyclohexyl-5-methyloxazol-4-yl)ethanol 141819-91-2P, 2-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethanol 141819-92-3P, 2-(5-Methyl-2-(naphthalen-2-yl)oxazol-4-yl)ethanol 157133-02-3P, 3-(3-Bromopropoxy)biphenyl 164513-32-0P, (4-Bromo-3-bromomethylphenoxy)-tert-butyl dimethylsilane 169315-83-7P, (4-Bromo-3-methylphenoxy)-tert-butyl dimethylsilane 171269-97-9P 171270-04-5P 171817-43-9P, 3-Methyl-5-(naphthalen-1-yl)-1H-pyrazole 171817-44-0P, 3-Methyl-5-(naphthalen-2-yl)-1H-pyrazole 175136-30-8P, 2-(5-Methyl-2-phenylthiazol-4-yl)ethanol 189680-06-6P, 2-Bromo-5-hydroxybenzonitrile 196810-78-3P, 2-(5-Methyl-3-phenylpyrazol-1-yl)ethanol 262450-98-6P, 2-(5-Benzyloxy-2-bromophenyl)ethylamine 312690-77-0P, 2-[5-Methyl-2-(1-methylcyclohexyl)oxazol-4-yl]ethanol 328918-80-5P, 4,5-Dimethyl-2-(4-bromophenyl)oxazole oxide 328918-81-6P, 2-(4-Bromophenyl)-4-(chloromethyl)-5-methyloxazole 328918-82-7P, 2-(4-Bromophenyl)-5-methyl-4-oxazoleacetic acid 328918-83-8P, 2-(4-Bromophenyl)-4-(cyanomethyl)-5-methyloxazole 328918-84-9P, 2-(4-Bromophenyl)-5-methyl-4-oxazoleethanol 328918-85-0P, 2-((Biphenyl-4-yl)-5-methyloxazol-4-yl)ethanol 328918-86-1P, Toluene-4-sulfonic acid 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethyl ester 328918-89-4P, Toluene-4-sulfonic acid 2-[2-(4-Bromophenyl)-5-methyloxazol-4-yl]ethyl ester 328918-97-4P, 2-(3-Bromophenyl)-5-methyl-4-

oxazoleethanol 328918-98-5P, Toluene-4-sulfonic acid  
 2-[2-(3-bromophenyl)-5-methyloxazol-4-yl]ethyl ester 328919-26-2P,  
 Toluene-4-sulfonic acid 2-(2-(biphenyl-3-yl)-5-methyloxazol-4-yl)ethyl  
 ester 328919-31-9P, 2-(4-Benzyloxy-2-formylphenoxy)-2-methylpropionic  
 acid ethyl ester 328919-34-2P, 2-(4-Hydroxy-2-hydroxymethylphenoxy)-2-  
 methylpropionic acid ethyl ester 328919-74-0P, 2-(2-(Biphenyl-4-yl)-5-  
 methylthiazol-4-yl)ethanol 328919-76-2P, Toluene-4-sulfonic acid  
 2-(2-(biphenyl-4-yl)-5-methylthiazol-4-yl)ethyl ester 401790-96-3P,  
 Toluene-4-sulfonic acid 2-(5-methyl-2-thiophen-2-yloxazol-4-yl)ethyl ester  
 401791-03-5P, Toluene-4-sulfonic acid 2-(2-cyclohexyl-5-methyloxazol-4-  
 yl)ethyl ester 401791-06-8P, Toluene-4-sulfonic acid  
 2-[5-methyl-2-(1-methylcyclohexyl)oxazol-4-yl]ethyl ester 401791-19-3P  
 401791-20-6P, 4-Oxo-3-(3-phenylpropionylamino)pentanoic acid methyl ester  
 401791-21-7P, (5-Methyl-2-phenethyloxazol-4-yl)acetic acid methyl ester  
 401791-22-8P, (5-Methyl-2-phenethyloxazol-4-yl)acetic acid 401791-23-9P,  
 2-(5-Methyl-2-phenethyloxazol-4-yl)ethanol 401791-24-0P,  
 Toluene-4-sulfonic acid 2-(5-methyl-2-phenethyloxazol-4-yl)ethyl ester  
 403611-91-6P, 2-[2-(4-Benzyloxyphenyl)-5-methyloxazol-4-yl]ethanol  
 403611-92-7P, Toluene-4-sulfonic acid 2-[2-(4-benzyloxyphenyl)-5-  
 methyloxazol-4-yl]ethyl ester 403612-73-7P, Toluene-4-sulfonic acid  
 2-(5-methyl-2-phenylthiazol-4-yl)ethyl ester 403612-78-2P,  
 2-[2-Hydroxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-  
 methylpropionic acid ethyl ester 403612-79-3P, 2-[2-Methoxymethyl-4-[2-  
 (5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl  
 ester 403612-81-7P, 2-[2-Bromomethyl-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl ester 403612-82-8P,  
 2-Methyl-2-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2-m-  
 tolyloxymethylphenoxy]propionic acid ethyl ester 478540-84-0P,  
 2-(5-Methylthiophen-2-yl)-4-oxazoleethanol 478540-85-1P,  
 2-[5-Methyl-2-(tetrahydropyran-4-yl)oxazol-4-yl]ethanol 478540-86-2P,  
 Toluene-4-sulfonic acid 2-[5-methyl-2-(tetrahydropyran-4-yl)oxazol-4-  
 yl]ethyl ester 478540-87-3P, 2-(2-Benzyl-5-methyloxazol-4-yl)ethanol  
 478540-88-4P, Toluene-4-sulfonic acid 2-(2-benzyl-5-methyloxazol-4-  
 yl)ethyl ester 478540-89-5P, Toluene-4-sulfonic acid  
 2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethyl ester  
 478540-90-8P, 2-[2-(4-Butoxyphenyl)-5-methyloxazol-4-yl]ethanol  
 478540-91-9P, Toluene-4-sulfonic acid 2-[2-(4-butoxyphenyl)-5-methyloxazol-  
 4-yl]ethyl ester 478540-92-0P, 2-[2-(2-Bromophenyl)-5-methyloxazol-4-  
 yl]ethanol 478540-93-1P, Toluene-4-sulfonic acid 2-[2-(2-bromophenyl)-5-  
 methyloxazol-4-yl]ethyl ester 478540-94-2P, Toluene-4-sulfonic acid  
 2-[2-(6-chloropyridin-3-yl)-5-methyloxazol-4-yl]ethyl ester  
 478540-95-3P, 2-[2-(6-Chloropyridin-3-yl)-5-methyloxazole-4-yl]acetic acid  
 methyl ester 478540-96-4P, 2-[2-(6-Chloropyridin-3-yl)-5-methyloxazole-4-  
 yl]ethanol 478540-97-5P, Toluene-4-sulfonic acid 2-[5-methyl-2-[4-  
 (methylphenylamino)phenyl]oxazol-4-yl]ethyl ester 478540-98-6P,  
 4-(2-Benzyloxyethyl)-2-(4-bromophenyl)-5-methyloxazole 478540-99-7P  
 478541-00-3P, 2-[5-Methyl-2-[4-(methylphenylamino)phenyl]oxazol-4-  
 yl]ethanol 478541-01-4P, Toluene-4-sulfonic acid 2-[5-methyl-2-(4-  
 phenylaminophenyl)oxazol-4-yl]ethyl ester 478541-02-5P,  
 Toluene-4-sulfonic acid 2-[5-methyl-2-[4-(morpholin-4-yl)phenyl]oxazol-4-  
 yl]ethyl ester 478541-03-6P, Toluene-4-sulfonic acid  
 2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]ethyl ester 478541-04-7P,  
 4-(2-Benzyloxyethyl)-5-methyl-2-(4-phenoxyphenyl)oxazole 478541-05-8P,  
 4-Methyl-3-nitrobenzenesulfonic acid 2-[5-methyl-2-(4-nitrophenyl)oxazol-4-  
 yl]ethyl ester 478541-06-9P, Toluene-4-sulfonic acid  
 2-(5-methoxy-2-phenyloxazol-4-yl)ethyl ester 478541-07-0P,  
 2-(5-Methoxy-2-phenyloxazol-4-yl)acetic acid methyl ester 478541-08-1P,  
 2-(5-Methoxy-2-phenyloxazol-4-yl)ethanol 478541-09-2P,  
 2-(2-(Biphenyl-4-yl)-5-methoxyoxazol-4-yl)ethanol 478541-10-5P,  
 Toluene-4-sulfonic acid 2-(2-(biphenyl-4-yl)-5-methoxyoxazol-4-yl)ethyl

ester 478541-11-6P, Toluene-4-sulfonic acid 2-[5-methyl-2-(6-phenylpyridin-3-yl)thiazol-4-yl]ethyl ester 478541-12-7P,  
 [5-Methyl-2-(6-phenylpyridin-3-yl)thiazol-4-yl]acetic acid methyl ester  
 478541-13-8P 478541-14-9P, 2-[5-Methyl-2-(5-phenylpyridin-3-yl)thiazol-4-yl]ethanol 478541-15-0P, Toluene-4-sulfonic acid 2-[5-methyl-2-(5-phenylpyridin-3-yl)thiazol-4-yl]ethyl ester 478541-16-1P,  
 Toluene-4-sulfonic acid 2-[5-methyl-2-(6-phenoxyphenyl)thiazol-4-yl]ethyl ester 478541-17-2P, Toluene-4-sulfonic acid  
 2-[5-methyl-2-(6-(morpholin-4-yl)pyridin-3-yl)thiazol-4-yl]ethyl ester  
 478541-18-3P 478541-19-4P, Toluene-4-sulfonic acid 2-[5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl]ethyl ester 478541-20-7P,  
 Toluene-4-sulfonic acid 2-[5-methyl-2-(4-phenylpiperazin-1-yl)thiazol-4-yl]ethyl ester 478541-21-8P, Toluene-4-sulfonic acid  
 2-(5-methyl-2-(pyridin-2-yl)thiazol-4-yl)ethyl ester 478541-22-9P,  
 Toluene-4-sulfonic acid 2-(5-methyl-2-(pyridin-3-yl)thiazol-4-yl)ethyl ester 478541-23-0P, Toluene-4-sulfonic acid 2-(5-methyl-2-(pyridin-4-yl)thiazol-4-yl)ethyl ester 478541-24-1P, Toluene-4-sulfonic acid  
 2-[2-(2-methoxyethylamino)-5-methylthiazol-4-yl]ethyl ester  
 478541-25-2P, Toluene-4-sulfonic acid 2-(5-methyl-3-phenylpyrazol-1-yl)ethyl ester 478541-26-3P, 2-(3-(Biphenyl-4-yl)-5-methylpyrazol-1-yl)ethanol 478541-27-4P, 5-(Biphenyl-4-yl)-3-methyl-1H-pyrazole  
 478541-28-5P, 2-[3-(4-Bromophenyl)-5-methylpyrazol-1-yl]ethanol  
 478541-29-6P, 2-(5-Methyl-3-(naphthalen-2-yl)pyrazol-1-yl)ethanol  
 478541-30-9P, 2-(5-Methyl-3-(naphthalen-1-yl)pyrazol-1-yl)ethanol  
 478541-31-0P, 2-(2-Bromoethoxy)-6-methoxynaphthalene 478541-32-1P,  
 6-(2-Bromoethoxy)-3-phenylbenzofuran 478541-33-2P, 3-(2-Bromoethoxy)biphenyl 478541-34-3P, 6-(3-Bromopropoxy)-3-phenylbenzofuran  
 478541-35-4P, 2-(3-Bromopropoxy)-6-methoxynaphthalene 478541-36-5P,  
 2-(4-Bromobutoxy)-6-methoxynaphthalene 478541-37-6P,  
 6-(4-Bromobutoxy)-3-phenylbenzofuran 478541-38-7P, 3-(4-Bromobutoxy)biphenyl 478541-39-8P, 3-(2-Aminomethyl-4-hydroxyphenyl)propionic acid tert-butyl ester 478541-40-1P,  
 3-(2-Formyl-4-hydroxyphenyl)acrylic acid tert-butyl ester 478541-41-2P,  
 3-[4-Hydroxy-2-(hydroxyiminomethyl)phenyl]acrylic acid tert-butyl ester  
 478541-42-3P, 3-(2-Aminomethyl-4-hydroxyphenyl)propionic acid tert-butyl ester ethanedioate (2:1) 478541-43-4P, 3-[2-(tert-Butoxycarbonylaminoethyl)-4-hydroxyphenyl]propionic acid methyl ester  
 478541-44-5P, 3-(2-Aminomethyl-4-hydroxyphenyl)propionic acid hydrochloride 478541-45-6P, 3-[4-Hydroxy-2-(isopropoxycarbonylaminoethyl)phenyl]propionic acid tert-butyl ester 478541-46-7P,  
 3-[4-Hydroxy-2-(isobutoxycarbonylaminoethyl)phenyl]propionic acid tert-butyl ester 478541-47-8P, 3-[2-[[Cyclopropyl(methoxycarbonyl)amino]methyl]-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-48-9P,  
 3-[2-[[[Cyclobutoxy]carbonyl]amino]methyl]-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-49-0P, 3-[2-(Cyclopentylloxycarbonylaminoethyl)-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-50-3P,  
 3-[4-Hydroxy-2-(isopropoxycarbonylaminoethyl)phenyl]propionic acid methyl ester 478541-51-4P, 3-[4-Hydroxy-2-(3-isopropylureidomethyl)phenyl]propionic acid tert-butyl ester 478541-52-5P, 3-[2-[[2,5-Dichloro-3-thienylcarbonyl]amino]methyl]-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-53-6P, 3-[4-Hydroxy-2-[[pyrazine-2-carbonyl]amino]methyl]phenyl]propionic acid tert-butyl ester  
 478541-54-7P, 3-[4-Hydroxy-2-[[2-pyridylcarbonyl]amino]methyl]phenyl]propionic acid tert-butyl ester 478541-55-8P, 3-[2-(Benzoylaminoethyl)-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-56-9P,  
 3-[2-[(Cyclobutanecarbonylamino)ethyl]-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-57-0P, 3-[2-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)-4-hydroxyphenyl]propionic acid tert-butyl ester 478541-58-1P,  
 2-[2-Bromo-5-(tert-butyltrimethylsilyloxy)benzyl]isoindole-1,3-dione  
 478541-59-2P, 3-[2-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)-4-

hydroxyphenyl]acrylic acid tert-butyl ester 478541-60-5P 478541-61-6P,  
 3-[5-Benzyloxy-2-(isopropoxycarbonylamino)methyl]phenyl]propionic acid  
 tert-butyl ester 478541-63-8P, 3-[5-Hydroxy-2-[[methyl(2-  
 pyridylcarbonyl)amino]methyl]phenyl]propionic acid tert-butyl ester  
 478541-64-9P, 3-[2-(1,3-Dioxo-1,3-dihydroisoindol-2-ylmethyl)-4-[2-(5-  
 methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester  
 478541-66-1P, 3-[2-Aminomethyl-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenyl]propionic acid tert-butyl ester acetic acid salt  
 478541-67-2P, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-  
 [[(2,5-dichloro-3-thienylcarbonyl)amino]methyl]phenyl]propionic acid  
 tert-butyl ester 478541-69-4P, 3-[4-[2-[5-Methyl-2-(4-  
 phenylphenyl)oxazol-4-yl]ethoxy]-2-[(isopropoxycarbonylamino)methyl]phenyl  
 ]propionic acid tert-butyl ester 478541-71-8P, 3-[2-  
 (Isopropoxycarbonylamino)methyl)-4-[2-(5-methyl-2-(morpholin-4-yl)thiazol-4-  
 yl)ethoxy]phenyl]propionic acid tert-butyl ester 478541-74-1P  
 478541-89-8P, 3-[4-[2-[2-(4-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-  
 (isopropoxycarbonylamino)methyl]phenyl]propionic acid tert-butyl ester  
 478541-90-1P, 3-[4-[2-[2-(3-Bromophenyl)-5-methyloxazol-4-yl]ethoxy]-2-  
 (isopropoxycarbonylamino)methyl]phenyl]propionic acid tert-butyl ester  
 478541-92-3P, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-[4-  
 (pyridin-3-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid tert-butyl  
 ester 478542-23-3P, 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-  
 2-[4-[4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl]phenyl]oxazol-4-  
 yl]ethoxy]phenyl]propionic acid 478542-55-1P, 3-[2-  
 (Isopropoxycarbonylamino)methyl)-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-  
 yl]ethoxy]phenyl]propionic acid tert-butyl ester 478542-70-0P,  
 3-[2-(Isopropoxycarbonylamino)methyl)-4-[2-[2-(4-isopropoxyphenyl)-5-  
 methyloxazol-4-yl]ethoxy]phenyl]propionic acid tert-butyl ester  
 478542-97-1P, 4-[4-[2-[4-(2-tert-Butoxycarbonylethyl)-3-  
 (isopropoxycarbonylamino)methyl]phenoxy]ethyl]-5-methyloxazol-2-yl]benzoic  
 acid methyl ester 478542-98-2P, 4-[4-[2-[4-(2-tert-Butoxycarbonylethyl)-  
 3-(isopropoxycarbonylamino)methyl]phenoxy]ethyl]-5-methyloxazol-2-  
 yl]benzoic acid 478543-14-5P, 3-[4-[2-[2-[3-(Cyclohexylcarbonyl)phenyl]-  
 5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propio  
 nic acid tert-butyl ester 478543-16-7P, 3-[4-[2-[2-(4-Aminophenyl)-5-  
 methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylamino)methyl]phenyl]propioni  
 c acid tert-butyl ester 478543-43-0P, 3-[2-(Benzothiazol-2-  
 ylamino)methyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic  
 acid tert-butyl ester 478543-46-3P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-  
 yl)ethoxy]-2-[(4-trifluoromethylphenylamino)methyl]phenyl]propionic acid  
 tert-butyl ester 478543-52-1P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-  
 yl)ethoxy]-2-[(2,2,2-trifluoroacetyl)amino]methyl]phenyl]propionic acid  
 tert-butyl ester 478543-53-2P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-  
 yl)ethoxy]-2-[[methyl(2,2,2-trifluoroacetyl)amino]methyl]phenyl]propionic  
 acid tert-butyl ester 478543-54-3P, 3-[2-Methylaminomethyl-4-[2-(5-  
 methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester  
 478543-55-4P, 3-[2-[[[(2,5-Dichloro-3-thienylcarbonyl)methylamino]methyl]-4-  
 [2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl  
 ester 478543-79-2P, 3-(3-Allyl-4-benzyloxyphenyl)propionic acid methyl  
 ester 478543-80-5P, 3-(4-Benzyloxy-3-carboxymethylphenyl)propionic acid  
 methyl ester 478543-81-6P, 3-[4-Benzyloxy-3-(tert-  
 butoxycarbonylamino)methyl]phenyl]propionic acid methyl ester  
 478543-82-7P, 3-[4-Benzyloxy-3-(carbonylmethyl)phenyl]propionic acid  
 methyl ester 478543-83-8P, 3-[3-(tert-Butoxycarbonylamino)methyl)-4-  
 hydroxyphenyl]propionic acid methyl ester 478543-84-9P,  
 3-[3-(tert-Butoxycarbonylamino)methyl)-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenyl]propionic acid methyl ester 478543-85-0P,  
 3-[3-Aminomethyl-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenyl]propionic acid methyl ester 478543-86-1P,  
 3-[3-Aminomethyl-4-[2-(5-methyl-2-phenyloxazol-4-

yl)ethoxy]phenyl]propionic acid methyl ester trifluoroacetic acid salt  
 478543-88-3P, 5-Benzyloxy-2-bromo(2-nitrovinyl)benzene 478543-89-4P,  
 [2-(5-Benzyloxy-2-bromophenyl)ethyl]carbamic acid tert-butyl ester  
 478543-90-7P, 3-[4-Benzyloxy-2-(2-tert-butoxycarbonylaminoethyl)phenyl]acr-  
 ylic acid methyl ester 478543-91-8P, 3-[2-(2-tert-  
 Butoxycarbonylaminoethyl)-4-hydroxyphenyl]propionic acid methyl ester  
 478543-92-9P, 3-[2-(2-tert-Butoxycarbonylaminoethyl)-4-[2-(5-methyl-2-  
 phenyloxazol-4-yl)ethoxy]phenyl]propionic acid methyl ester  
 478543-93-0P, 3-[2-(2-Aminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenyl]propionic acid methyl ester 478543-94-1P,  
 3-[2-(2-Isopropoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenyl]propionic acid ethyl ester 478544-04-6P,  
 3-[4-Hydroxy-2-(2-isopropoxycarbonylaminoethyl)phenyl]propionic acid  
 methyl ester 478544-13-7P, 2-(2-Allyl-4-benzyloxyphenoxy)-2-  
 methylpropionic acid ethyl ester 478544-14-8P, 2-(4-Benzyloxy-2-  
 carboxymethylphenoxy)-2-methylpropionic acid ethyl ester 478544-15-9P,  
 2-[4-Benzyloxy-2-(2,3-dihydroxypropyl)phenoxy]-2-methylpropionic acid  
 ethyl ester 478544-16-0P, 2-(4-Benzyloxy-2-formylmethylphenoxy)-2-  
 methylpropionic acid ethyl ester 478544-17-1P, 2-[4-Benzyloxy-2-  
 (carbamoymethyl)phenoxy]-2-methylpropionic acid ethyl ester  
 478544-18-2P, 2-[4-Benzyloxy-2-(tert-butoxycarbonylaminomethyl)phenoxy]-2-  
 methylpropionic acid ethyl ester 478544-19-3P, 2-[2-(tert-  
 Butoxycarbonylaminomethyl)-4-hydroxyphenoxy]-2-methylpropionic acid ethyl  
 ester 478544-22-8P, 2-[2-Aminomethyl-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl ester 478544-23-9P,  
 2-[2-Aminomethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-  
 methylpropionic acid ethyl ester trifluoroacetic acid salt 478544-39-7P,  
 2-(3-Ethoxybuta-1,3-dienyl)-5-hydroxybenzonitrile 478544-40-0P,  
 2-(3-Ethoxybut-3-enyl)-5-hydroxybenzonitrile 478544-41-1P,  
 3-[2-Cyano-4-[2-[5-methyl-2-(4-phenoxyphenyl)oxazol-4-  
 yl]ethoxy]phenyl]propionic acid ethyl ester 478544-52-4P,  
 3-(4-Benzyloxy-2-formylphenyl)acrylic acid tert-butyl ester  
 478544-53-5P, 5-Benzyloxy-2-(2-tert-butoxycarbonylvinyl)benzoic acid  
 478544-54-6P, 5-Benzyloxy-2-(2-tert-butoxycarbonylvinyl)benzoic acid  
 2-trimethylsilanylethyl ester 478544-55-7P, 2-(2-tert-  
 Butoxycarbonylethyl)-5-hydroxybenzoic acid 2-trimethylsilanylethyl ester  
 478544-56-8P, 2-(2-tert-Butoxycarbonylethyl)-5-[2-(5-methyl-2-phenyloxazol-  
 4-yl)ethoxy]benzoic acid 2-trimethylsilanylethyl ester 478544-57-9P,  
 2-(2-tert-Butoxycarbonylethyl)-5-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]benzoic acid 478544-59-1P, 3-(2-Benzylaminocarbonyl-4-  
 benzyloxyphenyl)acrylic acid tert-butyl ester 478544-60-4P,  
 3-(2-Benzylaminocarbonyl-4-hydroxyphenyl)propionic acid tert-butyl ester  
 478545-20-9P, 3-[2-Formyl-4-[2-(5-methyl-2-phenyloxazol-4-  
 yl)ethoxy]phenyl]acrylic acid tert-butyl ester 478545-21-0P  
 478545-22-1P 478545-23-2P 478545-31-2P 478545-32-3P,  
 3-[4-(tert-Butyldiphenylsilanyloxy)-2-hydroxymethylphenyl]propionic acid  
 tert-butyl ester 478545-33-4P, 3-[4-(tert-Butyldiphenylsilanyloxy)-2-  
 [[[cyclohexylcarbamoylethoxy]methyl]phenyl]propionic acid tert-butyl ester  
 478545-34-5P, 3-(2-[[[Cyclohexylcarbamoylethoxy]methyl]-4-  
 hydroxyphenyl]propionic acid tert-butyl ester 478545-45-8P,  
 3-[2-Cyclohexylcarbamoylethoxymethyl-4-[2-[5-methyl-2-[4-(morpholin-4-  
 yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid tert-butyl ester  
 478545-49-2P  
 , 3-[2-Methoxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic  
 acid tert-butyl ester 478545-66-3P, 3-[2-Bromomethyl-4-[2-(5-methyl-2-  
 phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester  
 478545-90-3P, 3-[2-Bromomethyl-4-(tert-butyldiphenylsilanyloxy)phenyl]prop-  
 ionic acid tert-butyl ester 478545-91-4P, 3-[4-(tert-  
 Butyldiphenylsilanyloxy)-2-(4-trifluoromethylphenoxy)methyl]phenyl]propioni-  
 c acid tert-butyl ester 478545-92-5P, 3-[4-Hydroxy-2-(4-

trifluoromethylphenoxyethyl)phenyl]propionic acid tert-butyl ester  
 478545-93-6P, 3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]-2-(4-trifluoromethylphenoxyethyl)phenyl]propionic acid tert-butyl ester  
 478546-00-8P, 3-[2-Benzyloxymethyl-4-(tert-butyl-diphenylsilyloxy)phenyl]propionic acid tert-butyl ester 478546-01-9P, 3-(2-Benzyloxymethyl-4-hydroxyphenyl)propionic acid tert-butyl ester 478546-02-0P,  
 3-[2-Benzyloxymethyl-4-[2-(2-cyclohexyl-5-methyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478546-10-0P  
 478546-12-2P 478546-13-3P, 3-[2-Cyclohexylcarbamoyloxymethyl-4-[2-(2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid ethyl ester 478546-15-5P,  
 3-[2-(Benzoylaminoethyl)-4-[3-(biphenyl-4-yloxy)propoxy]phenyl]propionic acid tert-butyl ester 478546-50-8P, Biphenyl-4-carboxylic acid  
 3-methoxycarbonyl-1-methyl-2-oxopropyl ester 478546-51-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 478542-64-2P, 3-[4-[2-[2-(4-Hydroxyphenyl)-5-methyloxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminoethyl)phenyl]propionic acid tert-butyl ester

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 57-71-6, 2,3-Butanedione monooxime 75-30-9, 2-Iodopropane 78-92-2, 2-Butanol 92-92-2, Biphenyl-4-carboxylic acid 93-91-4, Benzoylacetone 96-33-3, Methyl acrylate 96-49-1, Ethylene carbonate 98-56-6, 4-Trifluoromethylchlorobenzene 98-59-9 98-80-6, Phenylboronic acid 98-88-4, Benzoyl chloride 98-97-5, Pyrazine-2-carboxylic acid 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-61-8, N-Methylaniline, reactions 100-83-4, 3-Hydroxybenzaldehyde 108-23-6, Isopropyl chloroformate 108-39-4, m-Cresol, reactions 108-91-8, Cyclohexylamine, reactions 108-95-2, Phenol, reactions 109-04-6, 2-Bromopyridine 110-91-8, Morpholine, reactions 140-88-5, Ethyl acrylate 371-40-4, 4-Fluoroaniline 402-45-9, 4-Trifluoromethylphenol 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 600-00-0 615-20-3, 2-Chlorobenzothiazole 645-45-4, 3-Phenylpropionyl chloride 873-62-1, 3-Cyanophenol 1074-82-4, Potassium phthalimide 1122-91-4, 4-Bromobenzaldehyde 1663-39-4, tert-Butyl acrylate 1692-25-7, 3-Pyridineboronic acid 1711-07-5, 3-Fluorobenzoyl chloride 1722-12-9, 2-Chloropyrimidine 1795-48-8, Isopropyl isocyanate 2081-44-9, Tetrahydropyran-4-ol 2177-62-0 2916-68-9, 2-Trimethylsilylethanol 3173-53-3, Cyclohexylisocyanate 3218-36-8, 4-Biphenylcarboxaldehyde 3580-38-9, 2-Benzoylcyclohexanone 4124-41-8, Tosylic anhydride 4319-49-7, N-Aminomorpholine 4747-71-1, Cyclopentyl isocyanate 5111-66-0, 6-Methoxynaphthalen-2-ol 5326-23-8, 6-Chloronicotinic acid 6384-18-5, L-Aspartic acid dimethyl ester 13196-08-2, 3-Phenylbenzofuran-6-ol 14472-14-1, 4-Bromo-3-methyl phenol 14508-49-7, 2-Chloropyrazine 18162-48-6, tert-Butyldimethylsilyl chloride 24424-99-5, Di-tert-butyl dicarbonate 30414-53-0, Methyl propionylacetate 33252-28-7, 5-Cyano-2-chloropyridine 36157-40-1, 1-(2,5-Dichlorothiophen-3-yl)ethanone 56979-56-7, 5-Benzyloxy-2-hydroxybenzaldehyde 57248-14-3 58479-61-1, tert-Butylchlorodiphenylsilane 73183-34-3, Bis(pinacolato)diborane 83812-23-1, 3-(3-Allyl-4-hydroxyphenyl)propionic acid methyl ester 108357-63-7, [4-(3-Bromopropoxy)phenyl]phenylmethanone 170861-68-4, Toluene-4-sulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester 194981-61-8, 2-Allyl-4-benzyloxyphenol 196810-82-9, 2-(1-Methyl-4-phenyl-

1H-imidazol-2-yl)ethanol 208511-69-7 478541-62-7, 3-[5-Hydroxy-2-(isopropoxycarbonylaminoethyl)phenyl]propionic acid tert-butyl ester 478541-65-0, 3-[2-Aminomethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid tert-butyl ester 478541-72-9, Toluene-4-sulfonic acid 2-(5-methyl-2-(morpholin-4-yl)thiazol-4-yl)ethyl ester 478542-38-0, 3-[4-[2-[2-(4-Bromophenyl)-5-methoxyoxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminoethyl)phenyl]propionic acid tert-butyl ester 478542-44-8, 3-[4-[2-[2-(3-Bromophenyl)-5-methoxyoxazol-4-yl]ethoxy]-2-(isopropoxycarbonylaminoethyl)phenyl]propionic acid tert-butyl ester 478542-65-3, 3-[2-(Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid tert-butyl ester 478543-75-8, 3-[2-(Isopropoxycarbonylaminoethyl)-4-[2-[5-methyl-2-[3-(pyridin-3-yl)phenyl]oxazol-4-yl]ethoxy]phenyl]propionic acid tert-butyl ester 478544-25-1, 2-[2-(tert-Butoxycarbonylaminoethyl)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy]-2-methylpropionic acid ethyl ester  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

IT 9004-10-8, Insulin, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sensitizers and secretagogues, compn. component; compns. of (isoxazolylalkoxyphenyl)propionic acid PPAR modulators with known therapeutic agents for treatment of diabetes and related conditions)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alisa, B; WO 0216332 A 2002 HCAPLUS
- (2) Alisa, B; WO 0218355 A 2002 HCAPLUS
- (3) Dominianni, S; WO 0116120 A 2001 HCAPLUS
- (4) Eisai Co Ltd; WO 0125181 A 2001 HCAPLUS
- (5) Eisai Co Ltd; EP 1216980 A 2002 HCAPLUS
- (6) van Zandt, M; WO 0100566 A 2001 HCAPLUS


IT 478535-83-0P, 3-[2-[[[(Phenylmethoxy)carbonyl]amino]methyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); THU (Therapeutic use); PREP (Preparation); USES (Uses)

(PPAR modulator; prepn. of (oxazolylalkoxyphenyl)propionic acid and analogs as PPAR modulators for treatment of diabetes and related conditions)

RN 478535-83-0 HCAPLUS

CN Benzenepropanoic acid, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-[[[(phenylmethoxy)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2003 ACS


AN 2002:888555 HCAPLUS

KATHLEEN FULLER EIC 1700/PARKER LAW 308-4290

DN 137:370079  
 TI Preparation of carboxylic acid substituted oxazole derivatives as  
 PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes  
 IN Binggeli, Alfred; Boehringer, Markus; Grether, Uwe; Hilpert, Hans; Maerki,  
 Hans-Peter; Meyer, Markus; Mohr, Peter; Ricklin, Fabienne  
 PA F. Hoffmann-La Roche A.-G., Switz.  
 SO PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-421  
 ICS A61K031-422; A61P003-10; C07D263-22; C07D413-12  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092084	A1	20021121	WO 2002-EP4962	20020506
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	EP 2001-111745	A	20010515		
OS	MARPAT 137:370079				
GI					



AB The present invention relates to carboxylic acid substituted oxazole derivs. (shown as I; e.g. (S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid) wherein R1 to R7 are as defined below, and pharmaceutically acceptable salts and esters thereof. The compds. are useful for the treatment of diseases such as diabetes, non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases or metabolic syndrome. In I: R1 = aryl or heteroaryl; R2, R3, R4 and R6 = H, hydroxy, lower-alkenyl, halogen, lower-alkyl or lower-alkoxy, wherein at least one of R2, R3, R4 and R6 is not H, or R3 and R4 are bonded to each other to form a ring together with the C atoms to which they are attached, and R3 and R4 together are -CH:CH-S-, -S-CH:CH-, -CH:CH-O-, -O-CH:CH-, -CH:CH-CH:CH-, -(CH2)3-5-, -O-(CH2)2-3- or -(CH2)2-3-O-; R5 is lower-alkoxy, lower-alkenyloxy, 2-benzoylanilino, NHCR8:CR9C(O)R10; R7, R8, R9 = H or lower-alkyl; R10 is aryl; n = 1-3; wherein the bond between the C atom Ca and the C atom Cb is a single or double bond. About 160 example prepns. are included. I exhibit IC50 values of 0.1 nM to 50

.mu.M, preferably 1 nM to 10 .mu.M, particularly 1-3500 nM, more preferred 1-500 nM, for PPAR.alpha. and PPAR.gamma.. The compds. further exhibit EC50 values of 0.1 nM to 50 .mu.M, preferably 1 nM to 10 .mu.M, more preferably 1-3500 nM, particularly 1-500 nM, for PPAR.alpha. and PPAR.gamma..

- ST oxazole carboxylic acid prepn PPAR alpha gamma agonist antidiabetic
- IT Antiarteriosclerotics  
(antiatherosclerotics; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Drug delivery systems  
(for carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Lipids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(increased levels; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Antidiabetic agents  
Diabetes mellitus  
(non-insulin-dependent; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Absolute configuration  
(of 2-ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid)
- IT Carboxylic acids, preparation  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(oxazole derivs.; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Anticholesteremic agents  
Antidiabetic agents  
Antihypertensives  
Atherosclerosis  
Human  
Hypertension  
(prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Disease, animal  
(syndrome X; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Peroxisome proliferator-activated receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(.alpha., agonists; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT Peroxisome proliferator-activated receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(.gamma., agonists; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)
- IT 475479-96-0P, (2S)-2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate, x-ray crystallog.-detd. abs. configuration, drug

candidate; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

IT 475479-94-8P, (2Z)-2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid 475479-98-2P, (2Z)-3-[2,3-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxyacrylic acid 475480-02-5P, (2Z)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-7-yl]acrylic acid 475480-06-9P, (2Z)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-4-yl]acrylic acid 475480-21-8P, (2Z)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-4-yl]acrylic acid 475480-37-6P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

IT 475479-24-4P, 2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-25-5P, 2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-26-6P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]-2-propoxypropionic acid 475479-27-7P, 2-Butoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-28-8P, 2-Isobutoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-29-9P, 2-Hexyloxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-30-2P, 2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid 475479-31-3P, 2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid 475479-32-4P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]-2-propoxypropionic acid 475479-33-5P, 2-Butoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid 475479-34-6P, (S)-2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-35-7P, (S)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-36-8P, (S)-2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid 475479-37-9P, (S)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid 475479-38-0P, 2-(2-Benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid 475479-39-1P, 2-(2-Benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-40-4P, 3-[3,5-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxypropionic acid 475479-41-5P, 2-Ethoxy-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475479-42-6P, 2-(2-Benzoylphenylamino)-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475479-43-7P, 2-(2-Benzoylphenylamino)-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475479-44-8P, (S)-2-Methoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]naphthalen-1-yl]propionic acid 475479-45-9P, (S)-2-Ethoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]naphthalen-1-yl]propionic acid 475479-46-0P, (S)-2-Methoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-47-1P, (S)-2-Ethoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-48-2P, (S)-3-[4-[2-(2-Biphenyl-4-yl-5-methyloxazol-4-

yl)ethoxy]naphthalen-1-yl]-2-ethoxypropionic acid 475479-49-3P,  
 (S)-3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]naphthalen-1-yl]-  
 2-propoxypropionic acid 475479-50-6P, (S)-3-[4-[2-(2-(Biphenyl-4-yl)-5-  
 methyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]-2-propoxypropionic acid  
 475479-51-7P, (S)-3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-  
 yl)ethoxy]naphthalen-1-yl]-2-methoxypropionic acid 475479-52-8P,  
 (S)-3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]naphthalen-1-yl]-  
 2-(2,2,2-trifluoroethoxy)propionic acid 475479-53-9P,  
 (S)-3-[4-[2-(2-(Biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy]benzo[b]thiophen-  
 7-yl]-2-ethoxypropionic acid 475479-54-0P, (S)-3-[4-[2-[2-(4-  
 Isopropylphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-  
 methoxypropionic acid 475479-55-1P, (S)-3-[4-[2-[2-(4-Isopropylphenyl)-5-  
 methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-(2,2,2-  
 trifluoroethoxy)propionic acid 475479-56-2P, (S)-3-[4-[2-[2-(3,5-  
 Dimethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-  
 methoxypropionic acid 475479-57-3P, (S)-3-[4-[2-[2-(3,5-Dimethoxyphenyl)-  
 5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-methoxypropionic acid  
 475479-58-4P, (S)-3-[4-[2-[2-(3,5-Dimethylphenyl)-5-methyloxazol-4-  
 yl]ethoxy]naphthalen-1-yl]-2-methoxypropionic acid 475479-59-5P,  
 3-[4-[2-[2-(3,5-Dichlorophenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]-2-methoxypropionic acid 475479-60-8P,  
 3-[4-[2-[2-(3,5-Difluorophenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]-2-methoxypropionic acid 475479-61-9P,  
 2-Butoxy-3-[4-[2-[2-(3,5-difluorophenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-62-0P,  
 2-Butoxy-3-[4-[2-[2-(3,5-dimethoxyphenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-63-1P,  
 2-Butoxy-3-[4-[2-[2-(3,5-dimethylphenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-64-2P,  
 3-[4-[2-[2-(3,5-Difluorophenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]-2-ethoxypropionic acid 475479-65-3P,  
 2-Methoxy-3-[4-[3-[2-(4-methoxyphenyl)-5-methyloxazol-4-  
 yl]propoxy]naphthalen-1-yl]propionic acid 475479-66-4P,  
 3-[4-[3-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]propoxy]naphthalen-1-yl]-2-  
 methoxypropionic acid 475479-67-5P, 2-Methoxy-3-[4-[3-[5-methyl-2-(4-  
 trifluoromethylphenyl)oxazol-4-yl]propoxy]benzo[b]thiophen-7-yl]propionic  
 acid 475479-68-6P, 2-Ethoxy-3-[4-[3-[5-methyl-2-(4-  
 trifluoromethylphenyl)oxazol-4-yl]propoxy]benzo[b]thiophen-7-yl]propionic  
 acid 475479-69-7P, 3-[4-[3-[2-(4-Chlorophenyl)-5-methyloxazol-4-  
 yl]propoxy]naphthalen-1-yl]-2-isopropoxypropionic acid 475479-70-0P,  
 (S)-2-Methoxy-3-[4-[3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-  
 yl]propoxy]naphthalen-1-yl]propionic acid 475479-71-1P,  
 3-[4-[3-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]propoxy]benzo[b]thiophen-7-  
 yl]-2-methoxypropionic acid 475479-72-2P, 2-Ethoxy-3-[4-[3-[2-(4-  
 methoxyphenyl)-5-methyloxazol-4-yl]propoxy]naphthalen-1-yl]propionic acid  
 475479-73-3P, 2-Ethoxy-3-[4-[3-[2-(4-isopropylphenyl)-5-methyloxazol-4-  
 yl]propoxy]naphthalen-1-yl]propionic acid 475479-74-4P,  
 3-[4-[3-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]propoxy]naphthalen-1-yl]-2-  
 ethoxypropionic acid 475479-75-5P, 3-[4-[3-[2-(4-Isopropylphenyl)-5-  
 methyloxazol-4-yl]propoxy]naphthalen-1-yl]-2-methoxypropionic acid  
 475479-76-6P, 3-[4-[2-[2-(3,5-Dimethylphenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]-2-ethoxypropionic acid 475479-77-7P,  
 3-[4-[2-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-  
 yl]ethoxy]benzo[b]thiophen-7-yl]-2-ethoxypropionic acid 475479-78-8P,  
 2-Ethoxy-3-[4-[3-[2-(4-methoxyphenyl)-5-methyloxazol-4-  
 yl]propoxy]benzo[b]thiophen-7-yl]propionic acid 475479-79-9P,  
 2-Methoxy-3-[4-[3-[2-(4-methoxyphenyl)-5-methyloxazol-4-  
 yl]propoxy]benzo[b]thiophen-7-yl]propionic acid 475479-80-2P,  
 2-Ethoxy-3-[4-[3-[2-(4-isopropylphenyl)-5-methyloxazol-4-  
 yl]propoxy]benzo[b]thiophen-7-yl]propionic acid 475479-81-3P,

3-[4-[3-[2-(4-Isopropylphenyl)-5-methyloxazol-4-yl]propoxy]benzo[b]thiophen-7-yl]-2-methoxypropionic acid 475479-82-4P,  
 3-[4-[3-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]propoxy]benzo[b]thiophen-7-yl]-2-ethoxypropionic acid 475479-83-5P, 2-Ethoxy-3-[4-[2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-84-6P, (S)-2-[(But-3-enyl)oxy]-3-[4-[2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475479-85-7P, 3-[4-[2-[2-(4-Isopropylphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]-2-propoxypropionic acid 475479-86-8P, 2-Ethoxy-3-[4-[2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]propionic acid 475479-87-9P,  
 3-[4-[2-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-isopropoxypropionic acid 475479-88-0P, (S)-3-[4-[2-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-isopropoxypropionic acid 475479-89-1P, 3-[4-[3-[2-(4-Isopropylphenyl)-5-methyloxazol-4-yl]propoxy]benzo[b]thiophen-7-yl]-2-propoxypropionic acid 475479-90-4P, 3-[4-[2-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]-2-ethoxypropionic acid 475479-91-5P, 3-[4-[2-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]-2-propoxypropionic acid 475479-92-6P, 3-[4-[2-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]-2-isopropoxypropionic acid 475479-93-7P, 2-Isopropoxy-3-[4-[2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]propionic acid 475479-95-9P,  
 2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475479-97-1P, (2R)-2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475479-99-3P, 3-[2,3-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxypropionic acid 475480-00-3P, (2Z)-3-[2,6-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxyacrylic acid 475480-01-4P, 3-[2,6-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxypropionic acid 475480-03-6P, (2E)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-7-yl]acrylic acid 475480-04-7P, 2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-7-yl]propionic acid 475480-05-8P,  
 2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2,3-dihydrobenzofuran-7-yl]propionic acid 475480-07-0P, (2E)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-4-yl]acrylic acid 475480-08-1P, 2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-4-yl]propionic acid 475480-09-2P, 2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-2,3-dihydrobenzofuran-4-yl]propionic acid 475480-10-5P, 2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid 475480-11-6P, 3-[4-[2-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-ethoxypropionic acid 475480-12-7P, 2-Ethoxy-3-[4-[2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-13-8P, 2-Ethoxy-3-[4-[2-[2-(2-ethoxy-4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-14-9P, 2-Ethoxy-3-[4-[2-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-15-0P, 2-Ethoxy-3-[4-[2-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-16-1P, (S)-2-Methoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-4-yl]propionic acid 475480-17-2P, (2Z)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-yl]acrylic acid 475480-18-3P, (S)-2-Methoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-yl]propionic acid 475480-19-4P, 3-[4-[2-[2-(2-Ethoxy-4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]-2-methoxypropionic acid 475480-20-7P, 2-Methoxy-3-[4-[2-[2-(4-

methoxyphenyl)-5-methyloxazol-4-yl]ethoxy]naphthalen-1-yl]propionic acid  
475480-22-9P, 2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-4-yl]propionic acid 475480-23-0P,  
2-((Z)-1-Methyl-3-oxo-3-phenyl-1-propenylamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid  
475480-24-1P, 2-[(Z)-1-Methyl-3-oxo-3-(4-trifluoromethylphenyl)-1-propenylamino]-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-25-2P,  
3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]-2-((Z)-3-oxo-3-phenyl-1-trifluoromethyl-1-propenylamino)propionic acid  
475480-26-3P, 2-Ethoxy-3-[4-[(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)methoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid  
475480-27-4P, 2-Ethoxy-3-[4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid 475480-28-5P,  
2-Ethoxy-3-[4-[2-[2-(2-ethoxy-4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid 475480-29-6P,  
2-Ethoxy-3-[4-[2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid 475480-30-9P,  
2-Ethoxy-3-[4-[3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]propoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid 475480-31-0P,  
2-Ethoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid 475480-32-1P,  
2-Methoxy-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475480-33-2P, 2-Methoxy-3-[3-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid  
475480-34-3P, Lithium 2-ethoxy-3-[3-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionate 475480-35-4P, 3-[3,5-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-methoxypropionic acid  
475480-36-5P, 3-[2-Hydroxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-methoxypropionic acid 475480-38-7P,  
2-Ethoxy-3-[4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]benzofuran-7-yl]propionic acid 475480-39-8P, 2-Ethoxy-3-[4-[(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)methoxy]benzofuran-7-yl]propionic acid 475480-40-1P,  
2-Ethoxy-3-[4-[(2-(4-ethylphenyl)-5-methyloxazol-4-yl)methoxy]benzofuran-7-yl]propionic acid 475480-41-2P, 3-[4-[(2-(4-tert-Butylphenyl)-5-methyloxazol-4-yl)methoxy]benzofuran-7-yl]-2-ethoxypropionic acid  
475480-42-3P, 2-Ethoxy-3-[4-[(2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl)methoxy]benzofuran-7-yl]propionic acid 475480-43-4P,  
2-Ethoxy-3-[4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]-2,3-dihydrobenzofuran-7-yl]propionic acid 475480-44-5P, 2-Ethoxy-3-[4-[(2-(4-ethylphenyl)-5-methyloxazol-4-yl)methoxy]-2,3-dihydrobenzofuran-7-yl]propionic acid 475480-45-6P, 3-[4-[(2-(4-tert-Butylphenyl)-5-methyloxazol-4-yl)methoxy]-2,3-dihydrobenzofuran-7-yl]-2-ethoxypropionic acid 475480-46-7P, 2-Ethoxy-3-[4-[(2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl)methoxy]-2,3-dihydrobenzofuran-7-yl]propionic acid 475480-47-8P,  
2-Ethoxy-3-[2-methyl-4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]phenyl]propionic acid 475480-48-9P, 2-Ethoxy-3-[2-methyl-4-[(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)methoxy]phenyl]propionic acid  
475480-49-0P, 2-Ethoxy-3-[4-[(2-(4-ethylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid 475480-50-3P,  
3-[4-[(2-(4-tert-Butylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid 475480-51-4P, 2-Ethoxy-3-[4-[(2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid 475480-52-5P, (S)-2-[(But-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475480-53-6P  
475480-54-7P, 3-[4-[(2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]benzofuran-7-yl]-2-ethoxypropionic acid 475480-55-8P,  
3-[4-[(2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid 475480-56-9P, 3-[4-[(2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-yl)methoxy]benzofuran-7-yl]-2-ethoxypropionic acid

475480-57-0P, (2Z)-2-Ethoxy-3-[4-[(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]acrylic acid 475480-58-1P, 2-Ethoxy-3-[3-methyl-4-[(2-phenyloxazol-4-yl)methoxy]phenyl]propionic acid 475480-59-2P, (S)-3-[3,5-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-propoxypropionic acid 475480-60-5P, (2Z)-2-[(But-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid 475480-61-6P, (2E)-2-[(But-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid 475480-62-7P, 3-[4-[(2-(2-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid 475480-63-8P, 3-[4-[(2-(3-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid 475480-64-9P, 2-Ethoxy-3-[2-methyl-4-[3-(5-methyl-2-phenyloxazol-4-yl)propoxy]phenyl]propionic acid 475480-65-0P, 2-Ethoxy-3-[4-[(2-(4-fluoro-3-methylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid 475480-66-1P, 2-Ethoxy-3-[4-[(2-(2-methoxyphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid 475480-67-2P, 3-[4-[2-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]-2-ethoxypropionic acid 475480-68-3P, 2-Ethoxy-3-[4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]naphthalen-1-yl]propionic acid 475480-69-4P, 2-Ethoxy-3-[7-[(5-methyl-2-phenyloxazol-4-yl)methoxy]benzo[b]thiophen-4-yl]propionic acid 475480-70-7P, 2-Ethoxy-3-[7-[(2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl)methoxy]benzo[b]thiophen-4-yl]propionic acid 475480-71-8P, 2-Ethoxy-3-[7-[2-[2-(2-ethoxy-4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-4-yl]propionic acid 475480-72-9P, 3-[7-[2-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-4-yl]-2-ethoxypropionic acid 475480-73-0P, 3-[7-[(2-(4-tert-Butylphenyl)-5-methyloxazol-4-yl)methoxy]benzo[b]thiophen-4-yl]-2-ethoxypropionic acid 475480-74-1P, (S)-2-Ethoxy-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475480-75-2P, (2S)-3-[3,5-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxypropionic acid 475480-76-3P, 2-Ethoxy-3-[3-fluoro-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475480-77-4P, 2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-3-propylphenyl]propionic acid 475480-78-5P, (2S)-2-Ethoxy-3-[3-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475480-79-6P, (2S)-2-Ethoxy-3-[2-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid 475480-80-9P, 2-Isopropoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-81-0P, (S)-2-Isopropoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid 475480-82-1P, 3-[3-Allyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]-2-ethoxypropionic acid 475481-40-4P, 2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-yl]propionic acid 475481-75-5P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid calcium salt (2:1) RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

IT 475481-19-7P, 2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid ethyl ester  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process) (prepn. and chromatog. resoln.; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

IT 475481-20-0P, (2S)-2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-

yl)ethoxy]phenyl]propionic acid ethyl ester 475481-21-1P,  
(2R)-2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid ethyl ester

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

IT 55-21-0, Benzamide 57-71-6, Diacetyl monoxime 89-91-8, Methyl dimethoxyacetate 89-98-5, 2-Chlorobenzaldehyde 93-91-4, Benzoylacetone 95-01-2, 2,4-Dihydroxybenzaldehyde 95-48-7, o-Cresol, reactions 98-03-3, 2-Thiophenecarboxaldehyde 100-39-0, Benzyl bromide 100-44-7, Benzyl chloride, reactions 104-88-1, 4-Chlorobenzaldehyde, reactions 106-95-6, Allyl bromide, reactions 108-39-4, m-Cresol, reactions 108-68-9, 3,5-Dimethylphenol 121-33-5, 4-Hydroxy-3-methoxybenzaldehyde 122-03-2, 4-Isopropylbenzaldehyde 135-02-4, 2-Methoxybenzaldehyde 348-28-7, 4-Fluoro-2-hydroxybenzaldehyde 405-05-0, 3-Fluoro-4-hydroxybenzaldehyde 455-19-6, 4-Trifluoromethylbenzaldehyde 480-97-7, 4-Hydroxybenzofuran 526-75-0, 2,3-Dimethylphenol 529-35-1, 5,6,7,8-Tetrahydronaphthalen-1-ol 534-07-6, 1,3-Dichloroacetone 576-26-1, 2,6-Dimethylphenol 587-04-2, 3-Chlorobenzaldehyde 627-27-0, 3-Buten-1-ol 709-63-7, 4-Trifluoromethylacetophenone 817-95-8, Ethoxyacetic acid ethyl ester 824-94-2, 4-Methoxybenzyl chloride 834-17-3, 1-Benzyloxy-3-methylbenzene 939-97-9, 4-tert-Butylbenzaldehyde 1641-41-4, 4-Indanol 2233-18-3, 3,5-Dimethyl-4-hydroxybenzaldehyde 2426-87-1, 4-Benzyloxy-3-methoxybenzaldehyde 3218-36-8, 4-Phenylbenzaldehyde 3580-38-9, 2-Benzoylcyclohexanone 3938-96-3, Methoxyacetic acid ethyl ester 4748-78-1, 4-Ethylbenzaldehyde 4790-81-2, 7-Hydroxybenzofuran 5779-95-3, 3,5-Dimethylbenzaldehyde 7311-34-4, 3,5-Dimethoxybenzaldehyde 7770-45-8, 4-Hydroxynaphthalene-1-carboxaldehyde 10203-08-4, 3,5-Dichlorobenzaldehyde 10397-22-5, Butyl butoxyacetate 14144-70-8, Butoxyacetic acid ethyl ester 15174-69-3, 4-Hydroxy-3-methylbenzaldehyde 16847-90-8, (Ethoxy(ethoxycarbonyl)methyl)triphenylphosphonium chloride 18278-34-7, 4-Hydroxy-2-methoxybenzaldehyde 18962-05-5, 4-Isopropoxybenzaldehyde 32085-88-4, 3,5-Difluorobenzaldehyde 33445-07-7, Isopropoxyacetic acid 41052-88-4, 3-Allyl-4-hydroxybenzaldehyde 41438-18-0, 4-Hydroxy-2-methylbenzaldehyde 51220-57-6, (4-Methoxybenzoylamino)acetic acid ethyl ester 57941-71-6, Propoxyacetic acid ethyl ester 57941-72-7, Hexyloxyacetic acid ethyl ester 69555-14-2, N-(Diphenylmethylene)glycine ethyl ester 70159-96-5, Isobutoxyacetic acid ethyl ester 77898-35-2, Benzo[b]thiophen-7-ol 85428-65-5, (But-3-enyloxy)acetic acid ethyl ester 88568-95-0, N-(Benzyloxycarbonyl)-.alpha.-phosphonoglycine trimethyl ester 89682-88-2, 5-Benzyloxy-1,2,3,4-tetrahydronaphthalene 90719-32-7, (S)-4-Benzyl-2-oxazolidinone 103788-61-0, 4-Chloromethyl-5-methyl-2-phenyloxazole 103788-65-4, 2-(5-Methyl-2-phenyloxazole-4-yl)ethanol 109544-17-4, [2-(4-Chlorophenyl)-5-methyloxazol-4-yl]methanol 129952-14-3, (S)-4-Benzyl-3-methoxyacetyloxazolidin-2-one 135427-08-6, 4-Fluoro-3-methylbenzaldehyde 136058-69-0, 2-[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]ethanol 140130-20-7, (S)-4-Benzyl-3-ethoxyacetyloxazolidin-2-one 161010-40-8, 4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]naphthalene-1-carboxaldehyde 177785-24-9, (S)-4-Benzyl-3-[(2,2,2-trifluoroethoxy)acetyl]oxazolidin-2-one 180850-19-5, (Methoxy(methoxycarbonyl)methyl)triphenylphosphonium bromide 196810-30-7, 2-[2-(4-Fluorophenyl)-5-methyloxazol-4-yl]ethanol 199339-71-4, 4-Hydroxybenzo[b]thiophene-7-carboxaldehyde 213455-35-7, 4-Benzyloxybenzo[b]thiophene-7-carboxaldehyde 227029-27-8, Methanesulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester 258346-53-1, 3-(5-Methyl-2-phenyloxazol-4-yl)propan-1-ol 258346-68-8, 2-[2-(4-Isopropoxyphenyl)-5-methyloxazol-4-yl]ethanol 343870-70-2, 2-Ethoxy-3-(4-hydroxy-3-methylphenyl)propionic acid ethyl ester

369631-84-5, 4-[2-[(7-Bromomethylbenzo[b]thiophen-4-yl)oxy]ethyl]-5-methyl-2-phenyloxazole 475480-85-4, 5-Methyl-4-[2-[(naphthalen-1-yl)oxy]ethyl]-2-phenyloxazole 475480-97-8, 4-[2-(4-Bromomethyl-2-methylphenoxy)ethyl]-5-methyl-2-phenyloxazole 475481-04-0, (S)-4-Benzyl-3-propoxyacetyloxazolidin-2-one 475481-15-3, 3-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]propan-1-ol 475481-58-4, 3-Bromo-4,4,4-trifluoro-1-phenylbut-2-en-1-one 475481-87-9, 3,5-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 475482-02-1, 7-Benzyloxybenzo[b]thiophene

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

IT 30494-97-4P, 4-Chloromethyl-2-phenyloxazole 42415-64-5P, Ethyl isopropoxyacetate 73569-40-1P, Dimethoxyacetic acid 95123-53-8P, (But-3-enyloxy)acetic acid 101093-56-5P, 4-Benzyloxy-2-methylbenzaldehyde 141819-91-2P, 2-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethanol 174258-39-0P, 4-Chloromethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole 178610-92-9P, 3-Methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 185842-17-5P, 2-Hydroxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 197721-29-2P, (S)-4-Benzyl-3-[(but-3-enyl)oxy]acetyl]oxazolidin-2-one 202595-63-9P, 4-Chloromethyl-5-methyl-2-(thiophen-2-yl)oxazole 213455-52-8P, 4-Benzyloxynaphthalene-1-carboxaldehyde 217446-33-8P, 2-(4-Methoxybenzoylamino)pent-4-enoic acid 258346-69-9P, 1-(4-Trifluoromethylphenyl)butane-1,3-dione 334016-00-1P 343870-75-7P, 2-Ethoxy-3-(4-hydroxy-3-methoxyphenyl)propionic acid ethyl ester 475480-83-2P, 2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid ethyl ester 475480-84-3P, 4-[2-[(4-Bromomethylnaphthalen-1-yl)oxy]ethyl]-5-methyl-2-phenyloxazole 475480-86-5P, 2-Methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid ethyl ester 475480-87-6P, (4S)-4-Benzyl-3-[(2S,3R)-3-hydroxy-2-methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionyl]oxazolidin-2-one 475480-88-7P, 4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophene-7-carboxaldehyde 475480-89-8P, (4S)-4-Benzyl-3-[(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionyl]oxazolidin-2-one 475480-91-2P, (S)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid methyl ester 475480-92-3P, 2-(Benzhydrylideneamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid ethyl ester 475480-93-4P, 2-Amino-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid ethyl ester 475480-94-5P, 2-(2-Benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]naphthalen-1-yl]propionic acid ethyl ester 475480-95-6P, 4-[2-(2,6-Dimethylphenoxy)ethyl]-5-methyl-2-phenyloxazole 475480-96-7P, 4-[2-(4-Bromomethyl-2,6-dimethylphenoxy)ethyl]-5-methyl-2-phenyloxazole 475480-98-9P, 4,5-Dimethyl-2-(4-trifluoromethylphenyl)oxazole 3-oxide 475480-99-0P, [5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]acetonitrile 475481-00-6P, [5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]acetic acid 475481-01-7P, 4-[2-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]naphthalene-1-carboxaldehyde 475481-02-8P, (4S)-4-Benzyl-3-[(2S,3R)-3-hydroxy-2-methoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]naphthalen-1-yl]propionyl]oxazolidin-2-one 475481-03-9P, (4S)-4-Benzyl-3-[(2S)-2-methoxy-3-[4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]naphthalen-1-yl]propionyl]oxazolidin-2-one 475481-05-1P, 3-[4-[2-[2-(3,5-Dichlorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-3-hydroxy-2-methoxypropionic acid ethyl ester 475481-06-2P, 4-[2-[2-(3,5-Dichlorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophene-

7-carboxaldehyde 475481-07-3P, 3-[4-[2-[2-(3,5-Dichlorophenyl)-5-methyloxazol-4-yl]ethoxy]benzo[b]thiophen-7-yl]-2-methoxypropionic acid ethyl ester 475481-08-4P, 2-(4-Methoxybenzoylamino)pent-4-enoic acid ethyl ester 475481-09-5P, N-(1-Acetylbut-3-enyl)-4-methoxybenzamide 475481-10-8P, 4-Allyl-2-(4-methoxyphenyl)-5-methyloxazole 475481-11-9P, 3-[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]propan-1-ol 475481-12-0P, 4-[3-[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]propoxy]naphthalene-1-carboxaldehyde 475481-13-1P, 3-Hydroxy-2-methoxy-3-[4-[3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]propoxy]naphthalen-1-yl]propionic acid ethyl ester 475481-14-2P, 2-Methoxy-3-[4-[3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]propoxy]naphthalen-1-yl]propionic acid ethyl ester 475481-16-4P, 5-Methyl-2-phenyl-4-(2-m-tolyloxyethyl)oxazole 475481-17-5P, 2-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 475481-18-6P, (2Z)-2-Ethoxy-3-[2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid ethyl ester 475481-22-2P, 4-[2-(2,3-Dimethylphenoxy)ethyl]-5-methyl-2-phenyloxazole 475481-23-3P, 2,3-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 475481-24-4P, (2Z)-3-[2,3-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxyacrylic acid ethyl ester 475481-25-5P, 4-[2-(3,5-Dimethylphenoxy)ethyl]-5-methyl-2-phenyloxazole 475481-26-6P, 2,6-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 475481-27-7P, (2Z)-3-[2,6-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxyacrylic acid ethyl ester 475481-28-8P, 3-[2,6-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl ester 475481-29-9P, 4-[2-[(Benzofuran-4-yl)oxy]ethyl]-5-methyl-2-phenyloxazole 475481-30-2P, 4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-7-carboxaldehyde 475481-31-3P, (2Z)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-7-yl]acrylic acid ethyl ester 475481-32-4P, (2E)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-7-yl]acrylic acid ethyl ester 475481-33-5P, 4-[2-[(Benzofuran-7-yl)oxy]ethyl]-5-methyl-2-phenyloxazole 475481-34-6P, 7-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-4-carboxaldehyde 475481-35-7P, (2Z)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-4-yl]acrylic acid ethyl ester 475481-36-8P, (2E)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzofuran-4-yl]acrylic acid ethyl ester 475481-37-9P, 4-[2-[(Indan-4-yl)oxy]ethyl]-5-methyl-2-phenyloxazole 475481-38-0P, 7-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-carboxaldehyde 475481-39-1P, (2Z)-2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-yl]acrylic acid ethyl ester 475481-42-6P, 2-Ethoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-yl]propionic acid ethyl ester 475481-43-7P, 4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-5,6,7,8-tetrahydronaphthalene-1-carboxaldehyde 475481-45-9P, (2Z)-2-Ethoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]acrylic acid ethyl ester 475481-47-1P, 3-[4-Benzyloxybenzo[b]thiophen-7-yl]-2-ethoxyacrylic acid ethyl ester 475481-48-2P, 3-(4-Benzyloxybenzo[b]thiophen-7-yl)-2-ethoxypropionic acid methyl ester 475481-49-3P, 2-Ethoxy-3-(4-hydroxybenzo[b]thiophen-7-yl)propionic acid methyl ester 475481-50-6P, 2-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]ethanol 475481-51-7P, 2-[2-(2-Ethoxy-4-fluorophenyl)-5-methyloxazol-4-yl]ethanol 475481-52-8P, 7-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophene-4-carboxaldehyde 475481-53-9P, (4S)-4-Benzyl-3-[(2S,3R)-3-hydroxy-2-methoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-4-yl]propionyl]oxazolidin-2-one 475481-54-0P, (4S)-4-Benzyl-3-[(2S,3R)-3-hydroxy-2-methoxy-3-[7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]indan-4-yl]propionyl]oxazolidin-2-one 475481-55-1P, 3-(4-Hydroxynaphthalen-1-yl)-2-methoxypropionic acid methyl ester 475481-56-2P, 2-((Z)-1-Methyl-3-oxo-3-phenyl-1-propenylamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid ethyl ester 475481-57-3P, 2-Amino-3-[4-[2-(5-methyl-2-phenyloxazol-

4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid ethyl ester 475481-59-5P, 3-[4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]-2-((Z)-3-oxo-3-phenyl-1-trifluoromethyl-1-propenylamino)propionic acid ethyl ester 475481-60-8P, 4-Benzyloxy-5,6,7,8-tetrahydronaphthalene-1-carboxaldehyde 475481-61-9P, 2-Ethoxy-3-(4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)propionic acid ethyl ester 475481-62-0P, 2-Ethoxy-3-[4-[(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)methoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]propionic acid ethyl ester 475481-63-1P, 4-Chloromethyl-2-(4-isopropylphenyl)-5-methyloxazole 475481-64-2P, ((Benzyloxycarbonyl)(methoxy)methyl)triphenylphosphonium chloride 475481-65-3P, Dimethoxyacetic acid benzyl ester 475481-66-4P, 3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 475481-67-5P, 2-Methoxy-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid benzyl ester 475481-68-6P, 2-Ethoxy-3-[3-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid ethyl ester 475481-69-7P, 2-(4-Methoxybenzyloxy)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde 475481-70-0P, 2-Methoxy-3-[2-(4-methoxybenzyloxy)-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid benzyl ester 475481-71-1P, 2-Benzyloxycarbonylamino-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid methyl ester 475481-72-2P, 2-Amino-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid methyl ester hydrochloride 475481-73-3P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid methyl ester 475481-74-4P, 2-Amino-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid methyl ester 475481-76-6P, 4-Benzyloxybenzofuran 475481-77-7P, 4-Benzyloxybenzofuran-7-carboxaldehyde 475481-78-8P, (2Z)-3-(4-Benzyloxybenzofuran-7-yl)-2-ethoxyacrylic acid ethyl ester 475481-79-9P, 3-(4-Benzyloxybenzofuran-7-yl)-2-ethoxypropionic acid methyl ester 475481-80-2P, 2-Ethoxy-3-(4-hydroxybenzofuran-7-yl)propionic acid methyl ester 475481-81-3P, 4-Chloromethyl-2-(4-ethylphenyl)-5-methyloxazole 475481-82-4P, 2-(4-tert-Butylphenyl)-4-chloromethyl-5-methyloxazole 475481-83-5P, 4-Chloromethyl-2-(4-isopropoxyphenyl)-5-methyloxazole 475481-84-6P, 2-Ethoxy-3-(4-hydroxy-2,3-dihydrobenzofuran-7-yl)propionic acid ethyl ester 475481-85-7P, (2Z)-3-(4-Benzyloxy-2-methylphenyl)-2-ethoxyacrylic acid ethyl ester 475481-86-8P, 2-Ethoxy-3-(4-hydroxy-2-methylphenyl)propionic acid ethyl ester 475481-88-0P, (4S)-4-Benzyl-3-[(2S,3R)-2-[(but-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-3-hydroxypropionyl]oxazolidin-2-one 475481-89-1P, (2Z)-3-[3,5-Dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxyacrylic acid ethyl ester 475481-90-4P, 4-Chloromethyl-2-(3,5-dimethoxyphenyl)-5-methyloxazole 475481-91-5P, (4S)-4-Benzyl-3-[(2S,3R)-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-3-hydroxy-2-propoxypropionyl]oxazolidin-2-one 475481-92-6P, 2-[(But-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-3-hydroxypropionic acid ethyl ester 475481-93-7P, (2Z)-2-[(But-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid ethyl ester 475481-94-8P, (2E)-2-[(But-3-enyl)oxy]-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]acrylic acid ethyl ester 475481-95-9P, 3-[4-[(2-(2-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid ethyl ester 475481-96-0P, 4-Chloromethyl-2-(2-chlorophenyl)-5-methyloxazole 475481-97-1P, 4-Chloromethyl-2-(3-chlorophenyl)-5-methyloxazole 475481-98-2P, 4-Chloromethyl-2-(4-fluoro-3-methylphenyl)-5-methyloxazole 475481-99-3P, 4-Chloromethyl-2-(2-methoxyphenyl)-5-methyloxazole 475482-00-9P, 2-Ethoxy-3-(4-hydroxynaphthalen-1-yl)propionic acid ethyl ester 475482-01-0P, 2-Ethoxy-3-(7-hydroxybenzo[b]thiophen-4-yl)propionic acid methyl ester

475482-03-2P, (4S)-4-Benzyl-3-[(2S,3R)-2-ethoxy-3-hydroxy-3-[3-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionyl]oxazolidin-2-one  
 475482-04-3P, (4S)-4-Benzyl-3-[(2S,3R)-3-[3,5-dimethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-ethoxy-3-hydroxypropionyl]oxazolidin-2-one  
 475482-05-4P, [(Benzyloxycarbonyl)(ethoxy)methyl]triphenylphosphonium chloride  
 475482-06-5P, (4S)-4-Benzyl-3-[(2S,3R)-2-ethoxy-3-hydroxy-3-[3-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionyl]oxazolidin-2-one  
 475482-07-6P, 2-Methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde  
 475482-08-7P, (4S)-4-Benzyl-3-[(2S,3R)-2-ethoxy-3-hydroxy-3-[2-methoxy-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionyl]oxazolidin-2-one  
 475482-09-8P, 3-(3-Allyl-4-hydroxynaphthalen-1-yl)-2-ethoxypropionic acid ethyl ester  
 475482-10-1P, 3-(4-Allyloxynaphthalen-1-yl)-2-ethoxypropionic acid ethyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alisa, B; WO 0216331 A 2002 HCAPLUS
- (2) Glaxo Group Ltd; WO 0008002 A 2000 HCAPLUS
- (3) Hulin, B; CURRENT PHARMACEUTICAL DESIGN 1996, V2, P85 HCAPLUS
- (4) Malamas, M; EUR J MED CHEM 2001, V36(1), P31 HCAPLUS

IT 475480-37-6P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid


RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; prepn. of carboxylic acid substituted oxazole derivs. as PPAR-.alpha. and -.gamma. activators for treatment of type II diabetes)

RN 475480-37-6 HCAPLUS

CN Tyrosine, 3-methyl-N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:754366 HCAPLUS

DN 137:279197

TI Preparation of five-membered heterocyclic alkanolic acid derivatives as remedies for diabetes and hyperlipidemia

IN Momose, Yu; Maekawa, Tsuyoshi; Imoto, Hiroshi; Odaka, Hiroyuki; Kimura, Hiroyuki

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 165 pp.


CODEN: PIXXD2

DT Patent  
 LA Japanese  
 IC ICM C07D263-32  
 ICS C07D263-34; C07D413-12; C07D413-14; C07D417-12; A61K031-421;  
 A61K031-422; A61K031-427; A61K031-4439; A61K031-4709; A61K031-5377;  
 A61P003-06; A61P003-10; A61P043-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076959	A1	20021003	WO 2002-JP2741	20020322
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	JP 2002348281	A2	20021204	JP 2002-81621	20020322
PRAI	JP 2001-85572	A	20010323		
OS	MARPAT 137:279197				
GI					



AB The title compds. I [R1 represents an optionally substituted five-membered heterocyclic group; X represents a bond, etc.; Q represents a C1-20 divalent hydrocarbon group; Y represents a bond, etc.; ring A represents an arom. ring optionally having one to three substituents; Z represents (CH2)<sub>n</sub>Z1 (n is an integer of 0 to 8 and Z1 represents a bond, etc.), etc.; ring B represents a five-membered heterocycle optionally having one to three substituents; W represents a C1-20 divalent satd. hydrocarbon group; and R2 represents OH, etc.] are prepd. A process for prepg. I is disclosed. Compds. of this invention at 0.01% in feed given to diabetic mice for 4 days caused 43% to 42% decrease of blood sugar. Formulations are given.

ST heterocyclic alkanoate prepn diabetes hyperlipidemia remedy

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cloning of human PPAR .delta. gene and human RXR .alpha. gene in study  
 of effect of five-membered heterocyclic alkanoic acid derivs. as  
 remedies for diabetes and hyperlipidemia)

IT Lipids, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hyperlipidemia; prepn. and effect of five-membered heterocyclic  
 alkanoic acid derivs.)

IT Antiarteriosclerotics

Anticholesteremic agents

Antidiabetic agents

Arteriosclerosis

Diabetes mellitus

Hypercholesterolemia  
Hypolipemic agents  
(prepn. and effect of five-membered heterocyclic alkanolic acid derivs.)

IT Glycerides, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. and effect of five-membered heterocyclic alkanolic acid derivs.)

IT Peroxisome proliferator-activated receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. and effect of five-membered heterocyclic alkanolic acid derivs.  
as peroxisome proliferator-activated receptor ligands)

IT Retinoid X receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. and effect of five-membered heterocyclic alkanolic acid derivs.  
as remedies for diabetes and hyperlipidemia and as retinoid X ligands)

IT Mammalia  
(prepn. and effect of five-membered heterocyclic alkanolic acid derivs.  
or prodrugs thereof as remedies for diabetes and hyperlipidemia)

IT Human  
(prepn. of five-membered heterocyclic alkanolic acid derivs. as remedies  
for diabetes and hyperlipidemia)

IT Drug delivery systems  
(prodrugs; prepn. and effect of five-membered heterocyclic alkanolic  
acid derivs. or prodrugs thereof as remedies for diabetes and  
hyperlipidemia)

IT Saponification  
(sapon. of heterocyclylpropionic acid esters or of heterocyclylacetic  
acid esters)

IT Carbohydrates, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(tolerance; prepn. and effect of five-membered heterocyclic alkanolic  
acid derivs.)

IT Peroxisome proliferator-activated receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(.delta.; prepn. and effect of five-membered heterocyclic alkanolic acid  
derivs. as remedies for diabetes and hyperlipidemia)

IT **464184-58-5P**  
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN  
(Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(eprepn. of five-membered heterocyclic alkanolic acid derivs. as  
remedies for diabetes and hyperlipidemia)

IT 464184-95-0P  
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT  
(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL  
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES  
(Uses)  
(prepn. of five-membered heterocyclic alkanolic acid derivs. as remedies  
for diabetes and hyperlipidemia)

IT 464184-51-8P 464184-52-9P 464184-53-0P 464184-54-1P 464184-55-2P  
464184-56-3P **464184-57-4P** 464184-59-6P 464184-60-9P  
464184-61-0P 464184-62-1P 464184-63-2P 464184-64-3P 464184-65-4P  
464184-66-5P 464184-67-6P 464184-68-7P 464184-69-8P 464184-70-1P  
464184-71-2P 464184-72-3P 464184-73-4P 464184-74-5P 464184-75-6P  
464184-76-7P 464184-77-8P 464184-78-9P 464184-79-0P 464184-80-3P  
464184-81-4P 464184-82-5P 464184-83-6P 464184-84-7P 464184-85-8P  
464184-86-9P 464184-87-0P 464184-88-1P 464184-89-2P 464184-90-5P  
464184-91-6P 464184-92-7P 464184-93-8P 464184-94-9P  
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN  
(Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological  
study); PREP (Preparation); USES (Uses)

- (prepn. of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)
- IT 464185-47-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)
- IT 62-56-6, Thiourea, reactions 74-88-4, Methyl iodide, reactions 75-03-6, Iodoethane 100-39-0, Benzyl bromide 105-53-3, Diethyl malonate 109-01-3, N-Methylpiperazine 110-91-8, Morpholine, reactions 541-41-3, Ethyl chloroformate 598-52-7, N-Methylthiourea 631-61-8, Ammonium acetate 637-89-8, 4-Hydroxythiophenol 867-13-0, Ethyl diethylphosphonoacetate 927-67-3, N-Propylthiourea 1070-34-4, Succinic acid monoethyl ester 1140-69-8 1501-04-8 1875-19-0 1885-14-9, Phenyl chlorocarbonate 3747-74-8, 2-Chloromethylquinoline hydrochloride 3950-18-3 4142-98-7 5308-25-8, N-Ethylpiperazine 7726-95-6, Bromine, reactions 10068-07-2, 3-Hydroxyisoxazole-5-carboxylic acid methyl ester 14199-15-6, Methyl 4-hydroxyphenylacetate 18197-26-7, Diformamide sodium salt 19172-47-5, Lawesson's reagent 23780-13-4, 2-Phenyl-4-thiazolylmethanol 33252-28-7, 6-Chloro-3-cyanopyridine 36635-61-7, p-Toluenesulfonylmethylisocyanide 53266-94-7 58481-11-1, 2-Chloro-4-pyridinecarboxylic acid methyl ester 70502-03-3, 5-Methyl-2-phenyl-4-oxazolylmethanol 73781-91-6 84756-89-8 103626-03-5 103788-61-0, 4-Chloromethyl-5-methyl-2-phenyloxazole 141399-54-4 157169-76-1, 2-(5-Methyl-2-phenyl-4-oxazolylmethoxy)pyridine-5-carbaldehyde 250602-53-0, 4-(4-Chloromethylphenoxymethyl)-5-methyl-2-phenyloxazole 250602-91-6 250603-02-2, 4-(4-Chloromethyl-2-methoxyphenoxymethyl)-2-(2-furyl)-5-methyloxazole 250603-04-4, 4-(4-Chloromethyl-2-methoxyphenoxymethyl)-5-methyl-2-phenyloxazole 334018-22-3, (5-Methyl-2-phenyl-4-thiazolyl)methanol 342024-43-5, [2-(2-Furyl)-5-methyl-4-oxazolyl]methanol 441356-85-0, 4-Methoxymethoxymethyl-2-phenyloxazole-5-carbaldehyde 464185-84-0 464185-85-1 464185-86-2 464185-87-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)
- IT 111493-88-0P 142484-33-1P 205534-87-8P 339269-10-2P, 2-(5-Methyl-2-phenyl-4-oxazolylmethoxy)pyridine-5-methanol 339269-11-3P, 5-Chloromethyl-2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine 342024-08-2P 342024-09-3P, (1-Benzyl-3-benzyloxy-1H-pyrazol-4-yl)methanol 342024-10-6P 342024-11-7P 342024-12-8P 342024-21-9P, 2-(5-Methyl-2-phenyl-4-oxazolylmethoxy)-4-pyridinecarboxylic acid methyl ester 342024-22-0P, 2-(5-Methyl-2-phenyl-4-oxazolylmethoxy)-4-pyridylmethanol 342024-23-1P, 4-Chloromethyl-2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine 342024-30-0P 342024-32-2P, 3-(5-Methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolecarboxylic acid methyl ester 342024-34-4P, 3-(5-Methyl-2-phenyl-4-oxazolylmethoxy)-5-isoxazolylmethanol 342024-35-5P, 5-Chloromethyl-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)isoxazole 342024-51-5P 342024-52-6P, 3-(2-Quinolylmethoxy)-5-isoxazolylmethanol 342024-53-7P 342024-56-0P 342024-58-2P, 5-Chloromethyl-2-(2-phenyl-4-thiazolylmethoxy)pyridine 342024-63-9P, 6-[2-(2-Furyl)-5-methyl-4-oxazolylmethoxy]nicotinaldehyde 342024-64-0P, 6-[2-(2-Furyl)-5-methyl-4-oxazolylmethoxy]-3-pyridylmethanol 342024-65-1P, 5-Chloromethyl-2-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]pyridine 342024-95-7P, 1-Benzyl-3-benzyloxy-1H-pyrazol-4-ylacetonitrile 342024-96-8P 342024-97-9P 342028-31-3P, 5-Chloromethyl-2-(5-methyl-2-phenyl-4-thiazolylmethoxy)pyridine 383678-42-0P 441357-23-9P, 6-(5-Methyl-2-phenyl-4-thiazolylmethoxy)nicotinonitrile 441357-24-0P, 6-(5-Methyl-2-phenyl-4-

thiazolylmethoxy)nicotinaldehyde 441357-25-1P, 6-(5-Methyl-2-phenyl-4-thiazolylmethoxy)-3-pyridylmethanol 441357-26-2P, 6-[2-(2-Furyl)-5-methyl-4-oxazolylmethoxy]nicotinonitrile 464184-96-1P 464184-97-2P  
 464184-98-3P 464184-99-4P 464185-00-0P 464185-01-1P 464185-02-2P  
 464185-03-3P 464185-04-4P 464185-05-5P 464185-06-6P 464185-07-7P  
 464185-08-8P 464185-09-9P 464185-10-2P 464185-11-3P 464185-12-4P  
 464185-13-5P 464185-14-6P 464185-15-7P 464185-16-8P 464185-17-9P  
 464185-18-0P 464185-19-1P 464185-20-4P 464185-21-5P 464185-22-6P  
 464185-23-7P 464185-24-8P 464185-25-9P 464185-26-0P 464185-27-1P  
 464185-28-2P 464185-29-3P 464185-30-6P 464185-31-7P 464185-32-8P,  
 3-[2-[N-(Methyl)amino]-4-phenyl-5-thiazolyl]propionic acid methyl ester  
 464185-33-9P 464185-34-0P 464185-35-1P 464185-36-2P 464185-37-3P  
 464185-38-4P 464185-39-5P 464185-40-8P 464185-41-9P 464185-42-0P  
 464185-43-1P 464185-44-2P 464185-45-3P 464185-46-4P 464185-48-6P  
 464185-49-7P 464185-50-0P 464185-51-1P 464185-52-2P 464185-53-3P  
 464185-54-4P 464185-55-5P 464185-56-6P 464185-57-7P 464185-58-8P  
 464185-59-9P 464185-60-2P 464185-61-3P 464185-62-4P 464185-63-5P  
 464185-64-6P 464185-65-7P 464185-66-8P 464185-67-9P 464185-68-0P  
 464185-69-1P 464185-70-4P 464185-71-5P 464185-72-6P 464185-73-7P  
 464185-74-8P 464185-75-9P 464185-76-0P 464185-77-1P 464185-78-2P  
 464185-79-3P 464185-80-6P 464185-81-7P 464185-82-8P 464185-83-9P  
 464189-62-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (resistance; prepn. and effect of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)

RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Aventis Pharmaceuticals Products Inc; WO 0064876 A1 2000 HCAPLUS
- (2) Aventis Pharmaceuticals Products Inc; EP 1177176 A1 2000 HCAPLUS
- (3) Aventis Pharmaceuticals Products Inc; BR 200010126 A 2000
- (4) Aventis Pharmaceuticals Products Inc; AU 200048070 A 2000
- (5) Aventis Pharmaceuticals Products Inc; CZ 200103834 A3 2000
- (6) Aventis Pharmaceuticals Products Inc; NO 200105226 A 2000
- (7) Bristol-Myers Squibb Co; WO 0121602 A1 2001 HCAPLUS
- (8) Bristol-Myers Squibb Co; AU 2020075935 A 2001
- (9) Eli Lilly And Co; JP 10508030 A 1996
- (10) Eli Lilly And Co; US 5641796 A 1996 HCAPLUS
- (11) Eli Lilly And Co; EP 789570 A1 1996 HCAPLUS
- (12) Eli Lilly And Co; AU 9539719 A 1996 HCAPLUS
- (13) Eli Lilly And Co; WO 9613264 A1 1996 HCAPLUS
- (14) Glaxo Group Ltd; WO 0008002 A1 2000 HCAPLUS
- (15) Glaxo Group Ltd; EP 1102757 A1 2000 HCAPLUS
- (16) Glaxo Group Ltd; CN 1321152 A 2000
- (17) Glaxo Group Ltd; CZ 200100490 A3 2000
- (18) Glaxo Group Ltd; NO 200100628 A 2000
- (19) Glaxo Group Ltd; HU 200103469 A2 2000
- (20) Glaxo Group Ltd; KR 2001085340 A 2000
- (21) Glaxo Group Ltd; SK 200200196 A3 2000
- (22) Glaxo Group Ltd; BR 9912866 A 2000 HCAPLUS
- (23) Glaxo Group Ltd; AU 9957310 A 2000 HCAPLUS
- (24) Glaxo Group Ltd; WO 0117994 A1 2001 HCAPLUS
- (25) Glaxo Group Ltd; AU 200071153 A 2001
- (26) Ono Pharmaceutical Co Ltd; EP 1067109 A1 2001 HCAPLUS
- (27) Ono Pharmaceutical Co Ltd; KR 2001034586 A 2001
- (28) Ono Pharmaceutical Co Ltd; AU 9932759 A 2001 HCAPLUS


(29) Ono Pharmaceutical Co Ltd; WO 9946232 A1 2001 HCAPLUS  
(30) Takeda Chemical Industries Ltd; JP 07101945 A 1994 HCAPLUS  
(31) Takeda Chemical Industries Ltd; JP 07165735 A 1994 HCAPLUS  
(32) Takeda Chemical Industries Ltd; CN 1098411 A 1994 HCAPLUS  
(33) Takeda Chemical Industries Ltd; JP 2000191651 A 1994 HCAPLUS  
(34) Takeda Chemical Industries Ltd; JP 2000212174 A 1994 HCAPLUS  
(35) Takeda Chemical Industries Ltd; CA 2116387 A 1994 HCAPLUS  
(36) Takeda Chemical Industries Ltd; US 5665748 A 1994 HCAPLUS  
(37) Takeda Chemical Industries Ltd; US 5972970 A 1994 HCAPLUS  
(38) Takeda Chemical Industries Ltd; EP 612743 A1 1994 HCAPLUS  
(39) Takeda Chemical Industries Ltd; EP 612743 A1 1994 HCAPLUS  
(40) Takeda Chemical Industries Ltd; US 6147099 A 1994 HCAPLUS  
(41) Takeda Chemical Industries Ltd; NO 9400610 A 1994 HCAPLUS  
(42) Takeda Chemical Industries Ltd; FI 9400904 A 1994 HCAPLUS  
(43) Takeda Chemical Industries Ltd; ZA 9401321 A 1994 HCAPLUS  
(44) Takeda Chemical Industries Ltd; AU 9455158 A 1994 HCAPLUS  
(45) Takeda Chemical Industries Ltd; CN 1124246 A 1995 HCAPLUS  
(46) Takeda Chemical Industries Ltd; CA 2125549 A 1995 HCAPLUS  
(47) Takeda Chemical Industries Ltd; US 5591862 A 1995 HCAPLUS  
(48) Takeda Chemical Industries Ltd; EP 629624 A 1995 HCAPLUS  
(49) Takeda Chemical Industries Ltd; JP 753555 A 1995  
(50) Takeda Chemical Industries Ltd; NO 9404386 A 1995  
(51) Takeda Chemical Industries Ltd; FI 94053314 A 1995  
(52) Takeda Chemical Industries Ltd; ZA 9408919 A 1995 HCAPLUS  
(53) Takeda Chemical Industries Ltd; AU 9477684 A 1995 HCAPLUS  
(54) Takeda Chemical Industries Ltd; JP 09124623 A 1996 HCAPLUS  
(55) Takeda Chemical Industries Ltd; JP 09194467 A 1996 HCAPLUS  
(56) Takeda Chemical Industries Ltd; CN 1129698 A 1996 HCAPLUS  
(57) Takeda Chemical Industries Ltd; CA 2161944 A 1996 HCAPLUS  
(58) Takeda Chemical Industries Ltd; US 5932601 A 1996 HCAPLUS  
(59) Takeda Chemical Industries Ltd; EP 710659 A1 1996 HCAPLUS  
(60) Takeda Chemical Industries Ltd; NO 9504369 A 1996 HCAPLUS  
(61) Takeda Chemical Industries Ltd; BR 9505051 A 1996 HCAPLUS  
(62) Takeda Chemical Industries Ltd; FI 9505235 A 1996 HCAPLUS  
(63) Takeda Chemical Industries Ltd; ZA 9509204 A 1996 HCAPLUS  
(64) Takeda Chemical Industries Ltd; AU 9536607 A 1996 HCAPLUS  
(65) Takeda Chemical Industries Ltd; EP 1077957 A1 1999 HCAPLUS  
(66) Takeda Chemical Industries Ltd; CN 1300285 A 1999  
(67) Takeda Chemical Industries Ltd; MX 2000010576 A1 1999  
(68) Takeda Chemical Industries Ltd; SK 200001641 A3 1999  
(69) Takeda Chemical Industries Ltd; CZ 200004104 A3 1999  
(70) Takeda Chemical Industries Ltd; NO 200005531 A 1999  
(71) Takeda Chemical Industries Ltd; ZA 200006121 A 1999  
(72) Takeda Chemical Industries Ltd; JP 2000198772 A 1999 HCAPLUS  
(73) Takeda Chemical Industries Ltd; JP 200034266 A 1999  
(74) Takeda Chemical Industries Ltd; KR 2001021523 A 1999  
(75) Takeda Chemical Industries Ltd; HU 200103714 A2 1999  
(76) Takeda Chemical Industries Ltd; US 6251926 B1 1999 HCAPLUS  
(77) Takeda Chemical Industries Ltd; BR 9910371 A 1999 HCAPLUS  
(78) Takeda Chemical Industries Ltd; AU 9936297 A 1999 HCAPLUS  
(79) Takeda Chemical Industries Ltd; WO 9958510 A1 1999 HCAPLUS  
(80) Takeda Chemical Industries Ltd; WO 0001679 A1 2000 HCAPLUS  
(81) Takeda Chemical Industries Ltd; EP 1177176 A1 2000 HCAPLUS  
(82) Takeda Chemical Industries Ltd; BR 200010126 A 2000  
(83) Takeda Chemical Industries Ltd; AU 200048070 A 2000  
(84) Takeda Chemical Industries Ltd; CZ 200103834 A3 2000  
(85) Takeda Chemical Industries Ltd; NO 200105266 A 2000  
(86) Takeda Chemical Industries Ltd; WO 0138325 A1 2001 HCAPLUS  
(87) Takeda Chemical Industries Ltd; AU 200113031 A 2001  
(88) Takeda Chemical Industries Ltd; JP 2001226350 A 2001 HCAPLUS

IT 464184-58-5P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (eprepn. of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)

RN 464184-58-5 HCAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]propylamino]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:504648 HCAPLUS

DN 137:83637

TI Medicinal compositions containing diuretic and insulin resistance-improving agent

IN Takaoka, Masaya; Araki, Kazushi; Kanda, Shoichi

PA Sankyo Company, Limited, Japan

SO PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

IC ICM A61K045-06

ICS A61P003-10; A61P043-00; A61K031-433; A61K031-343; A61K031-4965;  
 A61K031-427; A61K031-4439; A61K031-421; A61K031-422; A61K031-4709

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051441	A1	20020704	WO 2001-JP11296	20011221
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
JP 2002255854	A2	20020911	JP 2001-386861	20011220
PRAI JP 2000-394424	A	20001226		

OS MARPAT 137:83637

AB Disclosed are medicinal compns. contg. a diuretic and an insulin resistance-improving agent whereby side effects assocg. the administration of an insulin resistance-improving agent (for example, megalocardia, edema, body fluid retention, pleural effusion) can be prevented or treated. Oral administration of furosemide prevented increases of heart wt. and blood plasma, and edema due to administration of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione hydrochloride.

ST insulin resistance improving agent diuretic; diuretic antidiabetic side effect prevention

IT Body fluid  
Pleura  
(effusion, prevention of; medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT Heart, disease  
(hypertrophy, prevention of; medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT Antidiabetic agents  
Diabetes mellitus  
Diuretics  
(medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT Antidiabetic agents  
Drug delivery systems  
(oral; medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT Edema  
(prevention of; medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT 179068-64-5, NC 2100  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(NC 2100; medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT 299176-11-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT 54-31-9, Furosemide 2609-46-3, Amiloride  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT 185428-18-6P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT 52-01-7, Spironolactone 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 59-66-5, Acetazolamide 77-36-1, Chlortalidone 133-67-5, Trichlormethiazide 135-07-9, Methyclothiazide 135-09-1, Hydroflumethiazide 396-01-0, Triamterene 652-67-5, Isosorbide 742-20-1, Cyclopenthiazide 1766-91-2, Penflutizide 1824-50-6, Benzylhydrochlorothiazide 2181-04-6, Potassium canrenoate 7195-27-9, Mefruside 17560-51-9, Metolazone 27589-33-9, Azosemide 28395-03-1, Bumetanide 55837-27-9, Piretanide 56211-40-6, Torasemide 97322-87-7, Troglitazone 111025-46-8, Pioglitazone 118384-10-4, T-174 122320-73-4, Rosiglitazone 161600-01-7, MCC-555 170861-63-9, JTT-501 196808-45-4, GI 262570 199914-96-0, YM-440 213252-19-8, KRP-297 222834-21-1, NN 622 251565-85-2, AZ-242 331741-94-7, BMS 298585 406701-59-5 406701-61-9 406701-63-1 406701-66-4 406701-68-6 406701-70-0 406701-72-2 406701-74-4 406701-76-6  
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)  
(medicinal compns. contg. diuretics and insulin resistance-improving agents)

IT 79-37-8, Oxalyl chloride 100-39-0, Benzylbromide 106-48-9, 4-Chlorophenol 124-63-0, Methanesulfonyl chloride 371-41-5,

4-Fluorophenol 405-79-8, 4-Fluorophenoxyacetic acid 725-15-5,  
 4'-(4-Fluorophenyl)acetophenone oxime 940-64-7 1798-04-5,  
 4-tert-Butylphenoxyacetic acid 4397-53-9, 4-Benzyloxybenzaldehyde  
 5470-11-1, Hydroxylamine chloride 13021-18-6 17739-45-6 62517-34-4,  
 3-(4-Hydroxyphenyl)lactic acid ethyl ester 90719-32-7,  
 (S)-4-Benzyl-2-oxazolidinone 129139-48-6 178055-46-4 178055-58-8  
 185428-88-0 197298-91-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of medicinal compns. contg. diuretics and insulin  
 resistance-improving agents)

IT 15516-47-9P, 4-Methylphenoxyacetyl chloride 82827-69-8P 141109-83-3P,  
 3-(4-Benzyloxyphenyl)lactic acid ethyl ester 178055-70-4P 197299-17-5P  
 223127-76-2P 223127-82-0P 223127-83-1P 406701-57-3P 406701-60-8P  
 406701-62-0P 406701-69-7P 406701-71-1P 406701-73-3P 406701-75-5P  
 406701-77-7P 406701-78-8P 406701-83-5P 406701-84-6P 406701-85-7P  
 406701-86-8P 406701-87-9P 406701-89-1P 406701-91-5P 406701-94-8P  
 406701-96-0P 406701-98-2P 406708-49-4P 406708-51-8P 406708-52-9P  
 406708-54-1P 406708-56-3P 439946-58-4P 439946-60-8P 439946-79-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of medicinal compns. contg. diuretics and insulin  
 resistance-improving agents)

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (resistance-improving agents; medicinal compns. contg. diuretics and  
 insulin resistance-improving agents)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Sankyo Co Ltd; JP 09295970 A 1996 HCAPLUS
- (2) Sankyo Co Ltd; CN 1157288 A 1996 HCAPLUS
- (3) Sankyo Co Ltd; JP 20001487 A 1996
- (4) Sankyo Co Ltd; CA 2177858 A 1996 HCAPLUS
- (5) Sankyo Co Ltd; EP 745600 A1 1996 HCAPLUS
- (6) Sankyo Co Ltd; NO 9602239 A 1996 HCAPLUS
- (7) Sankyo Co Ltd; ZA 9604518 A 1996 HCAPLUS
- (8) Sankyo Co Ltd; AU 9654627 A1 1996 HCAPLUS
- (9) Takeda Chemical Industries Ltd; WO 0061127 A2 2000 HCAPLUS
- (10) Takeda Chemical Industries Ltd; EP 1169037 A2 2000 HCAPLUS
- (11) Takeda Chemical Industries Ltd; NO 2001004935 A 2000
- (12) Takeda Chemical Industries Ltd; JP 2001355550 A 2000
- (13) Takeda Chemical Industries Ltd; WO 0117513 A2 2001 HCAPLUS
- (14) Takeda Chemical Industries Ltd; JP 2001316292 A 2001 HCAPLUS
- (15) Yamanouchi Pharmaceutical Co Ltd; CN 1196721 A 1997 HCAPLUS
- (16) Yamanouchi Pharmaceutical Co Ltd; CA 2232497 A 1997 HCAPLUS
- (17) Yamanouchi Pharmaceutical Co Ltd; EP 861831 A1 1997 HCAPLUS
- (18) Yamanouchi Pharmaceutical Co Ltd; ZA 9607800 A 1997 HCAPLUS
- (19) Yamanouchi Pharmaceutical Co Ltd; BR 9610530 A 1997 HCAPLUS
- (20) Yamanouchi Pharmaceutical Co Ltd; AU 9670007 A1 1997 HCAPLUS
- (21) Yamanouchi Pharmaceutical Co Ltd; WO 9711055 A1 1997 HCAPLUS
- (22) Yamanouchi Pharmaceutical Co Ltd; NO 9801241 A 1997 HCAPLUS

IT 331741-94-7, BMS 298585

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (medicinal compns. contg. diuretics and insulin resistance-improving  
 agents)

RN 331741-94-7 HCAPLUS



CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2003 ACS  
 AN 2002:502825 HCAPLUS  
 DN 137:63237  
 TI Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents  
 IN Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen, Sean; Zhang, Hao  
 PA Bristol-Myers Squibb Company, USA  
 SO U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-42  
 ICS A61K031-425; C07D277-30; C07D413-04  
 NCL 514374000  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 34  
 FAN.CNT 2

*applicant*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6414002	B1	20020702	US 2001-812960	20010320
PRAI	US 1999-155400P	P	19990922		
	US 2000-664598	A2	20000918		
OS	MARPAT 137:63237				
GI					



AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH<sub>2</sub>)<sub>x</sub>; Z = O, bond; X = CH, N; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, alkyl, alkoxy, halo, amino; R<sub>3</sub> = H, alkyl, aralkyl, aryloxy, carbonyl, alkoxy, carbonyl, aryl, carbonyl, alkyl, carbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxy, arylalkyl, etc.; R<sub>2a</sub>, R<sub>2b</sub>, R<sub>2c</sub> = H,

alkyl, alkoxy, halo, amino; Y = CO<sub>2</sub>R<sub>4</sub>, 1-tetrazolyl, PO(OR<sub>4a</sub>)R<sub>5</sub>; R<sub>4</sub> = H, alkyl, prodrug or ester; R<sub>4a</sub> = H, prodrug ester; R<sub>5</sub> = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepd. as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph<sub>3</sub>P, and DEAD were stirred in THF at 0.degree.-room temp. to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addn. of N-benzylglycine Et ester and NaBH(OAc)<sub>3</sub> in 1,2-dichloroethane afforded the benzylamine deriv. (55%), which was stirred with aq. NaOH in MeOH for 14 h to give the title compd. II (71%). I are useful for the treatment of diabetes, esp. Type II diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases (no data).

- ST oxazolylalkoxybenzylglycine thiazolylalkoxybenzylglycine prepn  
antidiabetic antiobesity antiatherosclerosis agent
- IT Antiarteriosclerotics  
(antiatherosclerotics; prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT Lipids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyperlipidemia; prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT Diabetes mellitus  
(non-insulin-dependent; prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT Antidiabetic agents  
Antiobesity agents  
Atherosclerosis  
Human  
Hyperglycemia  
Hypolipemic agents  
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT 9004-10-8, Insulin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyperinsulinemia; prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT 331746-96-4P, Oxazole, 5-methyl-2-phenyl-4-(2-propenyl)-  
RL: BYP (Byproduct); PREP (Preparation)  
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT **331739-69-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
- IT **331739-67-4P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- **331739-68-5P**, Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331739-70-9P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propynyl- **331739-71-0P**, Glycine, N-2-benzoxazolyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-72-1P**, Glycine, N-2-benzoxazolyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-73-2P**, Glycine,

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- **331739-74-3P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- **331739-75-4P**, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-76-5P**, Glycine,  
 N-[[5-(4-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-77-6P**, Glycine,  
 N-[[4-(3-fluorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-78-7P**, Glycine,  
 N-[[4-(3-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-79-8P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- **331739-80-1P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- **331739-81-2P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenylethyl)- **331739-82-3P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenylpropyl)- **331739-83-4P**, Glycine, N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-84-5P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- **331739-85-6P**, Glycine,  
 N-[(1,1'-biphenyl)-4-ylmethyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-86-7P**, Glycine,  
 N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-87-8P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- **331739-88-9P**, Glycine,  
 N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-89-0P**, Glycine,  
 N-[[3-(4-methoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-90-3P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- **331739-91-4P**, Glycine,  
 N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-92-5P**, Glycine, N-[(2E)-3,7-dimethyl-2,6-octadienyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-93-6P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- **331739-94-7P**, Glycine,  
 N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-95-8P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxy-2-thienyl)methyl]- **331739-96-9P**, Glycine,  
 N-[(2Z)-3-(2-furanyl)-2-propenyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-97-0P**, Glycine,  
 N-[(4-fluorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-98-1P**, Glycine,  
 N-[[2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331739-99-2P**, Glycine,  
 N-[[3-(3,5-dimethoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-00-2P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylmethyl)- **331740-01-3P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- **331740-02-4P**, Glycine, N-(1H-indol-2-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-03-5P**, Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-04-6P**, Glycine,

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl]- **331740-05-7P**,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(3-nitrophenyl)-2-furanyl]methyl]- **331740-06-8P**, Glycine,  
 N-[[5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-07-9P**,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl]- **331740-08-0P**,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-nitrophenyl)-2-furanyl]methyl]- **331740-09-1P**,  
 1H-Pyrrole-2-carboxylic acid, 5-[[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-,  
 2-(phenylmethyl) ester **331740-10-4P**, Glycine,  
 N-[[5-(4-bromophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-11-5P**, Glycine,  
 N-[[5-(3-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-12-6P**, Glycine,  
 N-[[5-(1,3-dioxolan-2-yl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-13-7P**, Glycine,  
 N-[[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-14-8P**,  
 Glycine, N-[[5-(2,4-dichlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-15-9P**, Glycine,  
 N-[[4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-16-0P**,  
 Glycine, N-[[4-benzoyl-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-17-1P**,  
 Glycine, N-[[2,2'-bithiophen]-5-ylmethyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-18-2P**, Glycine,  
 N-[[5-bromo-3,4-dimethylthieno[2,3-b]thien-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-19-3P**,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(phenylethynyl)-2-thienyl]methyl]- **331740-20-6P**, Glycine,  
 N-[[4-(2,4-dichlorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-21-7P**,  
 Glycine, N-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-22-8P**,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylethynyl)-2-thienyl]methyl]- **331740-23-9P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-nitro-4-phenoxyphenyl]methyl]- **331740-24-0P**, Glycine,  
 N-[[3-methyl-4-phenoxyphenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-25-1P**, Glycine,  
 N-[[3-chloro-4-phenoxyphenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-26-2P**, Glycine,  
 N-[[2-chloro-4-phenoxyphenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-27-3P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitro-3-phenoxyphenyl]methyl]- **331740-28-4P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-nitro-5-phenoxyphenyl]methyl]- **331740-29-5P**, Glycine,  
 N-[[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-30-8P**,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]- **331740-31-9P**,  
 Glycine, N-[[6-methoxy-2-naphthalenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-32-0P**,  
 Glycine, N-[[4-methoxy-1-naphthalenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

**331740-33-1P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl]- **331740-34-2P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]-  
**331740-35-3P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]-  
**331740-36-4P**, Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-37-5P**, Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-38-6P**, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-39-7P**, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-40-0P**, Glycine, N-[(3,5-dimethoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-41-1P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- **331740-42-2P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- **331740-43-3P**, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-44-4P**, Glycine, N-[[3-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-45-5P**, Glycine, N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-46-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- **331740-47-7P**, Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-48-8P**, Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-49-9P**, Glycine, N-[[3-[4-(1,1-dimethylethyl)phenoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-50-2P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- **331740-51-3P**, Glycine, N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-52-4P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenyl)methyl]- **331740-53-5P**, Glycine, N-[[4-(3-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-54-6P**, Glycine, N-[[4-(4-bromophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-55-7P**, Glycine, N-[[4-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-56-8P**, Glycine, N-[[4-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-57-9P**, Glycine, N-[[4-(4-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-58-0P**, Glycine, N-[[4-(2-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-59-1P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- **331740-60-4P**, Glycine, N-[[4-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-61-5P**, Glycine, N-[[4-(4-fluorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331740-62-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]- **331740-63-7P**, Glycine,

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[4-(methylthio)phenoxy]phenyl]methyl]- 331740-64-8P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxy-2-thienyl)methyl]- 331740-65-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- 331740-66-0P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-nitrophenoxy)phenyl]methyl]- 331740-67-1P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylamino)phenyl]methyl]- 331740-68-2P, Glycine,  
 N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-69-3P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(4-pyridinyl)phenyl]methyl]- 331740-70-6P, Glycine,  
 N-[[4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-71-7P, Glycine,  
 N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-72-8P, Glycine,  
 N-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-73-9P, Glycine,  
 N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-74-0P, Glycine,  
 N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-75-1P, Glycine,  
 N-[[4-(3-furanyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-76-2P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- 331740-77-3P, Glycine,  
 N-[(3-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-78-4P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- 331740-79-5P, Glycine,  
 N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-80-8P, Glycine,  
 N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-81-9P, Glycine,  
 N-[(2-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-82-0P, Glycine,  
 N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-83-1P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- 331740-84-2P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- 331740-85-3P, Glycine,  
 N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-86-4P, Glycine,  
 N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-87-5P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- 331740-88-6P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- 331740-89-7P, Glycine,  
 N-(1H-indol-2-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-90-0P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1R)-1-phenylethyl]- 331740-91-1P  
 , D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-92-2P, D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-93-3P, D-Alanine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-

phenoxyphenyl)methyl]- **331740-94-4P**, D-Phenylalanine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-  
 phenoxyphenyl)methyl]- **331740-95-5P**, L-Phenylalanine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-  
 phenoxyphenyl)methyl]- **331740-96-6P**, D-Valine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-  
 phenoxyphenyl)methyl]- **331740-97-7P**, Acetic acid,  
 (2,2-dimethylpropoxy)[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl][(4-phenoxyphenyl)methyl]amino]-, (2R)-  
**331740-98-8P**, D-Serine, N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methyl]-  
**331740-99-9P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethoxy)carbonyl]-  
**331741-00-5P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethoxy)carbonyl]-  
**331741-01-6P**, Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-  
 methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-02-7P**,  
 Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-03-8P**, Glycine,  
 N-[[3-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-04-9P**, Glycine,  
 N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-05-0P**, Glycine,  
 N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-06-1P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-  
 (phenylmethoxy)phenoxy]carbonyl]- **331741-07-2P**, Glycine,  
 N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-08-3P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-  
 (phenoxy)carbonyl]- **331741-09-4P**, Glycine, N-[(4-chloro-3-  
 fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-10-7P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-  
 phenoxyphenyl)methoxy]carbonyl]- **331741-11-8P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-  
 propynyloxy)carbonyl]- **331741-12-9P**, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-13-0P**, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-14-1P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-  
 nitrophenoxy)carbonyl]- **331741-15-2P**, Glycine,  
 N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- **331741-16-3P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-  
 nitrophenyl)methoxy]carbonyl]- **331741-17-4P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-  
 nitrophenoxy)carbonyl]- **331741-18-5P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-  
 phenoxyphenoxy)carbonyl]- **331741-19-6P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-  
 phenoxyphenyl)methoxy]carbonyl]- **331741-20-9P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-  
 phenoxyphenyl)methoxy]carbonyl]- **331741-21-0P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-  
 phenoxyphenoxy)carbonyl]- **331741-22-1P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-  
 phenoxyphenoxy)carbonyl]- **331741-23-2P**, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-

phenoxyethoxy)carbonyl]- 331741-24-3P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-25-4P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenyl-2-propynyl]oxy]carbonyl]- 331741-26-5P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenylethoxy)carbonyl]- 331741-27-6P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenylpropoxy)carbonyl]- 331741-28-7P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-29-8P, Glycine,  
 N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-30-1P, Glycine,  
 N-[(3-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-31-2P, Glycine,  
 N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-32-3P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- 331741-33-4P, Glycine,  
 N-[[3-methoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-34-5P, Glycine,  
 N-[[4-methoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-35-6P, Glycine,  
 N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-36-7P, Glycine,  
 N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-37-8P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331741-38-9P, Glycine,  
 N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-39-0P, Glycine,  
 N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-40-3P, Benzoic acid,  
 4-[[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester  
 331741-41-4P, Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
 331741-42-5P, Glycine, N-[[4-(1,3-dithiolan-2-yl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
 331741-43-6P, Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
 331741-44-7P, Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-45-8P,  
 Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-46-9P, Glycine,  
 N-[(4-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-47-0P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331741-48-1P, Glycine,  
 N-[(3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-49-2P, Glycine,  
 N-[(3-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-50-5P, Glycine,  
 N-[(3-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-51-6P, Glycine,  
 N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-52-7P, Glycine,  
 N-[(4-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-53-8P, Glycine,  
 N-[(3-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

oxazolyl)ethoxy]phenyl)methyl]- 331741-54-9P, Glycine,  
N-[[[2,3-dihydro-3-oxo-6-benzofuranyl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-55-0P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331741-56-1P, Glycine,  
N-[(3-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-57-2P, Glycine,  
N-[(3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-58-3P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331741-59-4P, Glycine,  
N-[(4-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-60-7P, Glycine,  
N-[(3-ethoxy-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-61-8P, Glycine,  
N-[(4-cyclopentylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-63-0P, Glycine,  
N-[(4-ethenylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-64-1P, Glycine,  
N-[[4-(3-methylbutyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-65-2P, Glycine,  
N-[(4-butylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-66-3P, Glycine,  
N-[(4-hexylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-67-4P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(4-morpholinyl)phenoxy]carbonyl]- 331741-68-5P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331741-69-6P, Glycine,  
N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-70-9P, Glycine,  
N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-71-0P, Glycine,  
N-[(3,4-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-72-1P, Glycine,  
N-[(3,5-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-73-2P, Glycine,  
N-[(3-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-74-3P, Glycine,  
N-[[4-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-75-4P, Glycine,  
N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-76-5P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- 331741-77-6P, Glycine,  
N-[(4-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-78-7P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-propylphenoxy)carbonyl]- 331741-79-8P, Glycine,  
N-[[[2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-80-1P, Glycine,  
N-[(3-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-81-2P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-pentylphenoxy)carbonyl]- 331741-82-3P, Glycine,  
N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-83-4P, Glycine,  
N-[[3-(3-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-84-5P, Glycine,  
N-[[3-(3-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU**  
(**Therapeutic use**); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related  
compds. as antidiabetic and antiobesity agents)

IT **331741-85-6P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- **331741-86-7P**, Glycine, N-[[[4-fluorophenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-87-8P**, Glycine, N-[[[4-chlorophenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-88-9P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- **331741-89-0P**, Glycine, N-[[[3,5-dimethoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-90-3P**, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-91-4P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[3-phenoxyphenyl]methoxy]carbonyl]- **331741-92-5P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-propynyloxy)carbonyl]- **331741-93-6P**, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-94-7P**, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331741-95-8P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-nitrophenoxy)carbonyl]- **331741-96-9P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxy carbonyl)- **331741-97-0P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[4-nitrophenyl]methoxy]carbonyl]- **331741-98-1P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitrophenoxy)carbonyl]- **331741-99-2P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenoxy)carbonyl]- **331742-00-8P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[2-phenoxyphenyl]methoxy]carbonyl]- **331742-01-9P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[4-phenoxyphenyl]methoxy]carbonyl]- **331742-02-0P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenoxy)carbonyl]- **331742-03-1P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyphenoxy)carbonyl]- **331742-04-2P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyethoxy)carbonyl]- **331742-05-3P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- **331742-06-4P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[3-phenyl-2-propynyl]oxy]carbonyl]- **331742-07-5P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenylethoxy)carbonyl]- **331742-08-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenylpropoxy)carbonyl]- **331742-09-7P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- **331742-10-0P**, Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- **331742-11-1P**, Glycine, N-[(3-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331742-12-2P, Glycine,  
 N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-13-3P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- 331742-14-4P, Glycine,  
 N-[(3-acetylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-15-5P, Glycine,  
 N-[[4-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-16-6P, Glycine,  
 N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-17-7P, Glycine,  
 N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-18-8P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331742-19-9P, Glycine,  
 N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-20-2P, Glycine,  
 N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-21-3P, Benzoic acid,  
 4-[[[(carboxymethyl)[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]amino]carbonyl]oxy]-, 1-methyl ester  
 331742-22-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-  
 331742-23-5P, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-24-6P,  
 Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-25-7P, Glycine,  
 N-[(4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-26-8P, Glycine,  
 N-[(4-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-27-9P, Glycine,  
 N-[(4-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-28-0P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331742-29-1P, Glycine,  
 N-[(3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-30-4P, Glycine,  
 N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-31-5P, Glycine,  
 N-[(3-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-32-6P, Glycine,  
 N-[(3,5-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-33-7P, Glycine,  
 N-[(3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-34-8P, Glycine,  
 N-[(3-chloro-4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-35-9P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331742-36-0P, Glycine,  
 N-[(4-chloro-3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-37-1P, Glycine,  
 N-[(3,4-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-38-2P, Glycine,  
 N-[(4-ethenylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-39-3P, Glycine,  
 N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-40-6P, Glycine,  
 N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-41-7P, Glycine,  
 N-[[3-methyl-4-(methylthio)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331742-42-8P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(1H-  
 pyrrol-1-yl)phenoxy]carbonyl]- 331742-43-9P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5,6,7,8-  
 tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331742-44-0P, Glycine,  
 N-[[[1,1'-biphenyl]-3-yloxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-45-1P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-  
 (trifluoromethyl)phenoxy]carbonyl]- 331742-46-2P, Glycine,  
 N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-47-3P, Glycine,  
 N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-48-4P, Glycine,  
 N-[[3,4-dimethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-49-5P, Glycine,  
 N-[[3,5-dimethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-50-8P, Glycine,  
 N-[[3-ethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-51-9P, Glycine,  
 N-[[4-chloro-3-methylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-52-0P, Glycine,  
 N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-53-1P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-  
 (phenylmethyl)phenoxy]carbonyl]- 331742-54-2P, Glycine,  
 N-[[4-ethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-55-3P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-  
 propylphenoxy]carbonyl]- 331742-56-4P, Glycine,  
 N-[[2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-57-5P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-  
 naphthalenyloxy]carbonyl]- 331742-58-6P, Glycine,  
 N-[[3-ethoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-59-7P, Glycine,  
 N-[[3,5-dichlorophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-60-0P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(1,2,3-  
 thiadiazol-4-yl)phenoxy]carbonyl]- 331742-61-1P, Glycine,  
 N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-62-2P, Glycine,  
 N-[[3-methoxy-5-methylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-63-3P, Glycine,  
 N-[[3-fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-64-4P, Glycine,  
 N-[[3-chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-65-5P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[3-  
 (trifluoromethoxy)phenyl)methoxy]carbonyl]- 331742-66-6P,  
 Glycine, N-[[[4-fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-67-7P, Glycine,  
 N-[[[4-chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-68-8P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[4-  
 (trifluoromethoxy)phenyl)methoxy]carbonyl]- 331742-69-9P,  
 Glycine, N-[[[3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-70-2P, Glycine,  
 N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331742-71-3P, Glycine,  
 N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331742-72-4P, Glycine,  
N-[(3-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-73-5P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxythioxomethyl)- 331742-74-6P, Glycine,  
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxythioxomethyl)- 331742-75-7P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(4-phenoxybenzoyl)- 331742-76-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-naphthalenylcarbonyl)- 331742-77-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-thienylcarbonyl)- 331742-78-0P, Glycine, N-(3,5-dimethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-79-1P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(1-naphthalenylcarbonyl)- 331742-80-4P, Glycine,  
N-(3,4-difluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-81-5P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(3-phenoxybenzoyl)- 331742-82-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[4-(phenylmethyl)benzoyl]- 331742-83-7P, Glycine, N-(3,5-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-84-8P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-85-9P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(5-methyl-2-thienyl)carbonyl]- 331742-86-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(5-nitro-2-thienyl)carbonyl]- 331742-87-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-methyl-2-thienyl)carbonyl]- 331742-88-2P, Glycine, N-(4-butoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-89-3P, Glycine,  
N-(4-methoxy-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-90-6P, Glycine,  
N-(3-chloro-4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-91-7P, Glycine,  
N-(3,4-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-92-8P, Glycine,  
N-(4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-93-9P, Glycine,  
N-(3-fluoro-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-94-0P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[4-(methylthio)benzoyl]- 331742-95-1P, Glycine,  
N-[4-(1-methylethyl)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-96-2P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[4-(2-methylpropyl)benzoyl]- 331742-97-3P, Glycine,  
N-(4-chloro-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-98-4P, Glycine,  
N-(3-methoxy-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-99-5P, Glycine,  
N-(1,3-benzodioxol-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-00-1P, Glycine,  
N-[4-(1-methylethoxy)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-02-3P, Glycine,  
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(3-thienylcarbonyl)- 331743-04-5P, Glycine, N-benzoyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-05-6P, Glycine, N-(3-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl)methyl]- 331743-06-7P, Glycine,  
 N-(4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-07-8P, Glycine,  
 N-(3,4-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-08-9P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(4-  
 propoxybenzoyl)- 331743-09-0P, Glycine, N-(4-ethoxybenzoyl)-N-  
 [[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-  
 331743-10-3P, Glycine, N-(3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-11-4P, Glycine,  
 N-(4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-12-5P, Glycine,  
 N-(3-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-13-6P, Glycine,  
 N-(4-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-14-7P, Glycine,  
 N-(4-butylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-15-8P, Glycine,  
 N-(3,5-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-16-9P, Glycine,  
 N-(3-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-17-0P, Glycine,  
 N-(3-chloro-4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-18-1P, Glycine,  
 N-(3-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-19-2P, Glycine,  
 N-[(5-chloro-2-thienyl)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-20-5P  
 , Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5-  
 (methylthio)-2-thienyl]carbonyl]- 331743-21-6P, Glycine,  
 N-[(4-methylphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-22-7P, Glycine,  
 N-[(3-fluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-23-8P, Glycine,  
 N-[(3,5-difluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-24-9P, Glycine,  
 N-(1,3-benzodioxol-5-ylacetyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-25-0P, Glycine,  
 N-[(4-ethoxyphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]- 331743-26-1P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-  
 nitrophenyl)acetyl]- 331743-27-2P, Glycine, N-[[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitrophenyl)acetyl]-  
 331743-28-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-(1-oxo-3-phenylpropyl)-  
 331743-29-4P, Glycine, N-([1,1'-biphenyl]-2-ylcarbonyl)-N-[[4-[2-  
 (5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-30-7P  
 , Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-  
 (4-phenoxybenzoyl)- 331743-31-8P, Glycine, N-[[4-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[2-(phenylmethyl)benzoyl]-  
 331743-32-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-[3-(phenylsulfinyl)benzoyl]-  
 331743-33-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-[2-[(4-methylphenyl)thio]benzoyl]-  
 331743-34-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-N-[2-(phenylsulfinyl)benzoyl]-  
 331743-35-2P, Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-  
 methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331743-36-3P,  
 Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-  
 phenoxybenzoyl)- 331743-37-4P, Glycine, N-([1,1'-biphenyl]-4-

ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-38-5P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- **331743-39-6P**  
 , Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-  
 [(2-phenoxyphenyl)acetyl]- **331743-40-9P**, Glycine,  
 N-([1,1'-biphenyl]-4-ylacetyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-41-0P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- **331743-42-1P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(1H-pyrrol-1-yl)benzoyl]- **331743-43-2P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)acetyl]- **331743-44-3P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)acetyl]- **331743-45-4P**, Glycine,  
 N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-46-5P**, Glycine,  
 N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-47-6P**, Glycine,  
 N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-48-7P**, Glycine,  
 N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-49-8P**, Glycine,  
 N-(3,4-dichlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-50-1P**, Glycine,  
 N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-51-2P**, Glycine,  
 N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-52-3P**, Glycine,  
 N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-53-4P**, Glycine,  
 N-[4-(1-methylethyl)benzoyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331743-54-5P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- **331743-55-6P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- **331743-56-7P**, Glycine, N-(4-butylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-57-8P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]-  
**331743-58-9P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-59-0P**, Glycine, N-[[4-(methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-60-3P**, Glycine, N-[[4-(methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-61-4P**, Glycine, N-[[([1,1'-biphenyl]-4-ylamino)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-62-5P**, Glycine, N-[[3,5-dimethoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-63-6P**, Glycine, N-[[3,5-dichlorophenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-64-7P**, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(methylthio)phenyl]amino]carbonyl]-  
**331743-65-8P**, Glycine, N-[[2,4-difluorophenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-66-9P**, Glycine, N-[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331743-67-0P**, Glycine, N-[[2-methoxyphenyl]amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

331743-68-1P, Glycine, N-[[[1,1'-biphenyl]-4-ylamino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-69-2P, Glycine, N-[[[3,5-dimethoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-70-5P, Glycine, N-[[[3,5-dichlorophenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-71-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(methylthio)phenyl]amino]carbonyl]-  
331743-72-7P, Glycine, N-[[[2,4-difluorophenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-73-8P, Glycine, N-[[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-74-9P, Glycine, N-[[[4-methoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-75-0P, Glycine, N-[[[2-methoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-76-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)-  
331743-77-2P, Glycine, N-[[[4-fluorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
331743-78-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- 331743-79-4P, Glycine, N-[[2,5-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-80-7P, Glycine, N-[[4-fluorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-81-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[phenylmethyl]sulfonyl]- 331743-82-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(1E)-2-phenylethenyl]sulfonyl]- 331743-83-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2,2,2-trifluoroethyl]sulfonyl]- 331743-84-1P, Glycine, N-[[2,5-dimethylphenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-85-2P, Glycine, N-[[3,4-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-86-3P, Glycine, N-[[2,5-dichloro-3-thienyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-87-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-pyridinylsulfonyl)-2-thienyl]sulfonyl]- 331743-88-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 331743-89-6P, Glycine, N-[[[3-methylphenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-90-9P, Glycine, N-[[[2-fluorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-91-0P, Glycine, N-[[4-chlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-92-1P, Glycine, N-[[[3,4-dichlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-93-2P, Glycine, N-[[[2-chloro-6-fluorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-94-3P, Glycine, N-[[[4-chlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-95-4P, Glycine, N-[[[2-chlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-96-5P, Glycine, N-[[[2,4-dichlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-97-6P, Glycine, N-[[[2-methylphenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-98-7P, Glycine,

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- **331743-99-8P**,  
 Glycine, N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-00-4P**,  
 Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-propylphenyl]sulfonyl]- **331744-01-5P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylsulfonyl)- **331744-02-6P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- **331744-03-7P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- **331744-04-8P**, Glycine,  
 N-[(4-chlorophenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-05-9P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)sulfonyl]- **331744-06-0P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[1E)-2-phenylethenyl]sulfonyl]- **331744-07-1P**, Glycine,  
 N-[(2,5-dimethylphenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-08-2P**, Glycine,  
 N-[(3,4-dichlorophenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-09-3P**, Glycine,  
 N-[[4-(2-chloro-6-nitrophenoxy)phenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT **331744-10-6P**, Glycine, N-(2-dibenzofuranylsulfonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-11-7P**,  
 Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- **331744-12-8P**,  
 Glycine, N-[[[3-methylphenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-13-9P**, Glycine,  
 N-[[[2-fluorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-14-0P**, Glycine,  
 N-[[[4-fluorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-15-1P**, Glycine,  
 N-[[[3,4-dichlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-16-2P**, Glycine,  
 N-[[[2-chloro-6-fluorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-17-3P**, Glycine,  
 N-[[[4-chlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-18-4P**, Glycine,  
 N-[[[2-chlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-19-5P**, Glycine,  
 N-[[[2,4-dichlorophenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-20-8P**, Glycine,  
 N-[[[2-methylphenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-21-9P**, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- **331744-22-0P**,  
 Glycine, N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-23-1P**, Glycine,  
 N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-N-[[4-phenoxyphenyl]methyl]- **331744-24-2P**, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[[4-phenoxyphenyl]methyl]- **331744-25-3P**, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[[4-phenoxyphenyl]methyl]-

**331744-26-4P**, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-  
**331744-27-5P**, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[(phenylmethoxy)carbonyl]-  
**331744-28-6P**, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-(phenylmethyl)- **331744-29-7P**, Carbamic acid, [[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl](1H-tetrazol-5-ylmethyl)-, 4-methoxyphenyl ester **331744-30-0P**, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-31-1P**, .beta.-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-32-2P**, .beta.-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-33-3P**, .beta.-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- **331744-34-4P**, .beta.-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- **331744-35-5P**, .beta.-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- **331744-36-6P**, .beta.-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- **331744-37-7P**, .beta.-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- **331744-38-8P**, .beta.-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- **331744-39-9P**, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-40-2P**, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-41-3P**, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-42-4P**, Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-43-5P**, Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-44-6P**, Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-45-7P**, Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-46-8P**, Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-47-9P**, Glycine, N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-48-0P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-propylphenoxy)carbonyl]- **331744-49-1P**, Glycine, N-[(4-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-50-4P**, Glycine, N-[[4-(cyclopropyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-51-5P**, Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-52-6P**, Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-53-7P**, Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-54-8P**, Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-55-9P**, Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-56-0P**, Glycine,

N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-57-1P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-propylphenoxy)carbonyl]- 331744-58-2P, Glycine,  
 N-[(3-cyclopropylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-59-3P, Glycine,  
 N-[(4-cyclopropylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-60-6P, Glycine,  
 N-[[4-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-61-7P, Benzoic acid,  
 2-(carboxymethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide 331744-62-8P, Benzoic acid,  
 2-(carboxymethyl)-2-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide 331744-63-9P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-64-0P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-65-1P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-66-2P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]- 331744-67-3P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]- 331744-68-4P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]- 331744-69-5P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]- 331744-70-8P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]- 331744-71-9P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]cyclopropyl]- 331744-72-0P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-73-1P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-74-2P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]- 331744-75-3P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]- 331744-76-4P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[3-methyl-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]- 331744-77-5P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-78-6P, Glycine,  
 N-[(3-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-79-7P, Glycine,  
 N-[(3-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-80-0P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-81-1P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-82-2P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-83-3P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-84-4P, Alanine,  
 N-[(4-methoxyphenoxy)carbonyl]-2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-85-5P,  
 Cyclopropanecarboxylic acid, 1-[[[4-(methoxyphenoxy)carbonyl][4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]-

**331744-86-6P**, Cyclopropanecarboxylic acid, 1-[[[4-methylphenoxy) carbonyl][[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- **331744-87-7P**, L-Alanine, N-[[4-(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-88-8P**, L-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy) carbonyl]- **331744-89-9P**, D-Alanine, N-[[4-(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-90-2P**, D-Alanine, N-[[4-(4-methylphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-91-3P**, D-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy) carbonyl]- **331744-92-4P**, Cyclopropanecarboxylic acid, 1-[[[4-(4-methoxyphenoxy) carbonyl][[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- **331744-93-5P**, Cyclopropanecarboxylic acid, 1-[[[4-(4-methylphenoxy) carbonyl][[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- **331744-94-6P**, Alanine, N-[(4-methoxyphenoxy) carbonyl]-2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-95-7P**, D-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-96-8P**, D-Alanine, N-[(4-methylphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-97-9P**, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy) carbonyl]- **331744-98-0P**, L-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331744-99-1P**, L-Alanine, N-[(4-methylphenoxy) carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331745-00-7P**, L-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy) carbonyl]- **331745-01-8P**, L-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-02-9P**, D-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-03-0P**, L-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-04-1P**, D-Alanine, N-[(4-methoxyphenoxy) carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- **331745-05-2P**, Glycine, N-[(4-methylphenoxy) carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-06-3P**, Glycine, N-[(4-methylphenoxy) carbonyl]-N-[[4-[5-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- **331745-07-4P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- **331745-08-5P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-09-6P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[[(2Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-2-propenyl]oxy]phenyl]methyl]- **331745-10-9P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[3-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-11-0P**, Glycine, N-[(4-methylphenoxy) carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-12-1P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- **331745-13-2P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[5-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- **331745-14-3P**, Glycine, N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-N-[(4-methylphenoxy) carbonyl]- **331745-15-4P**, Glycine, N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)propoxy]phenyl)methyl]- 331745-16-5P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- 331745-17-6P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- 331745-18-7P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- 331745-19-8P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- 331745-20-1P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl)methyl]- 331745-21-2P, Glycine,  
 N-[(4-methylphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl)methyl]- 331745-22-3P, Glycine,  
 N-(5-methyl-2-benzoxazolyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331745-23-4P, Glycine,  
 N-(5-methyl-2-benzoxazolyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331745-24-5P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- 331745-25-6P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]- 331745-26-7P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]- 331745-27-8P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl)methyl]- 331745-28-9P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]- 331745-29-0P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1,2-propadienyl]phenyl)methyl]- 331745-30-3P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-31-4P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1R,2R)-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]cyclopropyl]phenyl)methyl]-, rel- 331745-32-5P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-33-6P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethoxy)carbonyl]- 331745-34-7P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methyl]- 331745-35-8P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-(4-pyridinyl)-4-thiazolyl]ethoxy]phenyl)methyl]- 331745-36-9P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-1,2-propadienyl]phenyl)methyl]- 331745-37-0P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]- 331745-38-1P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl)methyl]- 331745-39-2P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-40-5P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]- 331745-41-6P, Glycine,  
 N-[[4-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- 331745-42-7P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]phenyl)methyl]- 331745-43-8P, Glycine,  
 N-[[3-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-44-9P  
 , Glycine, N-[[3-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-45-0P, Glycine, N-[[4-[2-[2-(2-chlorophenyl)-5-methyl-4-

oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-  
**331745-46-1P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(oxophenylacetyl)- **331745-47-2P**  
 , Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(oxophenylacetyl)- **331745-48-3P**, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(3-phenoxyphenyl)methyl]-  
**331745-49-4P**, Glycine, N-[[4-(4-methoxyphenyl)thio]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
**331745-60-9P**, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- **331745-69-8P**  
 , Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1S)-1-phenylethyl]- **331745-80-3P**, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, mono(trifluoroacetate) **331745-86-9P**, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, mono(trifluoroacetate) **331746-91-9P**, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[3-methyl-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]- **331746-92-0P**, Glycine, N-[[4-(4-methoxyphenyl)thio]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **331746-93-1P**, L-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- **331746-95-3P**, Glycine, N-(6-methyl-2-benzoxazolyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- **439276-48-9P**  
**439276-49-0P 439276-50-3P 439276-51-4P**  
**439276-54-7P 439276-55-8P 439276-57-0P**  
**439276-58-1P 439276-59-2P 439276-61-6P**  
**439276-62-7P 439579-19-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 65-85-0, Benzoic acid, reactions 66-99-9, 2-Naphthaldehyde 67-36-7, 4-Phenoxybenzaldehyde 85-46-1, 1-Naphthalenesulfonyl chloride 90-05-1, 2-Methoxyphenol 93-09-4, 2-Naphthalenecarboxylic acid 94-53-1, Piperonylic acid 96-32-2, Methyl bromoacetate 98-88-4, Benzoyl chloride 100-83-4, 3-Hydroxybenzaldehyde 102-29-4, Resorcinol monoacetate 103-16-2, 4-Benzyloxyphenol 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide 121-71-1, Ethanone, 1-(3-hydroxyphenyl)- 123-08-0, 4-Hydroxybenzaldehyde 151-18-8, 2-Cyanoethylamine 455-91-4, 3'-Fluoro-4'-methoxyacetophenone 501-53-1, Benzyl chloroformate 527-72-0, 2-Thiophenecarboxylic acid 591-35-5, 3,5-Dichlorophenol 615-18-9, 2-Chlorobenzoxazole 621-84-1, Benzyl carbamate 623-33-6, Glycine ethyl ester hydrochloride 626-02-8, 3-Iodophenol 626-55-1, 3-Bromopyridine 766-85-8, 3-Iodoanisole 768-35-4, 3-Fluorophenylboronic acid 815-60-1, 2,4-Dibromo-3-pentanone 937-62-2, 4-Methylphenyl chloroformate 1005-56-7, Phenyl chlorothionoformate 1066-54-2, Trimethylsilylacetylene 1132-21-4, 3,5-Dimethoxybenzoic acid 1700-37-4, 3-Benzyloxybenzaldehyde 2215-77-2, p-Phenoxybenzoic acid 2589-71-1, 1-Pentanone, 1-(4-hydroxyphenyl)- 2627-86-3, (S)-.alpha.-Methylbenzylamine 2835-98-5, Phenol, 2-amino-5-methyl- 3173-56-6, Benzyl isocyanate 3403-25-6 3424-93-9, 4-Methoxybenzamide 3886-69-9, Benzenemethanamine, .alpha.-methyl-, (.alpha.R)- 4949-44-4, Ethyl propionylacetate 5292-43-3, tert-Butyl bromoacetate 5345-54-0, 3-Chloro-4-methoxyaniline 5416-93-3, 4-Methoxyphenyl isocyanate 5680-79-5, Glycine methyl ester hydrochloride 5961-59-1, N-Methyl-p-anisidine 6436-90-4, N-Benzylglycine ethyl ester 6945-92-2, Ethyl hydrazinoacetate hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 7699-00-5,

Propanoic acid, 2-hydroxy-, ethyl ester, (2R)- 7745-91-7,  
 3-Bromo-4-methylaniline 15028-41-8, Methyl .alpha.-aminoisobutyrate  
 hydrochloride 15894-04-9, 4-Fluorobenzyl mercaptan 16728-01-1,  
 Cyclopropanecarboxylic acid, 1-(4-methoxyphenyl)- 19621-92-2,  
 2-Hydroxypyridine-6-carboxylic acid 22038-86-4, (R)-1-(4-  
 Methoxyphenyl)ethylamine 27492-46-2, Oxazole, 4,5-dimethyl-2-phenyl-,  
 3-oxide 27532-96-3, Glycine tert-butyl ester hydrochloride 30414-53-0,  
 Methyl propionylacetate 34035-03-5, 2-Furancarboxaldehyde,  
 5-(4-chlorophenyl)- 41851-59-6, (S)-1-(4-Methoxyphenyl)ethylamine  
 50428-03-0, 4-Pentynoic acid, 2-amino- 50868-72-9, Benzenamine,  
 5-methoxy-2-methyl- 59531-86-1 64318-28-1, Carbamic acid,  
 [2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester 66171-50-4, Methyl  
 2-hydroxypyridine-5-carboxylate 81228-89-9, Carbonochloridic acid,  
 (3-methoxyphenyl)methyl ester 87199-17-5, 4-Formylphenylboronic acid  
 103788-65-4, 4-Oxazoleethanol, 5-methyl-2-phenyl- 107367-98-6,  
 2-Phenyl-5-methyloxazole-4-acetic acid 164660-78-0, Phenol,  
 3-[(trimethylsilyl)ethynyl]-, acetate 175136-30-8, 4-Thiazoleethanol,  
 5-methyl-2-phenyl- 182913-11-7, Glycine, N-[(2-hydroxyphenyl)methyl]-,  
 methyl ester 331746-63-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-64-6,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-,  
 methyl ester 331746-65-7, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-66-8, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-,  
 mono(trifluoroacetate) 331746-68-0, Glycine, N-[[3-  
 (difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-69-1,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-  
 phenoxybenzoyl)-, 1,1-dimethylethyl ester 331746-70-4, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-  
 naphthalenylcarbonyl)-, 1,1-dimethylethyl ester 331746-71-5, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-  
 naphthalenylsulfonyl)-, 1,1-dimethylethyl ester 331746-72-6,  
 3-Pyridinemethanol, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-  
 331746-73-7, Benzenesulfonamide, N-[2-[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]ethyl]-2,4-dinitro- 331746-74-8, .beta.-Alanine,  
 N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-75-9, Glycine,  
 N-(chlorocarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-76-0, Glycine,  
 N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-78-2, Glycine,  
 N-[(1S)-1-(4-methoxyphenyl)ethyl]-, methyl ester 331746-80-6, Glycine,  
 N-[(1R)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, ethyl  
 ester 331746-81-7, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, ethyl ester 331746-82-8, Glycine,  
 N-[(4-hydroxyphenyl)methyl]-, methyl ester 331746-83-9, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-2-  
 propynyl]oxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-84-0,  
 Glycine, N-[(4-iodophenyl)methyl]-, methyl ester 331746-85-1, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1Z)-3-(5-methyl-2-phenyl-4-  
 oxazolyl)-1-propenyl]phenyl]methyl]-, methyl ester 331746-86-2, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1R,2R)-2-[(5-methyl-2-phenyl-4-  
 oxazolyl)methyl]cyclopropyl]phenyl]methyl]-, methyl ester, rel-  
 331746-87-3, Glycine, N-[(4-hydroxyphenyl)methyl]-N-  
 [(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester 331746-88-4,  
 Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-  
 [(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester 331746-89-5,  
 Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-  
 [(4-phenoxyphenyl)methyl]-, methyl ester 331746-90-8, Glycine,

N-[(4-hydroxyphenyl)methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related  
 compds. as antidiabetic and antiobesity agents)

IT 405-06-1P, Benzene, 2-fluoro-4-methoxy-1-methyl- 452-78-8P, Phenol,  
 3-fluoro-4-methyl- 621-27-2P, 3-Propylphenol 768-70-7P, Benzene,  
 1-ethynyl-3-methoxy- 2293-75-6P, 2-Methoxyphenyl chloroformate  
 2454-30-0P, Phenol, 3-ethenyl-, acetate 3621-83-8P, Benzoxazole,  
 2-chloro-6-methyl- 4847-94-3P, Piperonylamide 10401-12-4P, Phenol,  
 3-ethynyl-, acetate 18093-12-4P, 3-Chloro-4-methoxyphenol 23417-29-0P,  
 2(3H)-Benzoxazolethione, 6-methyl- 28857-88-7P, Phenol, 3-cyclopropyl-  
 30062-34-1P, 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-, methyl ester  
 36187-69-6P, Ethyl 4-bromo-3-oxopentanoate 42861-71-2P, Phenol, 3-iodo-,  
 acetate 52177-62-5P, 3-Methoxyphenyl chloroformate 52177-75-0P,  
 Carbonochloridic acid, 4-(phenylmethoxy)phenyl ester 60710-39-6P,  
 3-Bromo-4-methylphenol 62103-69-9P, Benzene, 1-methoxy-3-propyl-  
 68331-44-2P, Propanoic acid, 2-[(methylsulfonyl)oxy]-, ethyl ester, (2R)-  
 70170-23-9P, 4-Oxazolecarboxaldehyde, 5-methyl-2-phenyl- 72934-40-8P,  
 Cyclopropanamine, 1-(4-methoxyphenyl)- 74067-76-8P, 1-Penten-3-one,  
 4-bromo- 103360-04-9P, 4-Fluorobenzylsulfonyl chloride 103788-59-6P,  
 Benzaldehyde, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 103788-61-0P,  
 Oxazole, 4-(chloromethyl)-5-methyl-2-phenyl- 103788-64-3P,  
 4-Oxazoleacetic acid, 5-methyl-2-phenyl-, methyl ester 105983-77-5P,  
 Pentanoic acid, 4-bromo-3-oxo-, methyl ester 136058-69-0P,  
 4-Oxazoleethanol, 2-(4-methoxyphenyl)-5-methyl- 137208-84-5P, Ethanol,  
 2-[3-(phenylmethoxy)phenoxy]- 140130-09-2P, Benzamide,  
 N-(1-acetyl-3-butynyl)- 140130-10-5P, Oxazole, 5-methyl-2-phenyl-4-(2-  
 propynyl)- 157169-61-4P, 3-Pyridinecarboxaldehyde, 6-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]- 174258-60-7P, Ethanone, 1-[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl]- 196810-26-1P, 4-Oxazoleacetic acid,  
 2-(4-methoxyphenyl)-5-methyl-, methyl ester 223562-18-3P, Benzene,  
 1-methoxy-3-(1-propynyl)- 227029-27-8P, 4-Oxazoleethanol,  
 5-methyl-2-phenyl-, methanesulfonate (ester) 244152-94-1P, Benzaldehyde,  
 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 258346-53-1P,  
 4-Oxazolepropanol, 5-methyl-2-phenyl- 258346-54-2P, 4-  
 Oxazolepropanenitrile, 5-methyl-2-phenyl- 331745-61-0P, Glycine,  
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-  
 (phenylmethyl)-, ethyl ester 331745-62-1P, Glycine, N,N-bis[[4-[2-(5-  
 methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester  
 331745-63-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester 331745-64-3P, Glycine,  
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-,  
 1,1-dimethylethyl ester 331745-65-4P, Glycine, N-[[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-,  
 1,1-dimethylethyl ester 331745-66-5P, Glycine, N-[[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331745-67-6P, Glycine,  
 N-[(4-hydroxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-68-7P,  
 Glycine, N-[(4-boronophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, 1-(1,1-dimethylethyl) ester  
 331745-70-1P, Benzenemethanamine, .alpha.-methyl-N-[[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, (.alpha.S)- 331745-71-2P,  
 Glycine, N-(chlorocarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-72-3P,  
 Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-  
 [[4-(phenylmethoxy)phenoxy]carbonyl]-, 1,1-dimethylethyl ester  
 331745-73-4P, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester  
 331745-74-5P, Carbonochloridic acid, 3-(acetyloxy)phenyl ester  
 331745-75-6P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-

methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, 1,1-dimethylethyl ester  
 331745-76-7P, Glycine, N-[[[(4-methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-  
 methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester  
 331745-77-8P, Glycine, N-[[[(4-methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-  
 (5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester  
 331745-78-9P, 3-Pyridinecarboxylic acid, 6-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]-, methyl ester 331745-79-0P, Glycine,  
 N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl)methyl]-,  
 methyl ester 331745-81-4P, 2-Pyridinecarboxylic acid,  
 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester 331745-82-5P,  
 2-Pyridinemethanol, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-  
 331745-83-6P, 2-Pyridinecarboxaldehyde, 6-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]- 331745-84-7P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]-2-pyridinyl)methyl]-, methyl ester 331745-85-8P,  
 Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-  
 pyridinyl)methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester  
 331745-87-0P, Carbamic acid, [2-[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-88-1P,  
 Glycine, N-[(2,4-dinitrophenyl)sulfonyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-89-2P,  
 Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-,  
 1,1-dimethylethyl ester 331745-90-5P, Carbamic acid,  
 [2-[(2-cyanoethyl)amino]-2-oxoethyl][[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-, 4-methoxyphenyl ester 331745-91-6P,  
 Carbamic acid, [[1-(2-cyanoethyl)-1H-tetrazol-5-yl]methyl][[4-[2-(5-methyl-  
 2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, 4-methoxyphenyl ester  
 331745-92-7P, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, methyl ester 331745-93-8P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-, methyl ester 331745-94-9P, Phenol,  
 3-cyclopropyl-, acetate 331745-95-0P, Glycine, N-[(3-  
 cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]-, methyl ester 331745-96-1P, Acetic acid,  
 [3-(phenylmethoxy)phenoxy]-, ethyl ester 331745-97-2P, Benzene,  
 1-(2-bromoethoxy)-3-(phenylmethoxy)- 331745-98-3P, Benzene,  
 1-(ethenyloxy)-3-(phenylmethoxy)- 331745-99-4P, Benzene,  
 1-(cyclopropyloxy)-3-(phenylmethoxy)- 331746-00-0P, Phenol,  
 3-(cyclopropyloxy)- 331746-01-1P, Carbonochloridic acid,  
 3-fluoro-4-methylphenyl ester 331746-02-2P, Carbonochloridic acid,  
 3-bromo-4-methylphenyl ester 331746-03-3P, Benzoic acid,  
 2-(carboxymethyl)hydrazide 331746-04-4P, Benzoic acid,  
 2-(2-ethoxy-2-oxoethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl)methyl]hydrazide 331746-05-5P, Oxazole,  
 4-[2-[3-(bromomethyl)phenoxy]ethyl]-5-methyl-2-phenyl- 331746-06-6P,  
 Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-,  
 methyl ester 331746-07-7P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-  
 [3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester  
 331746-08-8P, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, methyl ester  
 331746-09-9P, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, methyl ester 331746-10-2P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-11-3P, 1-Pentanone,  
 1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- 331746-12-4P,  
 Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]-,  
 methyl ester 331746-13-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-  
 [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl  
 ester 331746-14-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-  
 (5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]-, methyl ester  
 331746-15-7P, 4-Thiazoleethanol, 5-methyl-2-phenyl-, methanesulfonate  
 (ester) 331746-16-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-

[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]-, ethyl ester  
 331746-17-9P, Glycine, N-[1-(4-methoxyphenyl)cyclopropyl]-, methyl ester  
 331746-18-0P, Glycine, N-[1-(4-hydroxyphenyl)cyclopropyl]-, methyl ester  
 331746-19-1P, Glycine, N-[1-(4-hydroxyphenyl)cyclopropyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, methyl ester 331746-20-4P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]cyclopropyl]-, methyl ester 331746-21-5P,  
 Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-22-6P, Alanine,  
 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
 331746-23-7P, L-Alanine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-, methyl ester  
 331746-24-8P, L-Alanine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-, methyl ester  
 331746-25-9P, L-Alanine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, methyl ester 331746-26-0P, L-Alanine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-  
 oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-27-1P,  
 4-Oxazolepropanoic acid, 5-methyl-2-phenyl-, ethyl ester 331746-28-2P,  
 4-Oxazolepropanol, 5-methyl-2-phenyl-, methanesulfonate (ester)  
 331746-29-3P, Benzaldehyde, 4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]-  
 331746-30-6P, Glycine, N-[[4-[3-(5-methyl-2-phenyl-4-  
 oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-31-7P, Glycine,  
 N-[(4-hydroxyphenyl)methyl]-N-[(4-methylphenoxy)carbonyl]-, methyl ester  
 331746-32-8P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[(5-methyl-2-  
 phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, methyl ester 331746-33-9P,  
 Oxazole, 4-(2,2-dibromoethenyl)-5-methyl-2-phenyl- 331746-34-0P,  
 2-Propyn-1-ol, 3-(5-methyl-2-phenyl-4-oxazolyl)- 331746-35-1P,  
 2-Propyn-1-ol, 3-(5-methyl-2-phenyl-4-oxazolyl)-, methanesulfonate (ester)  
 331746-36-2P, Benzaldehyde, 4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-  
 propynyl]oxy]- 331746-37-3P, Glycine, N-[[4-[[3-(5-methyl-2-phenyl-4-  
 oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-38-4P,  
 Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[3-(5-methyl-2-phenyl-4-  
 oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-39-5P,  
 4-Oxazoleacetic acid, .alpha.,5-dimethyl-2-phenyl-, methyl ester  
 331746-40-8P, 4-Oxazoleacetic acid, .alpha.,.alpha.,5-trimethyl-2-phenyl-,  
 methyl ester 331746-41-9P, 4-Oxazoleethanol, .beta.,.beta.,5-trimethyl-2-  
 phenyl- 331746-42-0P, Benzaldehyde, 4-[2-methyl-2-(5-methyl-2-phenyl-4-  
 oxazolyl)propoxy]- 331746-43-1P, Glycine, N-[[4-[2-methyl-2-(5-methyl-2-  
 phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-44-2P,  
 Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-methyl-2-(5-methyl-2-  
 phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-45-3P,  
 Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(2Z)-3-(5-methyl-2-phenyl-  
 4-oxazolyl)-2-propenyl]oxy]phenyl]methyl]-, 1,1-dimethylethyl ester  
 331746-46-4P, Benzaldehyde, 3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-  
 propynyl]oxy]- 331746-47-5P, Glycine, N-[[3-[[3-(5-methyl-2-phenyl-4-  
 oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-48-6P,  
 Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-  
 oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-50-0P,  
 4-Oxazoleethanol, 2-(4-methoxyphenyl)-5-methyl-, methanesulfonate (ester)  
 331746-51-1P, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, methyl ester 331746-52-2P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-  
 oxazolyl]ethoxy]phenyl]methyl]-, methyl ester 331746-53-3P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[[3-(5-methyl-2-phenyl-4-  
 oxazolyl)-2-propynyl]oxy]phenyl]ethyl]-, ethyl ester 331746-54-4P,  
 Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[[3-(5-methyl-2-  
 phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]-, ethyl ester  
 331746-55-5P, Glycine, N-[(4-iodophenyl)methyl]-N-[(4-  
 methoxyphenoxy)carbonyl]-, methyl ester 331746-56-6P, Glycine,  
 N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-  
 propynyl]phenyl]methyl]-, methyl ester 331746-57-7P, Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]-, methyl ester 331746-58-8P, Oxazole, 4-(3-bromo-2-propynyl)-5-methyl-2-phenyl- 331746-59-9P, Oxazole, 5-methyl-2-phenyl-4-[3-(tributylstannyl)-2-propenyl]- 331746-60-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, methyl ester 331746-61-3P, Glycine, N-[[4-[(4-bromo-3-oxopentyl)oxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-62-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-(4-pyridinyl)-4-thiazolyl]ethoxy]phenyl]methyl]-, methyl ester 331746-67-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-77-1P, Carbonochloridic acid, 3-chloro-4-methylphenyl ester 331746-79-3P, Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester 331746-94-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)amino]carbonyl]-, ethyl ester 439276-63-8P 439573-59-8P 439573-60-1P 439573-63-4P 439573-65-6P 439573-66-7P 439573-67-8P 439573-68-9P 439573-69-0P 439573-70-3P 439573-71-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 439573-86-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Anon; WO 9222533 1992 HCAPLUS
- (2) Anon; EP 0520723 B1 1994 HCAPLUS
- (3) Anon; WO 9638415 1996 HCAPLUS
- (4) Anon; WO 9727847 1997 HCAPLUS
- (5) Anon; WO 9727857 1997 HCAPLUS
- (6) Anon; WO 9728137 1997 HCAPLUS
- (7) Anon; WO 9728149 1997 HCAPLUS
- (8) Anon; WO 9731907 1997 HCAPLUS
- (9) Anon; WO 9800137 1998 HCAPLUS
- (10) Anon; WO 9800403 1998 HCAPLUS
- (11) Anon; WO 9827974 1998 HCAPLUS
- (12) Anon; WO 9907357 1999 HCAPLUS
- (13) Anon; WO 9908501 1999 HCAPLUS
- (14) Anon; WO 9911255 1999 HCAPLUS
- (15) Anon; WO 9915520 1999 HCAPLUS
- (16) Anon; WO 9916758 1999 HCAPLUS
- (17) Anon; WO 9920275 1999 HCAPLUS
- (18) Anon; WO 9946232 1999 HCAPLUS
- (19) Anon; WO 0008002 2000 HCAPLUS
- (20) Anon; WO 0064876 2000 HCAPLUS
- (21) Anon; WO 0064888 2000 HCAPLUS
- (22) Cobb; J Med Chem 1998, V41, P5055 HCAPLUS
- (23) Collins; J Med Chem 1998, V41, P5037 HCAPLUS
- (24) Henke; J Med Chem 1998, V41, P5020 HCAPLUS

IT 331739-69-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331739-69-6 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-  
(9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:315133 HCAPLUS

DN 136:336180

TI Diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms

IN Hosford, David; Purvis, Ian James

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12Q001-68

ICS A61K031-54; A61K031-427

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 14

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002033121	A2	20020425	WO 2001-GB4660	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095752	A5	20020429	AU 2001-95752	20011019
PRAI GB 2000-25678	A	20001019		
WO 2001-GB4660	W	20011019		

OS MARPAT 136:336180

AB The invention provides a method of diagnosing diabetes or susceptibility to diabetes in an individual, comprising typing (i) the insulin receptor gene region or (ii) the insulin receptor protein of the individual. The invention also provides a diagnostic kit that comprises a polynucleotide, probe, primer, antibody (including an antibody fragment) or agent as defined herein. The invention also provides a nonhuman animal which has diabetes (typically type II diabetes) or is susceptible to diabetes and which is also transgenic for a polymorphism as mentioned above. The invention provides a method for treating a patient who has been diagnosed as having or being susceptible to diabetes by a method of the invention, comprising administering an effective amt. of an anti-diabetes agent or an agent that prevents the development of diabetes to the patient. The inventors have shown that naturally occurring polymorphisms in the insulin receptor are functional. These functional polymorphisms are assocd. with

migraine, a condition that is overrepresented in diabetics. The inventors isolated 48 single-nucleotide polymorphisms within the locus, of which we genotyped in a Caucasian population comprising 827 unrelated cases and 765 controls. Five single-nucleotide polymorphisms within the insulin receptor gene showed significant assocn. with migraine. This assocn. was independently replicated in a case-control population collected sep.

ST diabetes genotyping insulin receptor gene single nucleotide polymorphism  
IT Antidiabetic agents  
Diabetes mellitus.  
Genetic polymorphism  
Genotyping (method)  
Susceptibility (genetic)  
Test kits  
(diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Insulin receptors  
RL: ANT (Analyte); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)  
(diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Diagnosis  
(genetic; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Gene, animal  
RL: ANT (Analyte); ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)  
(insulin receptor; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Headache  
(migraine; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Diagnosis  
(mol.; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Diabetes mellitus  
(non-insulin-dependent; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Genetic polymorphism  
(single nucleotide; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Animal  
(transgenic; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT Electrophoresis  
(use for SNP anal.; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT 196808-45-4 196809-22-0 **258345-41-4 258346-02-0**  
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)  
(diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT 417737-36-1, 1: PN: WO0233121 SEQID: 1 unclaimed DNA 417737-37-2, 2: PN: WO0233121 SEQID: 2 unclaimed DNA 417737-38-3, 3: PN: WO0233121 SEQID: 3 unclaimed DNA 417737-39-4, 4: PN: WO0233121 SEQID: 4 unclaimed DNA 417737-40-7, 5: PN: WO0233121 SEQID: 5 unclaimed DNA 417737-41-8, 6: PN: WO0233121 SEQID: 6 unclaimed DNA 417737-42-9, 7: PN: WO0233121 SEQID: 7 unclaimed DNA 417737-43-0, 8: PN: WO0233121 SEQID: 8 unclaimed DNA 417737-44-1, 9: PN: WO0233121 SEQID: 9 unclaimed DNA 417737-45-2  
417737-46-3 417737-47-4 417737-48-5 417737-49-6 417737-50-9  
417737-51-0 417737-52-1 417737-53-2 417737-54-3 417737-55-4  
417737-56-5 417737-57-6 417737-58-7 417737-59-8 417737-60-1

417737-62-3, 28: PN: WO0233121 TABLE: 2 unclaimed DNA

RL: PRP (Properties)

(unclaimed nucleotide sequence; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT 417737-61-2 417737-63-4 417737-64-5 417737-65-6 417737-66-7  
 417737-67-8 417737-68-9 417737-69-0 417737-70-3 417737-71-4  
 417737-72-5 417737-73-6 417737-74-7 417737-75-8 417737-76-9  
 417737-77-0 417737-78-1 417737-79-2 417737-80-5 417737-81-6  
 417737-82-7 417737-83-8 417737-84-9 417737-85-0 417737-86-1  
 417737-87-2 417737-88-3 417737-89-4 417737-90-7 417737-91-8  
 417737-92-9 417737-93-0 417737-94-1 417737-95-2 417737-96-3  
 417737-97-4 417737-98-5 417737-99-6 417738-00-2 417738-01-3  
 417738-02-4 417738-03-5 417738-04-6 417738-05-7 417738-06-8  
 417738-07-9 417738-08-0 417738-09-1 417738-10-4 417738-11-5  
 417738-12-6 417738-13-7 417738-14-8

RL: PRP (Properties)

(unclaimed sequence; diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

IT 258345-41-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)

RN 258345-41-4 HCAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



L7 ANSWER 7 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:10261 HCAPLUS

DN 136:74645

TI Novel process for preparing crystalline pharmaceutical particles or carrier substances of a size suitable for inhalation therapy

IN Lancaster, Robert William; Singh, Hardev; Theophilus, Andrew Lewis

PA Glaxo Group Ltd., UK

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-16

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000200	A1	20020103	WO 2001-GB2936	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				

RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001067708 A5 20020108 AU 2001-67708 20010629

PRAI GB 2000-16002 A 20000629

WO 2001-GB2936 W 20010629

AB The present invention relates to a novel process for prepg. cryst. particles of a salt of a substance, particularly, pharmaceutical particles or carrier substances of a size suitable for inhalation therapy. Thus, a calcium salt of (2S)-2-{[(Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]amino}-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid (I) was prepd. under sono-crystn. conditions by treatment with CaCl<sub>2</sub> soln. The slurry was collected on a filter under continuous flow conditions. The filter cake was washed with water and then diisopropyl ether to give an easily handleable solid. This was dried to give cryst. calcium salt of I as the monohydrate.

ST inhalation therapy pharmaceutical particle cryst

IT Drug delivery systems

(inhalants; prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

IT Drug delivery systems

(oral; prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

IT Drug delivery systems

(particles; prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

IT Particle size distribution

(prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

IT **353239-32-4P 384818-03-5P**

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

IT 13392-18-2, Fenoterol 18559-94-9, Salbutamol 23031-25-6, Terbutaline 38677-81-5, Pirbuterol 51022-70-9, Salbutamol sulfate 54063-54-6, Reproterol 60205-81-4, Ipratropium 73573-87-2, Formoterol 89365-50-4, Salmeterol 94749-08-3, Salmeterol xinafoate 121679-13-8, Naratriptan 143388-64-1, Naratriptan hydrochloride 210237-78-8 278598-52-0 278598-83-7

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

IT **258345-41-4**

RL: RCT (Reactant); **THU (Therapeutic use)**; BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Astra Aktiebolag; WO 9632095 A 1996 HCAPLUS

(2) Bristol-Myers, S; WO 0044468 A 2000 HCAPLUS

(3) Dso Pharmachim; NL 7501406 A 1976 HCAPLUS

(4) Glaxo Group; WO 0038811 A 2000 HCAPLUS


IT **353239-32-4P**

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (prepn. of cryst. pharmaceutical particles or carrier substances of suitable for inhalation therapy)

RN 353239-32-4 HCAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



● 1/2 Ca

L7 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:581856 HCAPLUS

DN 135:152795

TI Process for synthesis of oxazolethoxyphenylpropanoic acid derivative for use as NIDDM medicament

IN Davis, Roman; Kennedy, Andrew

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D263-32

ICS A61K031-42; A61P003-10

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057001	A1	20010809	WO 2001-EP1041	20010201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI GB 2000-2667	A	20000204		
AB Process for synthesis of calcium salt of (2S)-2-([(Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]amino)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid and physiologically acceptable solvates thereof, useful as NIDDM medicament is disclosed.				
ST oxazolethoxyphenylpropanoic acid calcium salt prepn; noninsulin dependent				

diabetes mellitus oxazolethoxyphenylpropanoic acid calcium salt

IT Lipids, biological studies  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (dyslipidemia; synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT Diabetes mellitus  
 (non-insulin-dependent; synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT Hyperglycemia  
 (synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT Peroxisome proliferator-activated receptors  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (.alpha.; synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT Peroxisome proliferator-activated receptors  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (.gamma.; synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT **353239-32-4P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT 93-91-4, Benzoylacetone 3978-80-1 42406-77-9, L-Tyrosine benzyl ester 103788-65-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

IT 227029-27-8P 258345-41-4P 353239-33-5P 353239-34-6P 353239-35-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


(1) Glaxo Group Ltd; WO 0008002 A 2000 HCAPLUS  
 (2) Ligand Pharm Inc; WO 9805331 A 1998 HCAPLUS  
 (3) Pfizer; WO 9119702 A 1991 HCAPLUS  
 (4) Sumitomo Metal Ind; WO 9638415 A 1996 HCAPLUS

IT **353239-32-4P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis of oxazolethoxyphenylpropanoic acid deriv. for NIDDM medicament)

RN 353239-32-4 HCAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.



●1/2 Ca

L7 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2003 ACS  
 AN 2001:228872 HCAPLUS  
 DN 134:266299  
 TI Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents.  
 IN Cheng, Peter T. W.; Devasthale, Pratik; Jeon, Yoon T.; Chen, Sean; Zhang, Hao  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 362 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D263-32  
 ICS C07D263-58; C07D277-24; C07D495-04; C07D417-04; C07D413-14; C07D413-12; C07D417-12; A61K031-421; A61K031-426; A61K031-4439; A61P003-10; A61P003-06  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021602	A1	20010329	WO 2000-US25710	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1218361	A1	20020703	EP 2000-965172	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014189	A	20020820	BR 2000-14189	20000919
NO 2002001408	A	20020514	NO 2002-1408	20020321
PRAI US 1999-155400P	P	19990922		
WO 2000-US25710	W	20000919		
OS MARPAT 134:266299				
GI				



AB Title compds. [I; Q = C, N; A = O, S; B = (CH<sub>2</sub>)<sub>x</sub>; Z = O, bond; X = CH, N; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, alkyl, alkoxy, halo, amino; R<sub>3</sub> = H, alkyl, aralkyl, aryloxy, carbonyl, alkoxy, carbonyl, aryl, carbonyl, alkyl, carbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R<sub>2a</sub>, R<sub>2b</sub>, R<sub>2c</sub> = H, alkyl, alkoxy, halo, amino; Y = CO<sub>2</sub>R<sub>4</sub>, 1-tetrazolyl, PO(OR<sub>4a</sub>)R<sub>5</sub>; R<sub>4</sub> = H, alkyl, prodrug or ester; R<sub>4a</sub> = H, prodrug ester; R<sub>5</sub> = alkyl, aryl; x = 1-4; m, n = 1, 2], were prepd. as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). Thus, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph<sub>3</sub>P, and DEAD were stirred in THF at 0.degree.-room temp. to give 65% 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde. This was stirred 12 h with N-benzylglycine Et ester and NaBH(OAc)<sub>3</sub> in 1,2-dichloroethane to give 55% benzylamine deriv., which was stirred 14 h with aq. NaOH in MeOH to give 71% title compd. (II).

ST oxazolylalkoxybenzylglycine prepn antidiabetic antiobesity agent;  
anticancer oxazolylalkoxybenzylglycine thiazolylalkoxybenzylglycine prepn;  
thiazolylalkoxybenzylglycine prepn antidiabetic antiobesity agent;  
psoriasis treatment thiazolylalkoxybenzylglycine  
oxazolylalkoxybenzylglycine; antiosteoporotic thiazolylalkoxybenzylglycine  
oxazolylalkoxybenzylglycine; irritable bowel syndrome treatment  
thiazolylalkoxybenzylglycine oxazolylalkoxybenzylglycine

IT Intestine, disease  
(Crohn's, treatment; prepn. of oxazolyl- and  
thiazolylalkoxybenzylglycines and related compds. as antidiabetic and  
antiobesity agents)

IT Intestine, disease  
(irritable bowel syndrome, treatment; prepn. of oxazolyl- and  
thiazolylalkoxybenzylglycines and related compds. as antidiabetic and  
antiobesity agents)

IT Antidiabetic agents  
Antiobesity agents  
Antitumor agents  
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related  
compds. as antidiabetic and antiobesity agents)

IT Osteoporosis  
(therapeutic agents; prepn. of oxazolyl- and  
thiazolylalkoxybenzylglycines and related compds. as antidiabetic and  
antiobesity agents)

IT Psoriasis  
(treatment; prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and  
related compds. as antidiabetic and antiobesity agents)

IT 331739-69-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331739-67-4P 331739-68-5P 331739-70-9P  
 331739-71-0P 331739-72-1P 331739-73-2P  
 331739-74-3P 331739-75-4P 331739-76-5P  
 331739-77-6P 331739-78-7P 331739-79-8P  
 331739-80-1P 331739-81-2P 331739-82-3P  
 331739-83-4P 331739-84-5P 331739-85-6P  
 331739-86-7P 331739-87-8P 331739-88-9P  
 331739-89-0P 331739-90-3P 331739-91-4P  
 331739-92-5P 331739-93-6P 331739-94-7P  
 331739-95-8P 331739-96-9P 331739-97-0P  
 331739-98-1P 331739-99-2P 331740-00-2P  
 331740-01-3P 331740-02-4P 331740-03-5P  
 331740-04-6P 331740-05-7P 331740-06-8P  
 331740-07-9P 331740-08-0P 331740-09-1P  
 331740-10-4P 331740-11-5P 331740-12-6P  
 331740-13-7P 331740-14-8P 331740-15-9P  
 331740-16-0P 331740-17-1P 331740-18-2P  
 331740-19-3P 331740-20-6P 331740-21-7P  
 331740-22-8P 331740-23-9P 331740-24-0P  
 331740-25-1P 331740-26-2P 331740-27-3P  
 331740-28-4P 331740-29-5P 331740-30-8P  
 331740-31-9P 331740-32-0P 331740-33-1P  
 331740-34-2P 331740-35-3P 331740-36-4P  
 331740-37-5P 331740-38-6P 331740-39-7P  
 331740-40-0P 331740-41-1P 331740-42-2P  
 331740-43-3P 331740-44-4P 331740-45-5P  
 331740-46-6P 331740-47-7P 331740-48-8P  
 331740-49-9P 331740-50-2P 331740-51-3P  
 331740-52-4P 331740-53-5P 331740-54-6P  
 331740-55-7P 331740-56-8P 331740-57-9P  
 331740-58-0P 331740-59-1P 331740-60-4P  
 331740-61-5P 331740-62-6P 331740-63-7P  
 331740-64-8P 331740-65-9P 331740-66-0P  
 331740-67-1P 331740-68-2P 331740-69-3P  
 331740-70-6P 331740-71-7P 331740-72-8P  
 331740-73-9P 331740-74-0P 331740-75-1P  
 331740-76-2P 331740-77-3P 331740-78-4P  
 331740-79-5P 331740-80-8P 331740-81-9P  
 331740-82-0P 331740-83-1P 331740-84-2P  
 331740-85-3P 331740-86-4P 331740-87-5P  
 331740-88-6P 331740-89-7P 331740-90-0P  
 331740-91-1P 331740-92-2P 331740-93-3P  
 331740-94-4P 331740-95-5P 331740-96-6P  
 331740-97-7P 331740-98-8P 331740-99-9P  
 331741-00-5P 331741-01-6P 331741-02-7P  
 331741-03-8P 331741-04-9P 331741-05-0P  
 331741-06-1P 331741-07-2P 331741-08-3P  
 331741-09-4P 331741-10-7P 331741-11-8P  
 331741-12-9P 331741-13-0P 331741-14-1P  
 331741-15-2P 331741-16-3P 331741-17-4P  
 331741-18-5P 331741-19-6P 331741-20-9P  
 331741-21-0P 331741-22-1P 331741-23-2P  
 331741-24-3P 331741-25-4P 331741-26-5P

331741-27-6P 331741-28-7P 331741-29-8P  
 331741-30-1P 331741-31-2P 331741-32-3P  
 331741-33-4P 331741-34-5P 331741-35-6P  
 331741-36-7P 331741-37-8P 331741-38-9P  
 331741-39-0P 331741-40-3P 331741-41-4P  
 331741-42-5P 331741-43-6P 331741-44-7P  
 331741-45-8P 331741-46-9P 331741-47-0P  
 331741-48-1P 331741-49-2P 331741-50-5P  
 331741-51-6P 331741-52-7P 331741-53-8P  
 331741-54-9P 331741-55-0P 331741-56-1P  
 331741-57-2P 331741-58-3P 331741-59-4P  
 331741-60-7P 331741-61-8P 331741-63-0P  
 331741-64-1P 331741-65-2P 331741-66-3P  
 331741-67-4P 331741-68-5P 331741-69-6P  
 331741-70-9P 331741-71-0P 331741-72-1P  
 331741-73-2P 331741-74-3P 331741-75-4P  
 331741-76-5P 331741-77-6P 331741-78-7P  
 331741-79-8P 331741-80-1P 331741-81-2P  
 331741-82-3P 331741-83-4P 331741-84-5P  
 331741-85-6P 331741-86-7P 331741-87-8P  
 331741-88-9P 331741-89-0P 331741-90-3P  
 331741-91-4P 331741-92-5P 331741-93-6P  
 331741-94-7P 331741-95-8P 331741-96-9P  
 331741-97-0P 331741-98-1P 331741-99-2P  
 331742-00-8P 331742-01-9P 331742-02-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331742-03-1P 331742-04-2P 331742-05-3P  
 331742-06-4P 331742-07-5P 331742-08-6P  
 331742-09-7P 331742-10-0P 331742-11-1P  
 331742-12-2P 331742-13-3P 331742-14-4P  
 331742-15-5P 331742-16-6P 331742-17-7P  
 331742-18-8P 331742-19-9P 331742-20-2P  
 331742-21-3P 331742-22-4P 331742-23-5P  
 331742-24-6P 331742-25-7P 331742-26-8P  
 331742-27-9P 331742-28-0P 331742-29-1P  
 331742-30-4P 331742-31-5P 331742-32-6P  
 331742-33-7P 331742-34-8P 331742-35-9P  
 331742-36-0P 331742-37-1P 331742-38-2P  
 331742-39-3P 331742-40-6P 331742-41-7P  
 331742-42-8P 331742-43-9P 331742-44-0P  
 331742-45-1P 331742-46-2P 331742-47-3P  
 331742-48-4P 331742-49-5P 331742-50-8P  
 331742-51-9P 331742-52-0P 331742-53-1P  
 331742-54-2P 331742-55-3P 331742-56-4P  
 331742-57-5P 331742-58-6P 331742-59-7P  
 331742-60-0P 331742-61-1P 331742-62-2P  
 331742-63-3P 331742-64-4P 331742-65-5P  
 331742-66-6P 331742-67-7P 331742-68-8P  
 331742-69-9P 331742-70-2P 331742-71-3P  
 331742-72-4P 331742-73-5P 331742-74-6P  
 331742-75-7P 331742-76-8P 331742-77-9P  
 331742-78-0P 331742-79-1P 331742-80-4P  
 331742-81-5P 331742-82-6P 331742-83-7P  
 331742-84-8P 331742-85-9P 331742-86-0P  
 331742-87-1P 331742-88-2P 331742-89-3P  
 331742-90-6P 331742-91-7P 331742-92-8P

331742-93-9P 331742-94-0P 331742-95-1P  
 331742-96-2P 331742-97-3P 331742-98-4P  
 331742-99-5P 331743-00-1P 331743-02-3P  
 331743-04-5P 331743-05-6P 331743-06-7P  
 331743-07-8P 331743-08-9P 331743-09-0P  
 331743-10-3P 331743-11-4P 331743-12-5P  
 331743-13-6P 331743-14-7P 331743-15-8P  
 331743-16-9P 331743-17-0P 331743-18-1P  
 331743-19-2P 331743-20-5P 331743-21-6P  
 331743-22-7P 331743-23-8P 331743-24-9P  
 331743-25-0P 331743-26-1P 331743-27-2P  
 331743-28-3P 331743-29-4P 331743-30-7P  
 331743-31-8P 331743-32-9P 331743-33-0P  
 331743-34-1P 331743-35-2P 331743-36-3P  
 331743-37-4P 331743-38-5P 331743-39-6P  
 331743-40-9P 331743-41-0P 331743-42-1P  
 331743-43-2P 331743-44-3P 331743-45-4P  
 331743-46-5P 331743-47-6P 331743-48-7P  
 331743-49-8P 331743-50-1P 331743-51-2P  
 331743-52-3P 331743-53-4P 331743-54-5P  
 331743-55-6P 331743-56-7P 331743-57-8P  
 331743-58-9P 331743-59-0P 331743-60-3P  
 331743-61-4P 331743-62-5P 331743-63-6P  
 331743-64-7P 331743-65-8P 331743-66-9P  
 331743-67-0P 331743-68-1P 331743-69-2P  
 331743-70-5P 331743-71-6P 331743-72-7P  
 331743-73-8P 331743-74-9P 331743-75-0P  
 331743-76-1P 331743-77-2P 331743-78-3P  
 331743-79-4P 331743-80-7P 331743-81-8P  
 331743-82-9P 331743-83-0P 331743-84-1P  
 331743-85-2P 331743-86-3P 331743-87-4P  
 331743-88-5P 331743-89-6P 331743-90-9P  
 331743-91-0P 331743-92-1P 331743-93-2P  
 331743-94-3P 331743-95-4P 331743-96-5P  
 331743-97-6P 331743-98-7P 331743-99-8P  
 331744-00-4P 331744-01-5P 331744-02-6P  
 331744-03-7P 331744-04-8P 331744-05-9P  
 331744-06-0P 331744-07-1P 331744-08-2P  
 331744-09-3P 331744-10-6P 331744-11-7P  
 331744-12-8P 331744-13-9P 331744-14-0P  
 331744-15-1P 331744-16-2P 331744-17-3P  
 331744-18-4P 331744-19-5P 331744-20-8P  
 331744-21-9P 331744-22-0P 331744-23-1P 331744-24-2P  
 331744-25-3P 331744-26-4P 331744-27-5P  
 331744-28-6P 331744-29-7P 331744-30-0P  
 331744-31-1P 331744-32-2P 331744-33-3P  
 331744-34-4P 331744-35-5P 331744-36-6P  
 331744-37-7P 331744-38-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331744-39-9P 331744-40-2P 331744-41-3P  
 331744-42-4P 331744-43-5P 331744-44-6P  
 331744-45-7P 331744-46-8P 331744-47-9P  
 331744-48-0P 331744-49-1P 331744-50-4P  
 331744-51-5P 331744-52-6P 331744-53-7P  
 331744-54-8P 331744-55-9P 331744-56-0P  
 331744-57-1P 331744-58-2P 331744-59-3P

331744-60-6P 331744-61-7P 331744-62-8P  
 331744-63-9P 331744-64-0P 331744-65-1P  
 331744-66-2P 331744-67-3P 331744-68-4P  
 331744-69-5P 331744-70-8P 331744-71-9P  
 331744-72-0P 331744-73-1P 331744-74-2P  
 331744-75-3P 331744-76-4P 331744-77-5P  
 331744-78-6P 331744-79-7P 331744-80-0P  
 331744-81-1P 331744-82-2P 331744-83-3P  
 331744-84-4P 331744-85-5P 331744-86-6P  
 331744-87-7P 331744-88-8P 331744-89-9P  
 331744-90-2P 331744-91-3P 331744-92-4P  
 331744-93-5P 331744-94-6P 331744-95-7P  
 331744-96-8P 331744-97-9P 331744-98-0P  
 331744-99-1P 331745-00-7P 331745-01-8P  
 331745-02-9P 331745-03-0P 331745-04-1P  
 331745-05-2P 331745-06-3P 331745-07-4P  
 331745-08-5P 331745-09-6P 331745-10-9P  
 331745-11-0P 331745-12-1P 331745-13-2P  
 331745-14-3P 331745-15-4P 331745-16-5P  
 331745-17-6P 331745-18-7P 331745-19-8P  
 331745-20-1P 331745-21-2P 331745-22-3P  
 331745-23-4P 331745-24-5P 331745-25-6P  
 331745-26-7P 331745-27-8P 331745-28-9P  
 331745-29-0P 331745-30-3P 331745-31-4P  
 331745-32-5P 331745-33-6P 331745-34-7P  
 331745-35-8P 331745-36-9P 331745-37-0P  
 331745-38-1P 331745-39-2P 331745-40-5P  
 331745-41-6P 331745-42-7P 331745-43-8P  
 331745-44-9P 331745-45-0P 331745-46-1P  
 331745-47-2P 331745-48-3P 331745-49-4P  
 331745-60-9P 331745-69-8P 331745-80-3P 331745-86-9P  
 331746-91-9P 331746-92-0P 331746-93-1P  
 331746-95-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 331746-96-4P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

IT 65-85-0, Benzoic acid, reactions 66-99-9, 2-Naphthaldehyde 67-36-7, 4-Phenoxybenzaldehyde 85-46-1, 1-Naphthalenesulfonyl chloride 90-05-1, 2-Methoxyphenol 93-09-4, 2-Naphthalenecarboxylic acid 98-88-4, Benzoyl chloride 100-83-4, 3-Hydroxybenzaldehyde 102-29-4, Resorcinol monoacetate 103-16-2, 4-Benzyloxyphenol 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide 121-71-1 123-08-0, 4-Hydroxybenzaldehyde 151-18-8, 2-Cyanoethylamine 455-91-4, 3'-Fluoro-4'-methoxyacetophenone 501-53-1, Benzyl chloroformate 527-72-0, 2-Thiophenecarboxylic acid 591-35-5, 3,5-Dichlorophenol 615-18-9, 2-Chlorobenzoxazole 623-33-6, Glycine ethyl ester hydrochloride 626-02-8, 3-Iodophenol 626-55-1, 3-Bromopyridine 766-85-8, 3-Iodoanisole 768-35-4, 3-Fluorophenylboronic acid 815-60-1, 2,4-Dibromo-3-pentanone 937-62-2, 4-Methylphenyl chloroformate 1005-56-7, Phenyl chlorothionoformate 1066-54-2, Trimethylsilylacetylene 1132-21-4, 3,5-Dimethoxybenzoic acid 1700-37-4, 3-Benzyloxybenzaldehyde 2215-77-2, p-Phenoxybenzoic acid 2589-71-1 2627-86-3, (S)-.alpha.-Methylbenzylamine 2835-98-5 3173-56-6, Benzyl isocyanate 3403-25-6, D-Phenylalanine tert-butyl ester

hydrochloride 3424-93-9, 4-Methoxybenzamide 3886-69-9 5292-43-3,  
 tert-Butyl bromoacetate 5345-54-0, 3-Chloro-4-methoxyaniline  
 5416-93-3, 4-Methoxyphenyl isocyanate 5680-79-5, Glycine methyl ester  
 hydrochloride 5961-59-1, N-Methyl-p-anisidine 6436-90-4,  
 N-Benzylglycine ethyl ester 6945-92-2, Ethyl hydrazinoacetate  
 hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 7699-00-5  
 7745-91-7, 3-Bromo-4-methylaniline 15028-41-8, Methyl  
 .alpha.-aminoisobutyrate hydrochloride 15894-04-9, 4-Fluorobenzyl  
 mercaptan 16728-01-1 19621-92-2, 2-Hydroxypyridine-6-carboxylic acid  
 22038-86-4, (R)-1-(4-Methoxyphenyl)ethylamine 27492-46-2 27532-96-3,  
 Glycine tert-butyl ester hydrochloride 30414-53-0, Methyl  
 propionylacetate 34035-03-5 41851-59-6, (S)-1-(4-  
 Methoxyphenyl)ethylamine 50428-03-0 50868-72-9 59531-86-1, D-Alanine  
 tert-butyl ester hydrochloride 64318-28-1 66171-50-4, Methyl  
 2-hydroxypyridine-5-carboxylate 81228-89-9 87199-17-5,  
 4-Formylphenylboronic acid 103788-65-4 107367-98-6,  
 2-Phenyl-5-methyloxazole-4-acetic acid 164660-78-0 175136-30-8  
 182913-11-7 331746-63-5 331746-64-6 331746-65-7 331746-66-8  
 331746-68-0 331746-69-1 331746-70-4 331746-71-5 331746-72-6  
 331746-73-7 331746-74-8 331746-75-9 331746-76-0 331746-78-2  
 331746-80-6 331746-81-7 331746-82-8 331746-83-9 331746-84-0  
 331746-85-1 331746-86-2 331746-87-3 331746-88-4 331746-89-5  
 331746-90-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related  
 compds. as antidiabetic and antiobesity agents)

IT 405-06-1P 452-78-8P 621-27-2P, 3-Propylphenol 768-70-7P  
 2293-75-6P, 2-Methoxyphenyl chloroformate 2454-30-0P 3621-83-8P  
 10401-12-4P 18093-12-4P, 3-Chloro-4-methoxyphenol 23417-29-0P  
 28857-88-7P 30062-34-1P 42861-71-2P 52177-62-5P, 3-Methoxyphenyl  
 chloroformate 52177-75-0P 60710-39-6P, 3-Bromo-4-methylphenol  
 62103-69-9P 68331-44-2P 70170-23-9P 72934-40-8P 74067-76-8P  
 103360-04-9P, 4-Fluorobenzylsulfonyl chloride 103788-59-6P  
 103788-61-0P 103788-64-3P 105983-77-5P 136058-69-0P 137208-84-5P  
 140130-09-2P 140130-10-5P 157169-61-4P 174258-60-7P 196810-26-1P  
 223562-18-3P 227029-27-8P 244152-94-1P 258346-53-1P 258346-54-2P  
 331745-61-0P 331745-62-1P 331745-63-2P 331745-64-3P 331745-65-4P  
 331745-66-5P 331745-67-6P 331745-68-7P 331745-70-1P 331745-71-2P  
 331745-72-3P 331745-73-4P 331745-74-5P 331745-75-6P 331745-76-7P  
 331745-77-8P 331745-78-9P 331745-79-0P 331745-81-4P 331745-82-5P  
 331745-83-6P 331745-84-7P 331745-85-8P 331745-87-0P 331745-88-1P  
 331745-89-2P 331745-90-5P 331745-91-6P 331745-92-7P 331745-93-8P  
 331745-94-9P 331745-95-0P 331745-96-1P 331745-97-2P 331745-98-3P  
 331745-99-4P 331746-00-0P 331746-01-1P 331746-02-2P 331746-03-3P  
 331746-04-4P 331746-05-5P 331746-06-6P 331746-07-7P 331746-08-8P  
 331746-09-9P 331746-10-2P 331746-11-3P 331746-12-4P 331746-13-5P  
 331746-14-6P 331746-15-7P 331746-16-8P 331746-17-9P 331746-18-0P  
 331746-19-1P 331746-20-4P 331746-21-5P 331746-22-6P 331746-23-7P  
 331746-24-8P 331746-25-9P 331746-26-0P 331746-27-1P 331746-28-2P  
 331746-29-3P 331746-30-6P 331746-31-7P 331746-32-8P 331746-33-9P  
 331746-34-0P 331746-35-1P 331746-36-2P 331746-37-3P 331746-38-4P  
 331746-39-5P 331746-40-8P 331746-41-9P 331746-42-0P 331746-43-1P  
 331746-44-2P 331746-45-3P 331746-46-4P 331746-47-5P 331746-48-6P  
 331746-50-0P 331746-51-1P 331746-52-2P 331746-53-3P 331746-54-4P  
 331746-55-5P 331746-56-6P 331746-57-7P 331746-58-8P 331746-59-9P  
 331746-60-2P 331746-61-3P 331746-62-4P 331746-67-9P 331746-77-1P  
 331746-79-3P 331746-94-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related

compds. as antidiabetic and antiobesity agents)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cobb, J; JOURNAL OF MEDICINAL CHEMISTRY 1998, V41(25), P5055 HCAPLUS

(2) Glaxo Group Limited; WO 9731907 A 1997 HCAPLUS

(3) Ono Pharmaceutical Co Ltd; WO 9946232 A 1999 HCAPLUS

IT 331739-69-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331739-69-6 HCAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:179723 HCAPLUS

DN 134:222524

TI Preparation of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as guanylate cyclase stimulators

IN Alonso-Alija, Cristina; Heil, Markus; Flubacher, Dietmar; Naab, Paul; Pernerstorfer, Josef; Stasch, Johannes-Peter; Wunder, Frank; Dembowski, Klaus; Perzborn, Elisabeth; Stahl, Elke

PA Bayer AG, Germany

SO Ger. Offen., 80 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM C07C229-38

ICS C07C275-24; C07C235-42; C07C255-54; C07C317-18; C07D227-02;

C07D247-00; C07D277-22; C07D271-06; C07D285-06; C07D333-06;

A61P009-00

CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds) Section cross-reference(s): 1


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19943635	A1	20010315	DE 1999-19943635	19990913
WO 2001019780	A2	20010322	WO 2000-EP8469	20000831
WO 2001019780	A3	20010907		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 BR 2000014179 A 20020521 BR 2000-14179 20000831  
 EP 1216225 A2 20020626 EP 2000-958516 20000831  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 NO 2002001226 A 20020503 NO 2002-1226 20020312  
 PRAI DE 1999-19943635 A 19990913  
 WO 2000-EP8469 W 20000831  
 OS MARPAT 134:222524  
 GI



AB Title compds., e.g., RZOZCH<sub>2</sub>CH<sub>2</sub>N(Z<sub>1</sub>R<sub>1</sub>)CH<sub>2</sub>Z<sub>2</sub>R<sub>2</sub> [R = N-attached heterocyclyl, (hetero)aryl, etc.; R<sub>1</sub>, R<sub>2</sub> = CO<sub>2</sub>H, alkoxycarbonyl, CONH<sub>2</sub>, etc.; Z = bond, alk(en)ylene, etc.; Z<sub>1</sub> = (un)interrupted alk(en)ylene, etc.; Z<sub>2</sub>, Z<sub>3</sub> = (un)substituted phenylene] were prep'd. Thus, 2-(MeO)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> was reductively alkylated by 4-(OHC)C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>Me and the product N-alkylated by Br(CH<sub>2</sub>)<sub>4</sub>CO<sub>2</sub>Me to give, in 2 addnl. steps, title compd. I. Data for biol. activity of title compds. were given.

ST carboxyalkylaminomethylbenzoate prepn guanylate cyclase stimulator;  
 cardiovascular agent carboxyalkylaminomethylbenzoate prepn

IT Cardiovascular agents  
 (prepn. of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as guanylate cyclase stimulators)

IT	329773-27-5P	329773-28-6P	329773-29-7P	329773-30-0P	329773-31-1P
	329773-32-2P	329773-33-3P	329773-35-5P	329773-36-6P	329773-37-7P
	329773-38-8P	329773-39-9P	329773-40-2P	329773-41-3P	329773-42-4P
	329773-43-5P	329773-44-6P	329773-45-7P	329773-46-8P	329773-47-9P
	329773-48-0P	329773-49-1P	329773-50-4P	329773-51-5P	329773-52-6P
	329773-53-7P	329773-54-8P	329773-55-9P	329773-56-0P	329773-57-1P
	329773-58-2P	329773-59-3P	329773-60-6P	329773-61-7P	329773-62-8P
	329773-63-9P	329773-64-0P	329773-65-1P	329773-66-2P	329773-67-3P
	329773-68-4P	329773-69-5P	329773-70-8P	329773-71-9P	329773-72-0P
	329773-73-1P	329773-74-2P	329773-75-3P	329773-76-4P	329773-77-5P
	329773-78-6P	329773-79-7P	329773-80-0P	329773-81-1P	329773-82-2P
	329773-83-3P	329773-84-4P	329773-85-5P	329773-86-6P	329773-87-7P
	<b>329773-88-8P</b>	329773-89-9P	329773-90-2P	329773-91-3P	
	329773-92-4P	329773-93-5P	329773-94-6P	329773-95-7P	329773-96-8P
	329773-97-9P	329773-98-0P	<b>329773-99-1P</b>	329774-00-7P	
	329774-01-8P	329774-02-9P	329774-03-0P	329774-04-1P	
	<b>329774-05-2P</b>	329774-06-3P	329774-07-4P	329774-08-5P	
	329774-09-6P	329774-10-9P	329774-11-0P	329774-12-1P	329774-13-2P
	329774-14-3P	329774-15-4P	329774-16-5P	329774-17-6P	329774-18-7P
	329774-19-8P	329774-20-1P	329774-21-2P	329774-22-3P	329774-23-4P

329774-24-5P 329774-25-6P 329774-26-7P 329774-27-8P 329774-28-9P  
 329774-29-0P 329774-30-3P 329774-31-4P 329774-32-5P 329774-33-6P  
 329774-34-7P 329774-35-8P 329774-36-9P 329774-37-0P 329774-38-1P  
 329774-39-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as guanylate cyclase stimulators)

IT 9054-75-5, Guanylate cyclase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as guanylate cyclase stimulators)

IT 92-54-6, 1-Phenylpiperazine 100-14-1, 4-Nitrobenzyl chloride 104-82-5, 4-Methylbenzyl chloride 104-83-6, 4-Chlorobenzyl chloride 106-95-6, Allyl bromide, reactions 106-96-7, 3-Bromo-1-propyne 111-24-0, 1,5-Dibromopentane 111-85-3, Octyl chloride 589-15-1, 4-Bromobenzyl bromide 611-19-8, 2-Chlorobenzyl chloride 629-04-9, Heptyl bromide 705-29-3, 3-Trifluoromethylbenzyl chloride 824-94-2, 4-Methoxybenzyl chloride 836-42-0, 4-Benzyloxybenzyl chloride 1467-05-6, 4-Ethylbenzyl chloride 1571-08-0, Methyl 4-formylbenzoate 1667-11-4, 4-Chloromethylbiphenyl 1679-18-1, 4-Chlorophenylboronic acid 1765-93-1, 4-Fluorophenylboronic acid 2039-67-0, 3-Methoxyphenethylamine 2045-79-6, 2-Methoxyphenethylamine 2567-29-5, 4-Phenylbenzyl bromide 2969-81-5, Ethyl 4-bromobutanoate 3395-91-3, Methyl 3-bromopropanoate 4463-31-4, 4-Cyclohexylbenzyl chloride 4771-31-7 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic acid 6065-32-3, Ethyl 4-bromo-2-butenate 6165-69-1, 3-Thienylboronic acid 6850-57-3, 2-Methoxybenzylamine 10149-21-0, Diethyl 2-(3-bromopropyl)malonate 13331-27-6, 3-Nitrophenylboronic acid 13633-25-5, 1-Bromo-4-phenylbutane 14469-83-1, 1-Bromo-5-phenylpentane 14660-52-7, Ethyl 5-bromovalerate 17450-63-4 17933-03-8, 3-Methylphenylboronic acid 17969-22-1 19692-45-6, 4-tert-Butylbenzyl chloride 22494-53-7 25542-62-5, Ethyl 6-bromohexanoate 30418-59-8, 3-Aminophenylboronic acid 31406-42-5 38212-33-8, 1-(4-Chlorophenyl)piperazine 41602-50-0, N-Chloroacetyl glycine ethyl ester 52178-50-4, Methyl 3-formylbenzoate 53874-66-1, 3-Phenoxybenzyl chloride 56850-91-0, Methyl 4-(2-bromoethoxy)benzoate 63503-60-6, 3-Chlorophenylboronic acid 68716-47-2, 2,4-Dichlorophenylboronic acid 73217-31-9 74483-45-7 75210-42-3, 4-Fluoro-3-phenoxybenzyl chloride 78887-39-5, 3-Acetamidophenylboronic acid 90178-74-8 101095-61-8, 4-Chloromethylstilbene 111818-34-9 144432-85-9, 3-Chloro-4-fluorophenylboronic acid 167688-18-8 197234-17-6, Ethyl 5-bromo-3,3-dimethyl-4-oxopentanoate 226250-00-6, 4-Chloromethyl-N-phenylbenzamide 329774-54-1 329774-55-2 329774-56-3 329774-57-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as guanylate cyclase stimulators)

IT 329774-40-5P 329774-41-6P 329774-42-7P 329774-43-8P 329774-44-9P  
 329774-45-0P 329774-46-1P 329774-47-2P 329774-48-3P 329774-49-4P  
 329774-50-7P 329774-51-8P 329774-52-9P 329774-53-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as guanylate cyclase stimulators)


IT **329773-88-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic**

use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 4-[[[(carboxyalkyl)amino]methyl]benzoates and analogs as  
 guanylate cyclase stimulators)

RN 329773-88-8 HCAPLUS

CN Benzoic acid, 4-[[[(5-methoxy-5-oxopentyl)[2-[2-[(2-phenyl-4-thiazolyl)methoxy]phenyl]ethyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:873308 HCAPLUS

DN 134:41915

TI Preparation of 3-Aromatic-substituted propionic acid or acrylic acid derivatives as antidiabetics

IN Kitajima, Hiroshi; Nakamura, Koji; Tamagawa, Hiroki

PA Wellfide K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 94 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM C07D213-30


ICS A61K031-4035; A61K031-404; A61K031-421; A61K031-422; A61K031-423;  
 A61K031-427; A61K031-428; A61K031-44; A61K031-4427; A61K031-4439;  
 A61K031-444; A61K031-454; A61K031-4545; A61K031-4709; A61K031-4725;  
 A61K031-496; A61K031-5377; A61K031-55; A61P003-10

CC 23-16 (Aliphatic Compounds)

Section cross-reference(s): 1, 27, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2000344748	A2	20001212	JP 2000-89964	20000328
PRAI	JP 1999-87308	A	19990329		
OS	MARPAT 134:41915				
GI					



AB Title compds. [ZY(CH<sub>2</sub>)<sub>n</sub>XArCRR<sub>1</sub>CR<sub>2</sub>(ACOR<sub>4</sub>)CO<sub>2</sub>R<sub>3</sub>; R = H, alkyl; R<sub>1</sub>R<sub>2</sub> independently = H, alkyl; R<sub>3</sub> = H, alkyl; R<sub>4</sub> = NH<sub>2</sub>, alkylamino, cycloalkylamino; A = CH<sub>2</sub>, NH, alkylamino; Ar = aryl, heterocyclyl; X = bond, NH, alkylamino, S, SO, SO<sub>2</sub>, CONR<sub>5</sub>, NR<sub>6</sub>CO; R<sub>5</sub> = H, alkyl; R<sub>6</sub> = alkyl, H; n = 1, 2, 3, 4, 5; Y = bond, NH, alkyl, S, SO, SO<sub>2</sub>, CONH; Z = pyridyl, benzimidazolyl, benzoxazolyl, oxazolyl, thiazolyl, benzothiazolyl] and pharmaceutical salts are prepd. as antidiabetics which promote insulin secretion and improve action toward insulin resistant. Thus, the title compd. I was prepd. and tested.

ST arylpropionic acid arylacrylic prepn antidiabetic; heterocyclylpropionic heterocyclylacrylic acid prepn antidiabetic

IT Antidiabetic agents

(prepn. of arom. substituted propionic acid or acrylic acid derivs. as antidiabetics)

IT 312688-42-9P 312688-85-0P 312689-08-0P 312689-09-1P 312689-10-4P  
312689-12-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arom. substituted propionic acid or acrylic acid derivs. as antidiabetics)

IT 62-53-3, Aniline, reactions 93-10-7, Quinoline-2-carboxylic acid  
98-59-9, p-Toluenesulfonyl chloride 98-88-4, Benzoyl chloride 98-98-6,  
2-Pyridinecarboxylic acid 100-46-9, Benzylamine, reactions 100-60-7,  
N-Methylcyclohexylamine 100-61-8, N-Methylaniline, reactions 103-63-9,  
Phenethyl bromide 103-67-3, N-Methylbenzylamine 103-74-2,  
2-Pyridineethanol 109-09-1, 2-Chloropyridine 111-14-8, n-Heptanoic  
acid 111-49-9 112-05-0, Pelargonic acid 112-37-8, n-Undecanoic acid  
123-08-0, p-Hydroxybenzaldehyde 123-25-1, Succinic acid diethyl ester  
124-07-2, n-Octanoic acid, reactions 334-48-5, n-Decanoic acid  
402-49-3, 4-Trifluoromethylbenzyl bromide 496-41-3, 2-  
Benzofurancarboxylic acid 501-52-0, 3-Phenylpropionic acid 589-08-2,  
N-Methylphenethylamine 615-18-9, 2-Chlorobenzoxazole 615-20-3,  
2-Chlorobenzothiazole 702-23-8, 4-Methoxyphenethyl alcohol 766-17-6,  
cis-2,6-Dimethylpiperidine 1125-01-5, 3-Aza-spiro[5.5]undecane  
hydrochloride 1521-38-6, 2,3-Dimethoxybenzoic acid 1972-28-7,  
Diethylazo dicarboxylate 2038-57-5, 3-Phenylpropylamine 2592-95-2,  
1-Hydroxybenzotriazole 2629-72-3, 3-(4-Pyridyl)propanol 2719-27-9,  
Cyclohexanoyl chloride 2859-67-8, 3-(3-Pyridyl)propanol 2969-81-5,  
4-Bromobutanoic acid ethyl ester 3173-53-3, Cyclohexyl isocyanate  
4442-79-9, 2-Cyclohexylethanol 5223-06-3, 2-(5-Ethyl-2-pyridyl)ethanol  
5292-43-3, Bromoacetic acid tert-butyl ester 6314-28-9,  
Benzo[b]thiophene-2-carboxylic acid 7417-21-2, 3,4-Dimethoxyphenethyl  
alcohol 25952-53-8, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide  
hydrochloride 50463-48-4 65845-61-6, N-Methyl-cyclohexylamine

hydrochloride 69682-13-9 89150-07-2 90437-47-1 90719-32-7,  
 (S)-4-Benzyl-2-oxazolidinone 102029-44-7, (R)-4-Benzyl-2-oxazolidinone  
 103788-59-6 103788-61-0, 4-Chloromethyl-5-methyl-2-phenyloxazole  
 103788-65-4, 2-(5-Methyl-2-phenyloxazol-4-yl)ethanol 161829-92-1  
 175136-30-8 188576-13-8 196810-39-6 196810-53-4 196811-62-8  
 198990-10-2 312689-52-4 312689-67-1 312689-74-0 312689-84-2  
 312689-88-6 312689-90-0 312689-92-2 312689-94-4 312689-97-7  
 312689-99-9 312690-01-0 312690-03-2 312690-05-4 312690-07-6  
 312690-09-8 312690-11-2 312690-13-4 312690-19-0 312690-21-4  
 312690-25-8 312690-31-6 312690-33-8 312690-35-0 312690-44-1  
 312690-49-6 312690-60-1 312690-64-5 312690-69-0 312690-71-4  
 312690-72-5 312690-73-6 312690-77-0 312690-81-6 312690-84-9  
 312690-88-3 312690-90-7 312691-12-6 312691-14-8 312691-18-2  
 312728-68-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of arom. substituted propionic acid or acrylic acid derivs. as  
 antidiabetics)

IT	23156-69-6P	83495-90-3P	90437-48-2P	178055-58-8P	199794-28-0P
	312689-53-5P	312689-54-6P	312689-55-7P	312689-56-8P	312689-57-9P
	312689-58-0P	312689-59-1P	312689-60-4P	312689-61-5P	312689-62-6P
	312689-63-7P	312689-64-8P	312689-65-9P	312689-66-0P	312689-68-2P
	312689-69-3P	312689-70-6P	312689-71-7P	312689-72-8P	312689-73-9P
	312689-75-1P	312689-76-2P	312689-77-3P	312689-78-4P	312689-79-5P
	312689-80-8P	312689-81-9P	312689-82-0P	312689-83-1P	312689-85-3P
	312689-86-4P	312689-87-5P	312689-89-7P	312689-91-1P	312689-93-3P
	312689-95-5P	312689-96-6P	312689-98-8P	312690-00-9P	312690-02-1P
	312690-04-3P	312690-06-5P	312690-08-7P	312690-10-1P	312690-12-3P
	312690-14-5P	312690-15-6P	312690-16-7P	312690-17-8P	312690-18-9P
	312690-20-3P	312690-22-5P	312690-23-6P	312690-24-7P	312690-26-9P
	312690-27-0P	312690-28-1P	312690-29-2P	312690-30-5P	312690-32-7P
	312690-34-9P	312690-36-1P	312690-37-2P	312690-38-3P	312690-39-4P
	312690-40-7P	312690-41-8P	312690-42-9P	312690-43-0P	312690-45-2P
	312690-46-3P	312690-47-4P	312690-48-5P	312690-50-9P	312690-51-0P
	312690-52-1P	312690-53-2P	312690-54-3P	312690-55-4P	312690-56-5P
	312690-57-6P	312690-58-7P	312690-59-8P	312690-61-2P	312690-62-3P
	312690-63-4P	312690-65-6P	312690-66-7P	312690-67-8P	312690-68-9P
	312690-70-3P	312690-74-7P	312690-75-8P	312690-76-9P	312690-78-1P
	312690-79-2P	312690-80-5P	312690-82-7P	312690-83-8P	312690-85-0P
	312690-86-1P	312690-87-2P	312690-89-4P	312690-91-8P	312690-92-9P
	312690-93-0P	312690-94-1P	312690-95-2P	312690-96-3P	312690-97-4P
	312690-98-5P	312690-99-6P	312691-00-2P	312691-01-3P	312691-02-4P
	312691-03-5P	312691-04-6P	312691-05-7P	312691-06-8P	312691-07-9P
	312691-08-0P	312691-09-1P	312691-10-4P	312691-11-5P	312691-13-7P
	312691-15-9P	312691-16-0P	312691-17-1P	312691-19-3P	312691-20-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of arom. substituted propionic acid or acrylic acid derivs. as  
 antidiabetics)

IT	312688-43-0P	312688-44-1P	312688-45-2P	<b>312688-46-3P</b>	
	312688-47-4P	312688-48-5P	312688-49-6P	312688-50-9P	312688-51-0P
	312688-52-1P	312688-53-2P	312688-54-3P	312688-55-4P	312688-56-5P
	312688-57-6P	312688-58-7P	312688-59-8P	312688-60-1P	312688-61-2P
	312688-62-3P	312688-63-4P	312688-64-5P	312688-65-6P	312688-67-8P
	312688-69-0P	312688-70-3P	312688-71-4P	312688-72-5P	312688-73-6P
	312688-74-7P	312688-75-8P	312688-76-9P	312688-77-0P	312688-78-1P
	312688-79-2P	312688-80-5P	312688-81-6P	312688-82-7P	312688-83-8P
	312688-84-9P	312688-86-1P	312688-87-2P	312688-88-3P	312688-89-4P
	312688-90-7P	312688-91-8P	312688-92-9P	312688-93-0P	312688-94-1P
	312688-95-2P	312688-96-3P	312688-97-4P	312688-98-5P	312688-99-6P
	312689-00-2P	312689-01-3P	312689-02-4P	312689-03-5P	312689-04-6P

312689-05-7P 312689-06-8P 312689-07-9P **312689-11-5P**  
 312689-13-7P 312689-14-8P 312689-15-9P 312689-16-0P 312689-17-1P  
 312689-18-2P 312689-19-3P 312689-20-6P 312689-21-7P 312689-22-8P  
 312689-23-9P 312689-24-0P 312689-25-1P 312689-26-2P 312689-27-3P  
 312689-28-4P 312689-29-5P 312689-30-8P 312689-31-9P 312689-32-0P  
 312689-33-1P 312689-34-2P 312689-35-3P 312689-36-4P 312689-37-5P  
 312689-38-6P 312689-39-7P 312689-40-0P 312689-41-1P 312689-42-2P  
 312689-43-3P 312689-44-4P 312689-45-5P 312689-46-6P 312689-47-7P  
 312689-48-8P 312689-49-9P 312689-50-2P 312689-51-3P 312691-21-7P

RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL

(Biological study); PREP (Preparation); USES (Uses)

(prepn. of arom. substituted propionic acid or acrylic acid derivs. as antidiabetics)

IT **312688-46-3P**

RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL


(Biological study); PREP (Preparation); USES (Uses)

(prepn. of arom. substituted propionic acid or acrylic acid derivs. as antidiabetics)

RN 312688-46-3 HCAPLUS

CN Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-N-[[[(3aR,7aS)-octahydro-2H-isoindol-2-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:127367 HCAPLUS

DN 132:303368

TI Neuroprotection by LY341122, a novel inhibitor of lipid peroxidation, against focal ischemic brain damage in rats

AU Huh, P. W.; Belayev, L.; Zhao, W.; Clemens, J. A.; Panetta, J. A.; Busto, R.; Ginsberg, M. D.

CS Cerebral Vascular Disease Research Center, Department of Neurology (D4-5), University of Miami School of Medicine, Miami, FL, USA

SO European Journal of Pharmacology (2000), 389(1), 79-88  
 CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-11 (Pharmacology)

AB LY341122 (2-(3,5-di-t-butyl-4-hydroxyphenyl)-4-(2-(4-methylethylaminomethyl-phenyloxy)ethyl)oxazole) is a potent inhibitor of lipid peroxidn. which has been shown to protect against global ischemia and traumatic brain injury in rats. The purpose of this study was to examine the effect of LY341122 on ischemic injury in a highly reproducible model of focal cerebral ischemia in rats. Male Sprague-Dawley rats were anesthetized with halothane and subjected to 120 min of temporary middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-l-lysine. The drug (LY341122, n=19) or vehicle

(phosphate-buffered saline (PBS), n=10) was administered i.v. (as a 5 or 10 mg/kg bolus followed by a 5 or 10 mg/kg/h infusion for 20 h, resp., starting 1 or 2 h after the onset of middle cerebral artery occlusion). Neurol. status was evaluated during middle cerebral artery occlusion (60 min) and daily for 3 days thereafter. Three days after ischemia, brains were perfusion-fixed and infarct vols. and brain edema were detd. LY341122 significantly improved the neurol. score compared to vehicle at 24, 48 and 72 h after middle cerebral artery occlusion. Treatment with LY341122 significantly reduced total infarct vol. in all treated groups compared to vehicle rats. Cortical infarct vol. was significantly reduced by LY341122 treatment in the 10 mg/kg (1 h) and LY341122 10 mg/kg (2 h) groups compared to vehicle rats (14.7.+-.9.5 vs. 106.8.+-.20.9 mm3, and 36.9.+-.20.1 vs. 106.8.+-.20.9 mm3, resp. (mean.+-.S.E.M.)). Striatal infarct vol. was also significantly reduced by treatment with LY341122 in the 10 mg/kg (1 h) group compared to vehicle (23.7.+-.3.4 vs. 68.2.+-.6.7 mm3). These results demonstrate the neuroprotective efficacy of LY341122 in focal cerebral ischemia.

ST focal cerebral ischemia stroke neuroprotectant LY341122; lipid peroxidn inhibitor LY341122 neuroprotectant brain

IT Brain, disease

(ischemia, focal; neuroprotection by LY341122 against focal ischemic brain damage in rats)

IT Peroxidation

(lipid; neuroprotection by LY341122 against focal ischemic brain damage in rats)

IT Cytoprotective agents

(neuroprotectants; neuroprotection by LY341122 against focal ischemic brain damage in rats)

IT Brain, disease

(stroke; neuroprotection by LY341122 against focal ischemic brain damage in rats)

IT 206121-94-0, LY 341122

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(neuroprotection by LY341122 against focal ischemic brain damage in rats)

IT 7782-44-7, Oxygen, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(neuroprotection by LY341122 against focal ischemic brain damage in rats)

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bederson, J; Stroke 1986, V17, P472 MEDLINE
- (2) Belayev, L; Brain Res 1998, V787, P277 HCAPLUS
- (3) Belayev, L; Stroke 1996, V27, P1616 MEDLINE
- (4) Cao, X; Brain Res 1994, V644, P267 HCAPLUS
- (5) Chan, P; NeuroReport 1993, V5, P293 HCAPLUS
- (6) Chan, P; Stroke 1996, V27, P1124 HCAPLUS
- (7) Clemens, J; J Cereb Blood Flow Metab 1999, V19(Suppl 1), PS183
- (8) De Ryck, M; Stroke 1989, V20, P1383 HCAPLUS
- (9) Folbergrova, J; Proc Natl Acad Sci U S A 1995, V92, P5057 HCAPLUS
- (10) Fridovich, I; Annu Rev Biochem 1975, V44, P147 HCAPLUS
- (11) Ginsberg, M; Neuroscientist 1995, V1, P95
- (12) Hall, E; Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management 1998, P710
- (13) Hall, E; Free Radical Damage and its Control 1994, P217 HCAPLUS
- (14) Hall, E; J Pharmacol Exp Ther 1997, V281, P895 HCAPLUS
- (15) Kuge, Y; Stroke 1995, V26, P1655 MEDLINE
- (16) Laing, R; Stroke 1993, V24, P294 MEDLINE

- (17) Liu, T; Am J Physiol 1989, V256, PH589 HCAPLUS
- (18) Liu, X; Brain Res 1994, V644, P257 HCAPLUS
- (19) Markgraf, C; Stroke 1994, V25, P153 MEDLINE
- (20) Martz, D; J Cereb Blood Flow Metab 1990, V10, P352 HCAPLUS
- (21) Moore, L; Adv Pharmacol 1994, V31, P565 HCAPLUS
- (22) Morimoto, T; J Cereb Blood Flow Metab 1996, V16, P92 HCAPLUS
- (23) Oliff, H; Brain Res 1995, V699, P329 HCAPLUS
- (24) Sakamoto, A; Brain Res 1991, V554, P186 HCAPLUS
- (25) Schmid-Elsaesser, R; Stroke 1997, V28, P2018 HCAPLUS
- (26) Siegel, S; Nonparametric Statistics for the Behavioral Sciences 1956
- (27) Soehle, M; Stroke 1998, V29, P1240 HCAPLUS
- (28) Swanson, R; J Cereb Blood Flow Metab 1990, V10, P290 MEDLINE
- (29) Traystman, R; J Appl Physiol 1991, V71, P1185 HCAPLUS
- (30) Wada, K; Neurosurgery 1999, V45, P601 MEDLINE
- (31) Watson, B; Cell Mol Neurobiol 1998, V18, P581 HCAPLUS
- (32) Yang, G; Stroke 1994, V25, P165 HCAPLUS
- (33) Zea, L; Stroke 1989, V20, P84
- (34) Zhao, W; J Cereb Blood Flow Metab 1997, V17, P1281 HCAPLUS
- (35) Zhao, W; Stroke 1996, V27, P1112 MEDLINE


IT 206121-94-0, LY 341122

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(neuroprotection by LY341122 against focal ischemic brain damage in rats)

RN 206121-94-0 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[2-[4-[(ethylmethylamino)methyl]phenoxy]ethyl]-2-oxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:117035 HCAPLUS

DN 132:151814

TI Preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators

IN Collins, Jon Loren; Dezube, Milana; Oplinger, Jeffrey Alan; Willson, Timothy Mark

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D263-32


ICS C07D277-24; A61K031-421; A61K031-426; C07D413-12; C07D417-12; A61K031-422; A61K031-427

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008002	A1	20000217	WO 1999-EP5666	19990805
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2339773	AA	20000217	CA 1999-2339773	19990805
	AU 9957310	A1	20000228	AU 1999-57310	19990805
	EP 1102757	A1	20010530	EP 1999-944335	19990805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9912866	A	20011030	BR 1999-12866	19990805
	ZA 2001000983	A	20020305	ZA 2001-983	20010205
	NO 2001000628	A	20010406	NO 2001-628	20010206
	US 6498174	B1	20021224	US 2001-762445	20010222
PRAI	GB 1998-17118	A	19980807		
	WO 1999-EP5666	W	19990805		
OS	MARPAT 132:151814				
GI					



AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, haloalkyl; R3 = alkyl, cycloalkyl, cycloalkenyl, etc.; R4 = (un)substituted 5-6 membered heterocyclyl contg. at least one O, N or S atom, Ph; R5 = H, halo, alkyl, haloalkyl; R6 = H, alkyl; X = O, S; n = 1-3], which are dual activators of hPPAR.gamma. and hPPAR.alpha., were prepd. Thus, refluxing a suspension of (2S)-2-amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid (prepn. given) and benzoylacetone in MeOH and trimethylorthoformate afforded 43% (2S)-(Z)-I [R1 = H; R2 = Me; R3 = Ph; R4 = Ph; R5 = H; R6 = Me; X = O; n = 2] which showed 39% glucose redn. in rats.

ST PPAR alpha gamma activator oxazole thiazole prepn; peroxisome proliferator activated receptor alpha gamma oxazole thiazole prepn; antidiabetic oxazole thiazole prepn

IT Antidiabetic agents  
(prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

IT Peroxisome proliferator-activated receptors  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (.alpha.; prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

IT Peroxisome proliferator-activated receptors  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (.gamma.; prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

IT 258345-41-4P 258345-42-5P 258345-43-6P  
 258345-44-7P 258345-45-8P 258345-46-9P  
 258345-47-0P 258345-48-1P 258345-49-2P  
 258345-50-5P 258345-51-6P 258345-52-7P  
 258345-53-8P 258345-54-9P 258345-55-0P  
 258345-56-1P 258345-57-2P 258345-58-3P  
 258345-59-4P 258345-60-7P 258345-61-8P  
 258345-62-9P 258345-63-0P 258345-64-1P  
 258345-65-2P 258345-66-3P 258345-67-4P  
 258345-68-5P 258345-69-6P 258345-70-9P  
 258345-71-0P 258345-72-1P 258345-74-3P  
 258345-75-4P 258345-77-6P 258345-79-8P  
 258345-81-2P 258345-83-4P 258345-85-6P  
 258345-87-8P 258345-88-9P 258345-90-3P  
 258345-92-5P 258345-94-7P 258345-96-9P  
 258345-98-1P 258346-00-8P 258346-02-0P  
 258346-04-2P 258346-06-4P 258346-08-6P  
 258346-10-0P 258346-12-2P 258346-14-4P  
 258346-15-5P 258346-16-6P 258346-17-7P  
 258346-18-8P 258346-19-9P 258346-20-2P  
 258346-21-3P 258346-22-4P 258346-23-5P  
 258346-24-6P 258346-25-7P 258346-26-8P  
 258346-27-9P 258346-28-0P 258346-29-1P  
 258346-30-4P 258346-31-5P 258346-32-6P  
 258346-33-7P 258346-34-8P 258346-35-9P  
 258346-36-0P 258346-37-1P 258346-38-2P  
 258346-39-3P 258346-40-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

IT 55-21-0, Benzamide 67-64-1, Acetone, reactions 93-91-4, Benzoylacetone  
 98-03-3, 2-Thiophenecarboxaldehyde 98-86-2, Acetophenone, reactions  
 99-61-6, 3-Nitrobenzaldehyde 99-91-2, 4'-Chloroacetophenone 100-06-1,  
 4'-Methoxyacetophenone 105-37-3, Ethyl propionate 105-54-4, Ethyl  
 butyrate 122-00-9, 4'-Methylacetophenone 326-06-7 403-42-9,  
 4'-Fluoroacetophenone 445-27-2, 2'-Fluoroacetophenone 539-82-2, Ethyl  
 valerate 554-12-1, Methyl propionate 555-16-8, 4-Nitrobenzaldehyde,  
 reactions 585-74-0, 3'-Methylacetophenone 638-45-9, 1-Iodoheptane  
 709-63-7, 4'-Trifluoromethylacetophenone 823-76-7, Cyclohexyl methyl  
 ketone 824-75-9, 4-Fluorobenzamide 1468-83-3, 3-Acetylthiophene  
 1550-35-2, 2,4-Difluorobenzaldehyde 1656-44-6, 2,4-Dinitrophenylsulfonyl  
 chloride 1891-90-3, 4-Trifluoromethylbenzamide 2142-68-9,  
 2'-Chloroacetophenone 2227-79-4, Thiobenzamide 2459-07-6 2646-91-5,  
 2,3-Difluorobenzaldehyde 3424-93-9, 4-Methoxybenzamide 3978-80-1,  
 N-tert-Butoxycarbonyl-L-tyrosine 4074-51-5, 4'-Isopropoxyacetophenone  
 4326-36-7 4529-04-8, Propynyllithium 6164-79-0 16636-62-7  
 22104-77-4, Hept-2-en-1-ol 22179-72-2, 4-Fluorothiobenzamide  
 25790-35-6, 1-(2-Furyl)-1,3-butanedione 29655-46-7 52851-15-7, Ethyl

4-bromo-3-oxo-hexanoate 59025-55-7, 2,4-Difluorophenyl isocyanate  
 105983-77-5 112641-20-0, 2-Fluoro-3-trifluoromethylbenzaldehyde  
 113264-43-0, Ethyl 3-bromo-2-oxo-pentanoate 161793-17-5,  
 2,3,4-Trifluorobenzaldehyde 165047-24-5, 2,4,5-Trifluorobenzaldehyde  
 258347-22-7 258347-23-8 258347-27-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR  
 alpha activators)

IT	3115-63-7P	4023-79-4P	4023-80-7P	5331-13-5P	5331-64-6P
	6302-55-2P	15972-15-3P	29681-98-9P	38440-21-0P	40568-55-6P
	40614-52-6P	56464-74-5P	61551-89-1P	68892-13-7P	70502-03-3P
	103788-64-3P	103788-65-4P	106971-51-1P	113366-61-3P	131513-64-9P
	136058-69-0P	138676-18-3P	141819-91-2P	175136-29-5P	175136-30-8P
	185679-35-0P	196810-26-1P	196810-28-3P	196810-30-7P	215257-01-5P
	227029-27-8P	258346-42-8P	258346-43-9P	258346-44-0P	258346-45-1P
	258346-46-2P	258346-47-3P	258346-48-4P	258346-49-5P	258346-50-8P
	258346-51-9P	258346-52-0P	258346-53-1P	258346-54-2P	258346-55-3P
	258346-56-4P	258346-57-5P	258346-58-6P	258346-59-7P	258346-60-0P
	258346-61-1P	258346-62-2P	258346-63-3P	258346-64-4P	258346-65-5P
	258346-66-6P	258346-67-7P	258346-68-8P	258346-69-9P	258346-70-2P
	258346-71-3P	258346-72-4P	258346-73-5P	258346-74-6P	258346-75-7P
	258346-76-8P	258346-77-9P	258346-78-0P	258346-79-1P	258346-80-4P
	258346-81-5P	258346-82-6P	258346-83-7P	258346-84-8P	258346-85-9P
	258346-86-0P	258346-87-1P	258346-88-2P	258346-89-3P	258346-90-6P
	258346-91-7P	258346-92-8P	258346-93-9P	258346-94-0P	258346-95-1P
	258346-96-2P	258346-97-3P	258346-98-4P	258347-00-1P	258347-02-3P
	258347-04-5P	258347-05-6P	258347-06-7P	258347-07-8P	258347-08-9P
	258347-09-0P	258347-10-3P	258347-11-4P	258347-12-5P	258347-13-6P
	258347-14-7P	258347-15-8P	258347-16-9P	258347-17-0P	258347-18-1P
	258347-19-2P	258347-20-5P	258347-21-6P	258347-24-9P	258347-25-0P
	258347-26-1P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR  
 alpha activators)

IT 190844-95-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR  
 alpha activators)

IT 258346-41-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(radioligand; prepn. of substituted oxazoles and thiazoles as hPPAR  
 gamma and hPPAR alpha activators)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Glaxo Group Ltd; WO 9731907 A 1997 HCAPLUS

(2) Pfizer Inc; WO 9119702 A 1991 HCAPLUS

(3) Sumitomo Metal Industries Ltd; WO 9638415 A 1996 HCAPLUS

IT 258345-41-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic  
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR  
 alpha activators)

RN 258345-41-4 HCAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-  
 phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L7 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2003 ACS  
 AN 1999:399056 HCAPLUS  
 DN 131:179618  
 TI Lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice  
 AU Ishikawa, Yuji; Takeno, Hidekazu; Watanabe, Kazuhiro; Tani, Tadato  
 CS New Drug Research Department, High Quality-Life Research Laboratories, Bio-Medical Division, Sumitomo Metal Industries, Kyoto, 619-0237, Japan  
 SO Biological & Pharmaceutical Bulletin (1999), 22(6), 572-576  
 CODEN: BPBLEO; ISSN: 0918-6158  
 PB Pharmaceutical Society of Japan  
 DT Journal  
 LA English  
 CC 1-10 (Pharmacology)  
 AB HQL-975 (3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2S-propylamino-propionic acid) is a new oral antidiabetic agent which has been shown to be effective in insulin-resistant diabetic animals. In the present study, we examd. the effects of HQL-975 on glucose utilization and insulin action in KK-Ay mice with genetically obese non-insulin diabetes. Dietary administration of HQL-975 (19 mg/kg/d for 7 d) improved hyperglycemia, hyperlipidemia and hyperinsulinemia in the mice. The HQL-975-treated mice showed enhanced net glucose utilization, i.e., glucose was significantly incorporated into total lipids in the white adipose tissue (WAT) and liver, and into glycogen in the diaphragm for the last 24 h of the drug administration period. Treatment improved the decreased stimulative action of insulin in the epididymal WAT and the agent increased insulin-stimulated lipogenesis from both glucose and acetate. Treatment also increased the activity of lipogenic enzymes such as glycerol-3-phosphate dehydrogenase and fatty acid synthetase. In vitro exposure of WAT to HQL-975 enhanced lipogenesis in the presence of insulin. From these findings, we conclude that HQL-975 improves glucose utilization of KK-Ay mice through the enhancement of insulin action, which is assocd. with its lipogenic effects.  
 ST lipogenesis antidiabetic HQL975 noninsulindependent diabetes  
 IT Lipids, biological studies  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (formation of; lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)  
 IT Antidiabetic agents  
 (lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)  
 IT Diabetes mellitus  
 (non-insulin-dependent; lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)  
 IT Adipose tissue  
 (white; lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)  
 IT 185679-16-7, HQL-975

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)

IT 9004-10-8, Insulin, biological studies 9045-77-6, Fatty acid synthetase 9075-65-4, Glycerol-3-phosphate dehydrogenase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)

IT 50-99-7, Glucose, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(utilization; lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Boden, G; Diabetes 1997, V46, P3 HCAPLUS
- (2) Carey, E; Biocim Biophys Acta 1970, V210, P371 HCAPLUS
- (3) Fujiwara, T; Diabetes 1988, V37, P1549 HCAPLUS
- (4) Greich, J; New Engl J Med 1989, V321, P1231
- (5) Hotamisligil, G; J Clin Invest 1995, V95, P2409 HCAPLUS
- (6) Ikeda, H; Arzneim-Forsch/Drug Res 1990, V40, P156 HCAPLUS
- (7) Ishikawa, Y; Biol Pharm Bull 1998, V21, P928 HCAPLUS
- (8) Ishikawa, Y; Diab Res Clin Pract 1998, V41, P101 HCAPLUS
- (9) Kern, P; J Clin Invest 1995, V95, P2111 HCAPLUS
- (10) May, J; Lipids 1982, V17, P626 HCAPLUS
- (11) Okada, H; J Nutr Sci Vitaminol 1992, V38, P27
- (12) Olefsky, J; Am J Med 1985, V79(Suppl 3B), P1
- (13) Puls, W; Front Horm Res 1980, V7, P235 HCAPLUS
- (14) Randle, P; Lancet 1963, V1, P785 MEDLINE
- (15) Roden, M; J Clin Invest 1996, V97, P2859 HCAPLUS
- (16) Saltiel, A; Diabetes 1996, V45, P1661 HCAPLUS
- (17) Sugiyama, Y; Arzneim - Forsch/Drug Res 1990, V40, P263 HCAPLUS
- (18) Takeno, S; WO 9638415 1996 HCAPLUS
- (19) Wise, L; J Biol Chem 1979, V254, P273 HCAPLUS

IT 185679-16-7, HQL-975


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice)

RN 185679-16-7 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 15 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:172591 HCAPLUS

KATHLEEN FULLER EIC 1700/PARKER LAW 308-4290

DN 130:209698  
 TI Preparation of aryloxazoles and analogs as analgesics  
 IN Panetta, Jill Ann; Shannon, Harlan Edgar  
 PA Eli Lilly and Company, USA  
 SO PCT Int. Appl., 144 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-425  
 ICS A61K031-42; C07D277-22; C07D263-34  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9909980	A1	19990304	WO 1998-US17667	19980826
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 5942530	A	19990824	US 1998-138495	19980824
	CA 2302504	AA	19990304	CA 1998-2302504	19980826
	AU 9890354	A1	19990316	AU 1998-90354	19980826
	EP 908186	A2	19990414	EP 1998-306807	19980826
	EP 908186	A3	19990421		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2001513557	T2	20010904	JP 2000-507370	19980826
PRAI	US 1997-57389P	P	19970828		
	WO 1998-US17667	W	19980826		
OS	MARPAT 130:209698				
GI					



AB Title compds. [I; R1 = (CH<sub>2</sub>)<sub>m</sub>CHR<sub>4</sub>Z<sub>1</sub>Z<sub>2</sub>R<sub>6</sub>; R<sub>2</sub> = ROZ<sub>3</sub>; R, R<sub>3</sub> = H or alkyl; R<sub>6</sub> = CO(CH<sub>2</sub>)<sub>n</sub>NR<sub>7</sub>R<sub>8</sub>, Z<sub>4</sub>NR<sub>7</sub>R<sub>8</sub>, etc.; R<sub>7</sub>, R<sub>8</sub> = H, (hydroxy)alkyl, piperidinylalkyl; NR<sub>7</sub>R<sub>8</sub> = heterocyclyl; Z = O or S; Z<sub>1</sub> = CHR<sub>5</sub>, O, S; R<sub>5</sub> = H; R<sub>4</sub>R<sub>5</sub> = bond; Z<sub>2</sub> = phenylene, pyridinediyl, etc.; Z<sub>3</sub> = 2,6-dialkyl-1,4-phenylene; Z<sub>4</sub> = alkylene; m = 0 or 1; n = 0-4] were prepd. as analgesics (no data). Thus, 3,5-di-tert-butyl-4-hydroxybenzamide was cyclocondensed with ClCH<sub>2</sub>COCH<sub>2</sub>CO<sub>2</sub>Et and the reduced product etherified by 4-(HO)C<sub>6</sub>H<sub>4</sub>CHO to give I (R<sub>1</sub> = CH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>R<sub>6</sub>-4, R<sub>2</sub> = 3,5-di-tert-butyl-4-hydroxyphenyl, R<sub>3</sub> = H) (II; R<sub>6</sub> = CHO) which was reductively aminated by EtNH<sub>2</sub> to give II (R<sub>6</sub> = CH<sub>2</sub>NHEt).

ST aryloxazole prepn analgesic  
 IT Analgesics  
 (aryloxazoles and analogs)  
 IT Drug interactions  
 (synergistic; prepn. of aryloxazoles and analogs as analgesics)

IT 206121-91-7P 206121-92-8P 206121-93-9P  
 206121-94-0P 206121-95-1P 206121-96-2P  
 206121-97-3P 206121-98-4P 206121-99-5P  
 206122-00-1P 206122-01-2P 206122-02-3P  
 206122-03-4P 206122-04-5P 206122-05-6P  
 206122-06-7P 206122-07-8P 206122-08-9P  
 206122-09-0P 206122-10-3P 206122-12-5P  
 206122-13-6P 206122-14-7P 206122-15-8P  
 206122-16-9P 206122-17-0P 206122-18-1P  
 206122-19-2P 206122-20-5P 206122-21-6P  
 206122-22-7P 206122-23-8P 206122-24-9P 206122-25-0P 206122-26-1P  
 206122-27-2P 206122-28-3P 206122-29-4P 206122-30-7P 206122-31-8P  
 206122-32-9P 206122-34-1P 206122-35-2P 206122-36-3P 206122-37-4P  
 206122-38-5P 206122-39-6P 206122-40-9P  
 206122-41-0P 206122-42-1P 206122-43-2P  
 206122-44-3P 206122-45-4P 206122-46-5P  
 220891-92-9P 220891-98-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryloxazoles and analogs as analgesics)

IT 95-01-2, 2,4-Dihydroxybenzaldehyde 99-93-4, 4-Hydroxyacetophenone  
 100-83-4, 3-Hydroxybenzaldehyde 106-95-6, Allyl bromide, reactions  
 107-10-8, Propylamine, reactions 108-39-4, reactions 108-68-9,  
 3,5-Dimethylphenol 109-01-3, 1-Methylpiperazine 109-89-7, reactions  
 110-73-6, N-Ethylethanolamine 110-91-8, Morpholine, reactions  
 111-26-2, 1-Hexanamine 111-42-2, reactions 123-08-0,  
 4-Hydroxybenzaldehyde 123-90-0, Thiomorpholine 288-32-4, Imidazole,  
 reactions 624-78-2, Methylethylamine 627-35-0, N-Methylpropylamine  
 638-07-3, Ethyl 4-chloroacetoacetate 824-94-2, 4-Methoxybenzyl chloride  
 1421-49-4, 3,5-Di-tert-butyl-4-hydroxybenzoic acid 2104-89-4, DL-Serine  
 methyl ester 2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 3328-70-9,  
 3-Formyl-4-hydroxybenzaldehyde 6148-64-7, Potassium ethyl malonate  
 7150-55-2, 4-Chloro-4'-hydroxybutyrophenone 7623-09-8, 2-Chloropropionyl  
 chloride 7770-45-8, 4-Hydroxy-1-naphthaldehyde 13889-98-0,  
 1-Acetylpiperazine 14191-95-8, 4-Hydroxybenzylcyanide 17362-17-3,  
 3-(4-Hydroxyphenyl)propionitrile 20193-20-8, N-Ethylpropylamine  
 56962-11-9, 2-Chloro-4-hydroxybenzaldehyde 81172-89-6,  
 Terephthalaldehyde mono-diethylacetal 86223-05-4, 4-(4-  
 Hydroxybutyl)phenol 91358-96-2, 4-Mercaptobenzaldehyde 106984-91-2,  
 6-Hydroxy-3-pyridinecarboxaldehyde 119045-87-3, N-Ethyl-4-  
 hydroxyphenethylamine 193629-30-0, 1-tert-Butoxycarbonyl-3-(3-  
 bromopropyl)piperidine 206123-49-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of aryloxazoles and analogs as analgesics)

IT 1758-10-7P, 1-Allyloxy-3-methylbenzene 20531-93-5P, 1-Allyloxy-3,5-  
 dimethylbenzene 41438-18-0P, 2-Methyl-4-hydroxybenzaldehyde  
 41833-17-4P, 1-(4-Hydroxybenzyl)imidazole 56643-95-9P,  
 1-(4-Methoxybenzyl)imidazole 60632-18-0P, 3,5-Di-tert-butyl-4-  
 hydroxybenzamide 69442-04-2P 70547-87-4P, 2,6-Dimethyl-4-  
 hydroxybenzaldehyde 99187-39-0P, 4-(4-Bromobutyl)phenol 103602-47-7P,  
 Ethyl 4-chloro-3-oxopentanoate 112163-08-3P 142922-60-9P  
 158984-83-9P 176162-36-0P 206122-77-2P 206122-78-3P 206122-79-4P  
 206122-80-7P 206122-81-8P 206122-83-0P 206122-84-1P 206122-85-2P  
 206122-87-4P 206122-88-5P 206122-89-6P 206122-90-9P 206122-92-1P,  
 4-Allyloxy-2-methylbenzaldehyde 206122-93-2P 206122-94-3P  
 206122-95-4P 206122-97-6P 206122-99-8P 206123-00-4P 206123-01-5P  
 206123-02-6P 206123-03-7P 206123-04-8P 206123-05-9P 206123-06-0P  
 206123-07-1P 206123-09-3P 206123-10-6P 206123-11-7P 206123-12-8P  
 206123-13-9P 206123-14-0P 206123-15-1P 206123-16-2P 206123-17-3P

206123-18-4P 206123-19-5P 206123-20-8P 206123-21-9P 220892-02-4P  
 220892-03-5P 220892-06-8P 220892-10-4P 220892-13-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of aryloxazoles and analogs as analgesics)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Barreau; US 5403852 A 1995 HCAPLUS
- (2) Bernauer; GB 2066250 A 1981 HCAPLUS
- (3) Malamas; US 5491159 A 1996 HCAPLUS
- (4) Musser; US 4895953 A 1990 HCAPLUS

IT 206121-91-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryloxazoles and analogs as analgesics)

RN 206121-91-7 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[2-[4-  
 [(ethylamino)methyl]phenoxy]ethyl]-2-oxazolyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

L7 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:172590 HCAPLUS

DN 130:209697

TI Preparation of aryloxazoles and analogs for treatment of neuralgia

IN Panetta, Jill Ann; Shannon, Harlan Edgar

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-425

ICS A61K031-42

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909979	A1	19990304	WO 1998-US17666	19980826
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA,				

GN, GW, ML, MR, NE, SN, TD, TG


US 5952360	.A	19990914	US 1998-138626	19980824
CA 2302442	AA	19990304	CA 1998-2302442	19980826
AU 9889207	A1	19990316	AU 1998-89207	19980826
EP 906755	A2	19990407	EP 1998-306806	19980826
EP 906755	A3	19990421		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

JP 2001513556	T2	20010904	JP 2000-507369	19980826
---------------	----	----------	----------------	----------

PRAI US 1997-57165P P 19970828  
WO 1998-US17666 W 19980826

OS MARPAT 130:209697  
GI



AB Title compds. [I; R1 = (CH2)mCHR4Z1Z2R6; R2 = ROZ3; R, R3 = H or alkyl; R6 = CO(CH2)nNR7R8, Z4NR7R8, etc.; R7, R8 = H, (hydroxy)alkyl, piperidinylalkyl; NR7R8 = heterocyclyl; Z = O or S; Z1 = CHR5, O, S; R5 = H; R4R5 = bond; Z2 = phenylene, pyridinediyl, etc.; Z3 = 2,6-dialkyl-1,4-phenylene; Z4 = alkylene; m = 0 or 1; n = 0-4] were prep'd. as analgesics (no data). Thus, 3,5-di-tert-butyl-4-hydroxybenzamide was cyclocondensed with ClCH2COCH2CO2Et and the reduced product etherified by 4-(HO)C6H4CHO to give I (R1 = CH2CH2OC6H4R6-4, R2 = 3,5-di-tert-butyl-4-hydroxyphenyl, R3 = H) (II; R6 = CHO) which was reductively aminated by EtNH2 to give II (R6 = CH2NHET).

ST aryloxazole prepn neuralgia treatment

IT Nerve, disease

(neuralgia; prepn. of aryloxazoles and analogs for treatment of neuralgia)

IT Analgesics

(prepn. of aryloxazoles and analogs for treatment of neuralgia)

IT 206121-91-7P 206121-92-8P 206121-93-9P  
206121-94-0P 206121-95-1P 206121-96-2P  
206121-97-3P 206121-98-4P 206121-99-5P  
206122-00-1P 206122-01-2P 206122-02-3P  
206122-03-4P 206122-04-5P 206122-05-6P  
206122-06-7P 206122-07-8P 206122-08-9P  
206122-09-0P 206122-10-3P 206122-12-5P  
206122-13-6P 206122-14-7P 206122-15-8P  
206122-16-9P 206122-17-0P 206122-18-1P  
206122-19-2P 206122-20-5P 206122-21-6P  
206122-22-7P 206122-23-8P 206122-24-9P 206122-25-0P 206122-26-1P  
206122-27-2P 206122-28-3P 206122-29-4P 206122-30-7P 206122-31-8P  
206122-32-9P 206122-34-1P 206122-35-2P 206122-36-3P 206122-37-4P  
206122-38-5P 206122-39-6P 206122-40-9P  
206122-41-0P 206122-42-1P 206122-43-2P  
206122-44-3P 206122-45-4P 206122-46-5P  
220891-92-9P 220891-98-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryloxazoles and analogs for treatment of neuralgia)

IT 95-01-2, 2,4-Dihydroxybenzaldehyde 99-93-4, 4-Hydroxyacetophenone  
100-83-4, 3-Hydroxybenzaldehyde 106-95-6, Allyl bromide, reactions  
107-10-8, Propylamine, reactions 108-39-4, reactions 108-68-9,  
3,5-Dimethylphenol 109-01-3, 1-Methylpiperazine 109-89-7, reactions  
110-73-6, N-Ethylethanolamine 110-91-8, Morpholine, reactions  
111-26-2, 1-Hexanamine 111-42-2, reactions 123-08-0,  
4-Hydroxybenzaldehyde 123-90-0, Thiomorpholine 288-32-4, Imidazole,  
reactions 624-78-2, Methylethylamine 627-35-0, N-Methylpropylamine  
638-07-3, Ethyl 4-chloroacetoacetate 824-94-2, 4-Methoxybenzyl chloride  
1421-49-4, 3,5-Di-tert-butyl-4-hydroxybenzoic acid 2104-89-4, DL-Serine  
methyl ester 2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 3328-70-9,  
3-Formyl-4-hydroxybenzaldehyde 6148-64-7, Potassium ethyl malonate  
7150-55-2, 4-Chloro-4'-hydroxybutyrophenone 7623-09-8, 2-Chloropropionyl  
chloride 7770-45-8, 4-Hydroxy-1-naphthaldehyde 13889-98-0,  
1-Acetylpiperazine 14191-95-8, 4-Hydroxybenzylcyanide 17362-17-3,  
3-(4-Hydroxyphenyl)propionitrile 20193-20-8, N-Ethylpropylamine  
56962-11-9, 2-Chloro-4-hydroxybenzaldehyde 81172-89-6,  
Terephthalaldehyde mono-diethylacetal 86223-05-4, 4-(4-  
Hydroxybutyl)phenol 91358-96-2, 4-Mercaptobenzaldehyde 106984-91-2,  
6-Hydroxy-3-pyridinecarboxaldehyde 119045-87-3, N-Ethyl-4-  
hydroxyphenethylamine 193629-30-0, 1-tert-Butoxycarbonyl-3-(3-  
bromopropyl)piperidine 206123-49-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of aryloxazoles and analogs for treatment of neuralgia)

IT 1758-10-7P, 1-Allyloxy-3-methylbenzene 20531-93-5P, 1-Allyloxy-3,5-  
dimethylbenzene 41438-18-0P, 2-Methyl-4-hydroxybenzaldehyde  
41833-17-4P, 1-(4-Hydroxybenzyl)imidazole 56643-95-9P,  
1-(4-Methoxybenzyl)imidazole 60632-18-0P, 3,5-Di-tert-butyl-4-  
hydroxybenzamide 69442-04-2P 70547-87-4P, 2,6-Dimethyl-4-  
hydroxybenzaldehyde 99187-39-0P, 4-(4-Bromobutyl)phenol 103602-47-7P,  
Ethyl 4-chloro-3-oxopentanoate 112163-08-3P 142922-60-9P  
158984-83-9P 176162-36-0P 206122-77-2P 206122-78-3P 206122-79-4P  
206122-80-7P 206122-81-8P 206122-83-0P 206122-84-1P 206122-85-2P  
206122-87-4P 206122-88-5P 206122-89-6P 206122-90-9P 206122-92-1P,  
4-Allyloxy-2-methylbenzaldehyde 206122-93-2P 206122-94-3P  
206122-95-4P 206122-97-6P 206122-99-8P 206123-00-4P 206123-01-5P  
206123-02-6P 206123-03-7P 206123-04-8P 206123-05-9P 206123-06-0P  
206123-07-1P 206123-09-3P 206123-10-6P 206123-11-7P 206123-12-8P  
206123-13-9P 206123-14-0P 206123-15-1P 206123-16-2P 206123-17-3P  
206123-18-4P 206123-19-5P 206123-20-8P 206123-21-9P 220892-02-4P  
220892-03-5P 220892-06-8P 220892-10-4P 220892-13-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. of aryloxazoles and analogs for treatment of neuralgia)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Barreau; US 5403852 A 1995 HCAPLUS
- (2) Bernauer; GB 2066250 A 1981 HCAPLUS
- (3) Malamas; US 5491159 A 1996 HCAPLUS
- (4) Musser; US 4895953 A 1990 HCAPLUS

IT 206121-91-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic  
use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryloxazoles and analogs for treatment of neuralgia)

RN 206121-91-7 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[2-[4-

[(ethylamino)methyl]phenoxy]ethyl]-2-oxazolyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

L7 ANSWER 17 OF 28, HCAPLUS COPYRIGHT 2003 ACS

AN 1999:166489 HCAPLUS

DN 130:223261

TI Preparation of [(aminoalkyl)phenoxy]alkyl]oxazoles and analogs as analgesics

IN Panetta, Jill Ann; Shannon, Harlan Edgar

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A01N043-76

ICS A01N043-78; A61K031-42; A61K031-425

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909829	A1	19990304	WO 1998-US17651	19980826
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302294	AA	19990304	CA 1998-2302294	19980826
AU 9890347	A1	19990316	AU 1998-90347	19980826
EP 908180	A2	19990414	EP 1998-306808	19980826
EP 908180	A3	19990421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001513532	T2	20010904	JP 2000-507235	19980826
PRAI US 1997-57164P	P	19970828		
WO 1998-US17651	W	19980826		
OS MARPAT 130:223261				
AB ROZZ1(CH2)mCHR4Z2Z3R3 [I; R = H or alkyl; R3 = CO(CH2)nR6, aminoalkyl, heterocyclalkyl, etc.; R4 = H; R6 = (di)(alkyl)amino, heterocyclalkyl, etc.; Z = 2,6-dialkyl-1,4-phenylene; Z1 = (5-alkyl) oxazole- or -thiazole-2,4-diyl; Z2 = CHR5, O, S; R5 = H; R4R5 = bond; Z3 = (un)substituted phenylene or -pyridinediyl; m = 0 or 1; n = 0-4] were prep'd. Thus, 3,5-bis(1,1-dimethylethyl)-4-hydroxybenzamide was				

cyclocondensed with ClCH<sub>2</sub>COCH<sub>2</sub>CO<sub>2</sub>Et and the reduced product etherified by 4-(HO)C<sub>6</sub>H<sub>4</sub>CHO to give, after reductive amination, HOZZ1CH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>NH<sub>2</sub>Et)-4 [Z = 2,6-bis(1,1-dimethylethyl)-1,4-phenylene, Z1 = oxazole-2,4-diyl]. Data for biol. activity of I were given.

ST oxazole aminoalkylphenoxyalkyl prepn analgesic; nociception treatment  
oxazole aminoalkylphenoxyalkyl prepn

IT Analgesics  
(prepn. of [(aminoalkyl)phenoxy]alkyl]oxazoles and analogs as analgesics)

IT 206121-91-7P 206121-92-8P 206121-93-9P  
206121-94-0P 206121-95-1P 206121-96-2P  
206121-97-3P 206121-98-4P 206121-99-5P  
206122-00-1P 206122-01-2P 206122-02-3P  
206122-03-4P 206122-04-5P 206122-05-6P  
206122-06-7P 206122-07-8P 206122-08-9P  
206122-09-0P 206122-10-3P 206122-12-5P  
206122-13-6P 206122-14-7P 206122-15-8P  
206122-16-9P 206122-17-0P 206122-18-1P  
206122-19-2P 206122-20-5P 206122-21-6P  
206122-22-7P 206122-23-8P 206122-24-9P 206122-25-0P 206122-26-1P  
206122-27-2P 206122-28-3P 206122-29-4P 206122-30-7P 206122-31-8P  
206122-32-9P 206122-34-1P 206122-35-2P 206122-36-3P 206122-37-4P  
206122-38-5P 206122-39-6P 206122-40-9P  
206122-41-0P 206122-42-1P 206122-43-2P  
206122-44-3P 206122-45-4P 206122-46-5P  
206122-47-6P 220891-92-9P 220891-98-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of [(aminoalkyl)phenoxy]alkyl]oxazoles and analogs as analgesics)

IT 95-01-2, 2,4-Dihydroxybenzaldehyde 99-93-4, 4-Hydroxyacetophenone  
100-83-4, 3-Hydroxybenzaldehyde 106-95-6, Allyl bromide, reactions  
107-10-8, Propylamine, reactions 108-39-4, reactions 108-68-9,  
3,5-Dimethylphenol 109-01-3, 1-Methylpiperazine 109-89-7, reactions  
110-73-6, N-Ethylethanolamine 110-91-8, Morpholine, reactions  
111-26-2, 1-Hexanamine 111-42-2, reactions 123-08-0,  
4-Hydroxybenzaldehyde 123-90-0, Thiomorpholine 288-32-4, Imidazole,  
reactions 624-78-2, Methylethylamine 627-35-0, Methylpropylamine  
638-07-3, Ethyl 4-chloroacetoacetate 824-94-2, p-Methoxybenzyl chloride  
1421-49-4, 3,5-Bis(1,1-dimethylethyl)-4-hydroxybenzoic acid 2104-89-4,  
DL-Serine methyl ester 2420-16-8, 3-Chloro-4-hydroxybenzaldehyde  
3328-70-9, 3-Formyl-4-hydroxybenzaldehyde 6148-64-7, Potassium ethyl  
malonate 7150-55-2, 4-Chloro-1-(4-hydroxyphenyl)-1-butanone 7623-09-8,  
2-Chloropropionyl chloride 7651-82-3, 6-Hydroxyisoquinoline 7770-45-8,  
4-Hydroxy-1-naphthaldehyde 13889-98-0, 1-Acetylpiperazine 14191-95-8,  
4-Hydroxybenzyl cyanide 17362-17-3, 3-(4-Hydroxyphenyl)propionitrile  
20193-20-8, Ethylpropylamine 56962-11-9, 2-Chloro-4-hydroxybenzaldehyde  
81172-89-6, Terephthalaldehyde monodiethyl acetal 86223-05-4,  
4-(4-Hydroxybutyl)phenol 91358-96-2, 4-Mercaptobenzaldehyde  
106984-91-2, 6-Hydroxy-3-pyridinecarboxaldehyde 119045-87-3,  
N-Ethyl-4-hydroxybenzeneethanamine 193629-30-0, 3-(3-Bromopropyl)-1-tert-  
butoxycarbonylpiperidine 206123-49-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of [(aminoalkyl)phenoxy]alkyl]oxazoles and analogs as analgesics)

IT 1758-10-7P, 3-Methyl-1-allyloxybenzene 20531-93-5P, 3,5-Dimethyl-1-  
allyloxybenzene 41438-18-0P, 2-Methyl-4-hydroxybenzaldehyde  
41833-17-4P, 1-(4-Hydroxybenzyl)imidazole 56643-95-9P,  
1-(4-Methoxybenzyl)imidazole 60632-18-0P, 3,5-Bis(1,1-dimethylethyl)-4-

hydroxybenzamide 69442-04-2P, N-Methyl-3,5-Bis(1,1-dimethylethyl)-4-hydroxybenzamide 70547-87-4P, 2,6-Dimethyl-4-hydroxybenzaldehyde 99187-39-0P, 4-(4-Bromobutyl)phenol 103602-47-7P, Ethyl 4-chloro-3-oxopentanoate 112163-08-3P 142922-60-9P 158984-83-9P 176162-36-0P 206122-78-3P 206122-79-4P 206122-80-7P 206122-81-8P 206122-82-9P 206122-83-0P 206122-84-1P 206122-85-2P, N-Ethyl-N-formyl-4-hydroxybenzeneethanamine 206122-86-3P 206122-87-4P 206122-88-5P 206122-89-6P 206122-90-9P 206122-92-1P, 4-Allyloxy-2-methylbenzaldehyde 206122-93-2P 206122-94-3P 206122-95-4P 206122-97-6P, 4-Allyloxy-2,6-dimethylbenzaldehyde 206122-99-8P 206123-00-4P 206123-01-5P 206123-02-6P 206123-03-7P 206123-04-8P 206123-05-9P 206123-06-0P 206123-07-1P 206123-09-3P 206123-10-6P 206123-11-7P 206123-12-8P 206123-13-9P 206123-14-0P 206123-15-1P 206123-16-2P 206123-17-3P 206123-18-4P 206123-19-5P 206123-20-8P 206123-21-9P 220892-02-4P 220892-03-5P 220892-06-8P 220892-10-4P 220892-13-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of [(aminoalkyl)phenoxy]alkyl]oxazoles and analogs as analgesics)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) American Home Care Products Corp; EP 310379 A1

(2) Anon; 2-Aryl-substituted heterocyclic compounds as antiallergic and antiinflammatory agents 1989 HCAPLUS


IT 206121-91-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [(aminoalkyl)phenoxy]alkyl]oxazoles and analogs as analgesics)

RN 206121-91-7 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[2-[4-[(ethylamino)methyl]phenoxy]ethyl]-2-oxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:615046 HCAPLUS

DN 129:339752

TI Actions of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic db/db mice

AU Ishikawa, Yuji; Takagi, Yoko; Takeno, Hidekazu; Watanabe, Kazuhiro; Tani, Tadato

CS New Drug Research Dep., High Quality-Life Research Lab., Bio-Medical Div., Sumitomo Metal Indust., Kyoto, 619-0237, Japan

KATHLEEN FULLER EIC 1700/PARKER LAW 308-4290

SO Biological & Pharmaceutical Bulletin (1998), 21(9), 928-933  
 CODEN: BPBLEO; ISSN: 0918-6158

PB Pharmaceutical Society of Japan

DT Journal

LA English

CC 1-10 (Pharmacology)

AB The hypoglycemic effect of the novel oral agent 3-{4-[2-(5-methyl-2-phenyloxazol-4-yl)-ethoxy]phenyl}-2S-propylaminopropionic acid (HQL-975) was examd. in db/db mice with genetically obese non-insulin dependent diabetes mellitus (NIDDM). The oral administration of HQL-975 at 3.5 and 35.3 mg/kg/d for 7 d decreased the plasma glucose level of these mice in a dose-dependent manner. HQL-975 also significantly decreased the plasma triglyceride, total cholesterol, non-esterified fatty acid and insulin levels. In the oral glucose tolerance test, HQL-975-treated mice showed improved glucose tolerance and decreased endogenous insulin secretion. HQL-975 increased glycemic response to exogenous insulin in the mice. In the HQL-975-treated db/db mice adipocytes, the glucose uptake, insulin binding, and GLUT4 expression were increased compared with those in untreated db/db mice adipocytes. These results indicate that HQL-975 improved insulin action in db/db mice through receptor and post-receptor effects. In conclusion, HQL-975 is a new oral antidiabetic agent with a hypoglycemic effect which is assocd. with an insulin-sensitizing effect. This agent may therefore be effective for the treatment of NIDDM.

ST NIDDM antidiabetic hypoglycemic HQL 975

IT Antidiabetic agents  
 Hypolipemic agents  
 Obesity  
 (antidiabetic, insulin-sensitizing and hypoglycemic actions of HQL-975 in db/db mice with genetically obese non-insulin dependent diabetes mellitus)

IT Diabetes mellitus  
 (non-insulin-dependent; antidiabetic, insulin-sensitizing and hypoglycemic actions of HQL-975 in db/db mice with genetically obese non-insulin dependent diabetes mellitus)

IT 185679-16-7, HQL 975  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antidiabetic, insulin-sensitizing and hypoglycemic actions of HQL-975 in db/db mice with genetically obese non-insulin dependent diabetes mellitus)

IT 9004-10-8, Insulin, biological studies  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (antidiabetic, insulin-sensitizing and hypoglycemic actions of HQL-975 in db/db mice with genetically obese non-insulin dependent diabetes mellitus)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Davis, M; Diabetes Care 1992, V15, P1844 MEDLINE
- (2) Ferner, R; Med Clin North Am 1988, V72, P1323 HCAPLUS
- (3) Fujiwara, T; Diabetes 1988, V37, P1549 HCAPLUS
- (4) Gerich, J; New Engl J Med 1989, V321, P1231 MEDLINE
- (5) Geurian, K; Ann Pharmacother 1992, V26, P1109 HCAPLUS
- (6) Igarashi, M; Diabetes 1996, V45(Suppl 2), P129A
- (7) Ikeda, H; Arzneim-Forsch/Drug Res 1990, V40, P156 HCAPLUS
- (8) Ishikawa, Y; Diab Res Clin Pract, in press
- (9) Kahn, B; J Clin Invest 1992, V89, P1367 HCAPLUS
- (10) Kashiwagi, A; J Clin Invest 1983, V76, P1246
- (11) Kolterman, O; J Clin Invest 1981, V68, P957 HCAPLUS

- (12) Okada, H; J Nutr Sci Vitaminol 1992, V38, P27
- (13) Olefsky, J; Am J Med 1985, V79(Suppl 3B), P1
- (14) Puls, W; Front Horm Res 1980, V7, P235 HCAPLUS
- (15) Reaven, G; Diabetes Metab 1991, V17, P78 MEDLINE
- (16) Rodbell, M; J Biol Chem 1964, V239, P375 HCAPLUS
- (17) Roden, M; J Clin Invest 1996, V97, P2859 HCAPLUS
- (18) Shimizu, Y; Am J Physiol 1993, V264, PE890 HCAPLUS
- (19) Steiner, G; Adv Exp Med Biol 1985, V189, P277 MEDLINE
- (20) Strowig, S; Diabetes Care 1992, V15, P1126 MEDLINE
- (21) Takeno, H; WO 9638415 1996 HCAPLUS
- (22) Vinik, A; Diabetes Care 1992, V15, P1926 MEDLINE

IT 185679-16-7, HQL 975


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antidiabetic, insulin-sensitizing and hypoglycemic actions of HQL-975 in db/db mice with genetically obese non-insulin dependent diabetes mellitus)

RN 185679-16-7 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:554139 HCAPLUS

DN 130:60891

TI Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals

AU Ishikawa, Yuji; Nagumo Isao Saito, Masahiko; Ikemoto, Tomoyuki; Takeno, Hidekazu; Watanabe, Kazubiro; Tani, Tadato

CS High Quality Life Research Laboratories, New Drug Research Department, Bio-Medical Division, Sumitomo Metal Industries, Souraku-gun, Kyoto, 619-02, Japan

SO Diabetes Research and Clinical Practice (1998), 41(2), 101-111  
CODEN: DRCPE9; ISSN: 0168-8227

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

CC 1-10 (Pharmacology)

AB The hypoglycemic effects of a novel oral antidiabetic agent, HQL-975, were studied in normal rats, streptozotocin-induced diabetic (STZD) rats and genetically insulin-resistant non-insulin-dependent diabetes mellitus (NIDDM) model animals, KK-Ay mice and Zucker diabetic fatty (ZDF) rats. After the dietary administration of HQL-975 to KK-Ay mice, significant decreases in plasma glucose, insulin, triglyceride and non-esterified fatty acid levels were obsd. The effective dosage of HQL-975 to decrease the plasma glucose level by 30% was 3.1 mg/kg per day. However, the plasma glucose level was not altered after the administration of HQL-975 in normal and STZD rats. The results suggest that HQL-975 is more effective against the abnormalities of glucose and lipid metab. of

insulin-resistant model animals than in that of normal and insulin-deficient diabetic animals. It is reported that ZDF rats indicate a severely diabetic state as a result of insulin resistance and further the presence of  $\beta$ -cell insulin secretory defects. Here, HQL-975 (1-30 mg/kg per day for 7 days) was administered to ZDF rats; slight decreases in the plasma glucose (18%) and lipids (41%) levels were obsd. in the rats given 30 mg/kg. To clarify the action mechanism of HQL-975, we studied the effects of HQL-975 administration on the insulin action of target tissues in KK-Ay mice. After the dietary administration of HQL-975 (0.001, 0.003, 0.010% for 7 days) to KK-Ay mice, hepatic glycolytic and gluconeogenic key enzyme activities were measured. The glucose 6-phosphatase activity was decreased (20-40%) as compared with control. The results suggest that HQL-975 enhances the insulin action in hepatic enzyme regulation. To investigate the actions of HQL-975 in peripheral tissues such as muscle and adipose, an in vivo glucose uptake study using 3H-2-deoxyglucose was performed in KK-Ay mice treated with HQL-975 (0.010% for 7 days). The 2-deoxyglucose uptake of the basal state was not altered, but the insulin-stimulated 2-deoxyglucose uptake in muscle (41-191%) and adipose (46-88%) tissues was increased by the HQL-975 treatment as compared with control. These results suggest that HQL-975 also enhances the insulin action of peripheral tissues. Based on these findings, HQL-975 is expected to be useful for treatment of insulin-resistant patients with NIDDM.

ST HQL975 antidiabetic insulin resistance NIDDM; insulin independent diabetes HQL975

IT Antidiabetic agents  
(actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals)

IT Diabetes mellitus  
(non-insulin-dependent; actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals)

IT 185679-16-7, HQL 975  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(HQL 975; actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals)

IT 9004-10-8, Insulin, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(enhancement of action of; actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals)

IT 9004-10-8, Insulin, biological studies  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(resistance; actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Andrikopoulos, S; Diabetes 1993, V42, P1731 HCAPLUS
- (2) Blair, J; Biochim Biophys Acta 1988, V964, P161 HCAPLUS
- (3) Chang, A; Diabetologia 1970, V6, P274 HCAPLUS
- (4) DeFronzo, R; Diabetes 1987, V37, P667
- (5) Ellingboe, J; J Med Chem 1992, V35, P1176 HCAPLUS
- (6) Ferner, R; Med Clin North Am 1988, V72, P1323 HCAPLUS
- (7) Fujiwara, T; Diabetes 1988, V37, P1549 HCAPLUS

- (8) Fujiwara, T; Metabolism 1991, V40, P1213 HCAPLUS
- (9) Furuya, E; Proc Natl Acad Sci USA 1980, V77, P5861 HCAPLUS
- (10) Gerich, J; Engl J Med 1989, V321, P1231 MEDLINE
- (11) Herman, W; Diabetes Care 1984, V7, P367 MEDLINE
- (12) Hofmann, C; Endocrinology 1991, V129, P1915 HCAPLUS
- (13) Iwatsuka, H; Endocrinol Jpn 1970, V17, P23 HCAPLUS
- (14) Kahn, A; Methods in Enzymology 1982, V90, P131 HCAPLUS
- (15) Kubo, K; Am J Physiol 1986, V250, PE100 HCAPLUS
- (16) Lkeda, H; Forch Drug Res 1990, V40, P156
- (17) Nagai, K; Int J Obes 1984, V8, P41 HCAPLUS
- (18) Odaka, H; J Nutr Sci Vitaminol 1992, V38, P27 HCAPLUS
- (19) Olefsky, J; Am J Med 1988, V85(Suppl 5), P86
- (20) Peterson, R; ILAR News 1990, V32, P16
- (21) Puls, W; Front Horm Res 1980, V7, P235 HCAPLUS
- (22) Ring, P; J Clin Invest 1992, V90, P1568
- (23) Riou, J; Proc Natl Acad USA 1977, V74, P4615 HCAPLUS
- (24) Seidman, I; Biochim Biophys Acta 1967, V146, P600 HCAPLUS
- (25) Shimizu, Y; J Biochem 1991, V110, P688 HCAPLUS
- (26) Slieker, L; Diabetes 1992, V41, P187 HCAPLUS
- (27) Stevenson, R; Diabetes 1990, V39, P1218 HCAPLUS
- (28) Stevenson, R; Metabolism 1991, V40, P1268 HCAPLUS
- (29) Sturis, J; Am J Physiol 1995, V269, PE786 HCAPLUS
- (30) Sugiyama, Y; Forch Drug Res 1990, V40, P263 HCAPLUS
- (31) Sugiyama, Y; Forsch Drug Res 1990, V40, P436 HCAPLUS
- (32) Takeno, S; WO 9638415 Novel 2-amino 3-phenylpropionic acid derivatives  
HCAPLUS
- (33) Taketomi, S; Horm Metab Res 1973, V35, P333
- (34) Taketomi, S; Horm Metab Res 1975, V7, P242 HCAPLUS
- (35) Trus, M; J Histochem Cytochem 1980, V28, P579 HCAPLUS
- (36) Weinstein, S; Metabolism 1993, V42, P1365 HCAPLUS

IT 185679-16-7, HQL 975


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HQL 975; actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals)

RN 185679-16-7 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:239111 HCAPLUS

DN 128:294777


TI Preparation of 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolyl]-2,6-di-tert-butylphenols and analogs as neuroprotectants

IN Heinz, Lawrence J.; Panetta, Jill A.; Phillips, Michael L.; Shadle, John K.

PA Eli Lilly and Company, USA; Heinz, Lawrence J.; Panetta, Jill A.;

Phillips, Michael L.; Shadle, John K.  
 SO PCT Int. Appl., 189 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-425  
 ICS A61K031-42; A61K031-415; C07D271-12; C07D413-00; C07D263-30;  
 C07D233-64; C07D233-68  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9815274	A1	19980416	WO 1997-US17963	19971006
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9747459	A1	19980505	AU 1997-47459	19971006
	AU 721355	B2	20000629		
	CN 1239889	A	19991229	CN 1997-180378	19971006
	EP 971709	A1	20000119	EP 1997-909975	19971006
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	US 6156748	A	20001205	US 1997-944468	19971006
	MX 9904211	A	20000131	MX 1999-4211	19990506
	NO 9902226	A	19990527	NO 1999-2226	19990507
	US 6166216	A	20001226	US 1999-368236	19990804
	US 6380213	B1	20020430	US 2000-715987	20001117
	US 2002065274	A1	20020530	US 2001-996005	20011128
	US 6423709	B2	20020723		
	US 6472387	B1	20021029	US 2002-109133	20020327
	US 2002177595	A1	20021128		
PRAI	US 1996-27560P	P	19961007		
	US 1997-944468	A3	19971006		
	WO 1997-US17963	W	19971006		
	US 1999-368236	A3	19990804		
	US 2000-715987	A3	20001117		
	US 2001-996005	A3	20011128		
OS	MARPAT 128:294777				
GI					



AB Title compds. [I; R = H or alkyl; R1, R2 = alkyl, alkoxy, Ph; R7 = (CH2)mCHR4YR8; R4 = H or OH; R8 = Z2R9; R9 = 1 or 2 of Z3R6, (CH2)4, or CH:CHCH:CH in which 1 CH2 or CH may be N; R6 = (di)(alkyl)amino, N-attached azolyl or azinyl, etc.; X = O or S; Y = O, S, CH2, CO, CH(OH);

Z = CHR3, ZR3, N, NR3; R3 = H or alkyl; Z1 = (CH2)q; Z2 = (un)substituted (hetero)arylene; Z3 = O(CH2)t, CO(CH2)n, alkylene; m = 0-2; n = 0-4; q = 0 or 1; t = 1-4] were prepd. as reactive oxygen scavengers (no data). Thus, 3,5-di-tert-butyl-4-hydroxybenzamide was cyclocondensed with ClCH2COCH2CO2Et to give, after sapon. and redn., I (R = H, R1 = R2 = CMe3, X = O, Z = CH, Z1 and dashed line = bond) (II; R7 = CH2OH) which was etherified by 4-(HO)C6H4CHO and the product reductively aminated by EtNH2 to give II [R7 = CH2CH2OC6H4(CH2NH2)-4].

- ST oxazolylyltertbutylphenol aminoalkylphenoxyalkyl prepn neuroprotectant;  
reactive oxygen scavenger oxazolylyltertbutylphenol aminoalkylphenoxyalkyl  
prepn
- IT Cytoprotective agents  
(neuroprotectants; 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolylyl]-2,6-di-tert-  
butylphenols and analogs)
- IT Oxidative stress, biological  
(treatment; prepn. of 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolylyl]-2,6-di-  
tert-butylphenols and analogs as neuroprotectants)
- IT 206121-91-7P 206121-92-8P 206121-93-9P  
206121-94-0P 206121-95-1P 206121-96-2P  
206121-97-3P 206121-98-4P 206121-99-5P  
206122-00-1P 206122-01-2P 206122-02-3P  
206122-03-4P 206122-04-5P 206122-05-6P  
206122-06-7P 206122-07-8P 206122-08-9P  
206122-09-0P 206122-10-3P 206122-11-4P  
206122-12-5P 206122-13-6P 206122-14-7P  
206122-15-8P 206122-16-9P 206122-17-0P  
206122-18-1P 206122-19-2P 206122-20-5P  
206122-21-6P 206122-22-7P 206122-23-8P 206122-24-9P  
206122-25-0P 206122-26-1P 206122-27-2P 206122-28-3P 206122-29-4P  
206122-30-7P 206122-31-8P 206122-32-9P 206122-33-0P 206122-34-1P  
206122-35-2P 206122-36-3P 206122-37-4P 206122-38-5P  
206122-39-6P 206122-40-9P 206122-41-0P  
206122-42-1P 206122-43-2P 206122-44-3P  
206122-45-4P 206122-46-5P 206122-47-6P  
206122-48-7P 206122-49-8P 206122-50-1P  
206122-51-2P 206122-52-3P 206122-53-4P  
206122-54-5P 206122-55-6P 206122-56-7P  
206122-57-8P 206122-58-9P 206122-59-0P  
206122-60-3P 206122-61-4P 206122-62-5P  
206122-63-6P 206122-64-7P 206122-65-8P  
206122-66-9P 206122-67-0P 206122-68-1P 206122-69-2P  
206122-71-6P 206122-73-8P 206122-75-0P  
206123-50-4P 206123-51-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic  
use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolylyl]-2,6-di-tert-  
butylphenols and analogs as neuroprotectants)
- IT 95-01-2, 2,4-Dihydroxybenzaldehyde 99-93-4, 4-Hydroxyacetophenone  
100-83-4, 3-Hydroxybenzaldehyde 104-47-2, 4-Methoxybenzyl cyanide  
106-95-6, Allyl bromide, reactions 107-10-8, Propylamine, reactions  
108-39-4, reactions 108-68-9, 3,5-Dimethylphenol 109-01-3,  
1-Methylpiperazine 110-73-6, N-Ethylethanolamine 110-91-8, Morpholine,  
reactions 111-26-2, Hexylamine 111-42-2, reactions 123-08-0,  
4-Hydroxybenzaldehyde 123-90-0, Thiomorpholine 288-32-4, Imidazole,  
reactions 542-81-4, 2-Chloroethyl methyl sulfide 624-78-2,  
Methylethylamine 627-35-0, N-MethylPropylamine 638-07-3, Ethyl  
4-chloroacetoacetate 824-94-2, 4-Methoxybenzyl chloride 1122-91-4,  
4-Bromobenzaldehyde 1421-49-4, 3,5-Di-tert-butyl-4-hydroxybenzoic acid  
2104-89-4, DL-Serine methyl ester 2420-16-8, 3-Chloro-4-

hydroxybenzaldehyde 3233-32-7, 4-Hydroxyphenyl acetate 3328-70-9,  
 3-Formyl-4-Hydroxybenzaldehyde 6148-64-7, Potassium ethyl malonate  
 7150-55-2, 4-Chloro-1-(4-hydroxyphenyl)-1-butanone 7623-09-8,  
 2-Chloropropionyl chloride 7651-82-3, 6-Hydroxyisoquinoline 7770-45-8,  
 4-Hydroxy-1-naphthaldehyde 10602-01-4, 2-(4-Bromophenyl)-1,3-dioxolane  
 13360-63-9, N-Ethylbutylamine 13889-98-0, 1-Acetylpiperazine  
 14588-60-4, 4-Benzyloxy-3,5-dimethoxybenzoic acid 17362-17-3,  
 3-(4-Hydroxyphenyl)propionitrile 19961-27-4, N-Ethylisopropylamine  
 20193-20-8, N-EthylPropylamine 20734-76-3, 2-Amino-4-methoxyphenol  
 38256-93-8, N-Methyl-2-Methoxyethanamine 56962-11-9,  
 2-Chloro-4-hydroxybenzaldehyde 81172-89-6, Terephthalaldehyde  
 monodiethyl acetal 86223-05-4, 4-(4-Hydroxybutyl)phenol 91358-96-2,  
 4-Mercaptobenzaldehyde 106984-91-2, 6-Hydroxy-3-Pyridinecarboxaldehyde  
 119045-87-3, N-Ethyl-4-hydroxybenzeneethanamine 193629-30-0  
 206123-49-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolyl]-2,6-di-tert-  
 butylphenols and analogs as neuroprotectants)

IT 1758-10-7P 3086-85-9P 20531-93-5P 29078-05-5P 41438-18-0P  
 41833-17-4P 56643-95-9P 60632-18-0P, 3,5-Di-tert-butyl-4-  
 hydroxybenzamide 69442-04-2P 70547-87-4P 99187-39-0P 103602-47-7P  
 112163-08-3P 142922-60-9P 158984-83-9P 176162-36-0P 206122-77-2P  
 206122-78-3P 206122-79-4P 206122-80-7P 206122-81-8P 206122-82-9P  
 206122-83-0P 206122-84-1P 206122-85-2P 206122-86-3P 206122-87-4P  
 206122-88-5P 206122-89-6P 206122-90-9P 206122-91-0P 206122-92-1P  
 206122-93-2P 206122-94-3P 206122-95-4P 206122-97-6P 206122-99-8P  
 206123-00-4P 206123-01-5P 206123-02-6P 206123-03-7P 206123-04-8P  
 206123-05-9P 206123-06-0P 206123-07-1P 206123-08-2P 206123-09-3P  
 206123-10-6P 206123-11-7P 206123-12-8P 206123-13-9P 206123-14-0P  
 206123-15-1P 206123-16-2P 206123-17-3P 206123-18-4P 206123-19-5P  
 206123-20-8P 206123-21-9P 206123-22-0P 206123-23-1P 206123-24-2P  
 206123-25-3P 206123-26-4P 206123-27-5P 206123-28-6P 206123-29-7P  
 206123-30-0P 206123-31-1P 206123-32-2P 206123-33-3P 206123-34-4P  
 206123-35-5P 206123-36-6P 206123-37-7P 206123-38-8P 206123-39-9P  
 206123-40-2P 206123-41-3P 206123-42-4P 206123-43-5P 206123-44-6P  
 206123-45-7P 206123-46-8P 206123-47-9P 206123-48-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolyl]-2,6-di-tert-  
 butylphenols and analogs as neuroprotectants)


IT **206121-91-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic  
 use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-[[[(aminoalkyl)phenoxy]alkyl]oxazolyl]-2,6-di-tert-  
 butylphenols and analogs as neuroprotectants)

RN 206121-91-7 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[2-[4-  
 [(ethylamino)methyl]phenoxy]ethyl]-2-oxazolyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

L7 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2003 ACS  
 AN 1998:199753 HCAPLUS  
 DN 128:213125  
 TI Effects of the novel oral antidiabetic agent HQL-975 on glucose and lipid metabolism in diabetic db/db mice  
 AU Ishikawa, Yuji; Watanabe, Kazuhiro; Takeno, Hidekazu; Tani, Tadato  
 CS New Drug Research Dep., High Quality-Life Research Lab., Bio-Medical Div., Sumitomo Metal Industries, Kyoto, 619, Japan  
 SO Arzneimittel-Forschung (1998), 48(3), 245-250  
 CODEN: ARZNAD; ISSN: 0004-4172  
 PB Editio Cantor Verlag  
 DT Journal  
 LA English  
 CC 1-10 (Pharmacology)  
 AB The antidiabetic effects of 3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)ethoxy]phenyl}-2S-propylamino-propionic acid (CAS 185679-16-7, HQL-975), a novel oral agent, on a genetically obese non-insulin-dependent diabetes mellitus (NIDDM) model (db/db mice) were examd. HQL-975 administration (3.7-34.1 mg/kg/d for 7 days) decreased the levels of blood plasma glucose, triglyceride, total cholesterol, non-esterified fatty acid, and insulin in the mice. In an i.p. glucose tolerance test (IPGTT), HQL-975 administration decreased the fasting plasma glucose level and improved the glucose tolerance in the mice. The HQL-975 administration also increased the glycogenesis and lipogenesis from <sup>14</sup>C-glucose in liver, but did not alter the glycogenesis in the diaphragm or the lipogenesis in adipose tissues at 2 h after the glucose loading. In the HQL-975-treated db/db mice, the radioactivity of <sup>14</sup>C-glucose incorporated into hepatic glycogen was higher than that incorporated into hepatic total lipids. After the administration of HQL-975 (34.1 mg/kg/d for 7 days) to db/db mice, the hepatic hexokinase and fatty acid synthetase activities were increased, the glycogen synthase I activity was increased but not significantly, and the glucose-6-phosphatase and the phosphoenolpyruvate carboxykinase activities were decreased. These results suggest that HQL-975 increases the hepatic glucose utilization and decreases the hepatic glucose prodn. Since hepatic glycogenesis is regulated by glucose itself but not by insulin in normoglycemic ICR mice, HQL-975 is thought to enhance the effect of glucose on the stimulation of hepatic glycogenesis. It is concluded that the enhancement of the hepatic glucose utilization played an important role in the hypoglycemic action of HQL-975.  
 ST HQL975 glucose lipid NIDDM oral antidiabetic  
 IT Glycerides, biological studies  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)  
 (blood; effects of HQL-975 on glucose and lipid metab. in diabetic db/db mice)

IT Fatty acids, biological studies  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);  
 BIOL (Biological study); OCCU (Occurrence)  
 (effects of HQL-975 on glucose and lipid metab. in diabetic db/db mice)

IT Diabetes mellitus  
 (non-insulin-dependent; effects of HQL-975 on glucose and lipid metab.  
 in diabetic db/db mice)

IT Antidiabetic agents  
 (oral; effects of HQL-975 on glucose and lipid metab. in diabetic db/db  
 mice)

IT 185679-16-7, L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-  
 N-propyl-  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); **THU (Therapeutic use)**; BIOL (Biological  
 study); USES (Uses)  
 (HQL-975; effects on glucose and lipid metab. in diabetic db/db mice)

IT 50-99-7, D-Glucose, biological studies 57-88-5, Cholest-5-en-3-ol  
 (3.beta.)-, biological studies  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);  
 BIOL (Biological study); OCCU (Occurrence)  
 (blood; effects of HQL-975 on glucose and lipid metab. in diabetic  
 db/db mice)

IT 9004-10-8, Insulin, biological studies  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);  
 BIOL (Biological study); OCCU (Occurrence)  
 (effects of HQL-975 on glucose and lipid metab. in diabetic db/db mice)


IT 9001-39-2, Glucose-6-phosphatase 9001-51-8, Hexokinase 9045-77-6,  
 Fatty acid synthetase 37341-55-2, Phosphoenolpyruvate carboxykinase  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BIOL (Biological study)  
 (effects of HQL-975 on hepatic enzyme activity in diabetic db/db mice)

IT 185679-16-7, L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-  
 N-propyl-  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); **THU (Therapeutic use)**; BIOL (Biological  
 study); USES (Uses)  
 (HQL-975; effects on glucose and lipid metab. in diabetic db/db mice)

RN 185679-16-7 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-N-propyl- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1998:55528 HCAPLUS

DN 128:115229



TI Preparation of oxazolylethyltyrosine and oxazolylethoxyarylserine  
 derivatives as hypoglycemic and hypolipidemic compounds

IN Dominianni, Samuel J.; Faul, Margaret M.; Stucky, Russell D.; Winneroski,  
 Leonard L., Jr.

PA Eli Lilly and Co., USA; Dominianni, Samuel J.; Faul, Margaret M.; Stucky,

Russell D.; Winneroski, Leonard L., Jr.  
 SO PCT Int. Appl., 88 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-42  
 ICS A61K031-44; A61K031-425; C07D211-82; C07D263-32; C07D277-22  
 CC 34-2 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1, 28, 63  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9800137	A1	19980108	WO 1997-US11576	19970630
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2259487	AA	19980108	CA 1997-2259487	19970630
	AU 9737199	A1	19980121	AU 1997-37199	19970630
	EP 925063	A1	19990630	EP 1997-934043	19970630
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
	JP 2000515133	T2	20001114	JP 1998-504453	19970630
	IL 121202	A1	20010826	IL 1997-121202	19970630
	ZA 9705865	A	19990104	ZA 1997-5865	19970701
	US 6194446	B1	20010227	US 1998-216471	19981218
	US 6353027	B1	20020305	US 2000-518537	20000303
PRAI	US 1996-21016P	P	19960701		
	WO 1997-US11576	W	19970630		
	US 1998-216471	A3	19981218		
OS	MARPAT 128:115229				
GI					



- AB This invention provides compds. I [Q = (CH<sub>2</sub>)<sub>p</sub>, CH<sub>2</sub>OCH<sub>2</sub>; R<sub>0</sub> = Q<sub>1</sub> (X = O, S), R<sub>6</sub>- and R<sub>7</sub>-substituted pyridyl, R<sub>7</sub>C<sub>6</sub>H<sub>4</sub>, naphthyl, Q<sub>2</sub>, Q<sub>3</sub>; R<sub>2</sub> = C<sub>1</sub>-4 alkylaminocarbonyl, arylcarbonyl, aryloxycarbonyl, aryloxy-C<sub>1</sub>-4 alkylcarbonyl, arylaminocarbonyl, aryl-C<sub>1</sub>-4 acyl, aryl-C<sub>1</sub>-4 alkoxy carbonyl, aryl-C<sub>1</sub>-4 alkylaminocarbonyl, aryl-C<sub>1</sub>-4 alkylsulfonyl, amino protective group; R<sub>3</sub>, R<sub>4</sub> = independently H, C<sub>1</sub>-4 alkyl, R<sub>5</sub> = CO<sub>2</sub>H, CONR<sub>10</sub>R<sub>11</sub>, CN, CONHOH, 5-tetrazolyl; R<sub>6</sub> = H, C<sub>1</sub>-4 alkyl, aryl, aryl-C<sub>1</sub>-4 alkyl, R<sub>7</sub> = H, halo, C<sub>1</sub>-4 alkyl; R<sub>9</sub> = H, C<sub>1</sub>-4 alkyl, aryl; R<sub>10</sub>, R<sub>11</sub> = independently H, C<sub>1</sub>-4 alkyl, aryl; W = (CH<sub>2</sub>)<sub>n</sub>; Y = O, S, S(O), SO<sub>2</sub>, NH, CONHR<sub>9</sub>, NR<sub>9</sub>SO<sub>2</sub>, SO<sub>2</sub>NR<sub>9</sub> attached at position 3 or 4; n = 1-4; p = 1-3] and their pharmaceutically acceptable salts, pharmaceutical formulations, and methods for treating hyperglycemia assocd. with non-insulin dependent diabetes and for treating hyperlipidemia. Thus, Mitsunobu coupling of 2-phenyl-4-(2-hydroxyethyl)oxazole (prepn. given) with Z-L-Tyr-OH (Z = PhCH<sub>2</sub>O<sub>2</sub>C) gave 36.5% desired compd. II (Q = CH<sub>2</sub>). Similarly, O-alkylation of Ph<sub>3</sub>C-L-Ser-OMe with 2-phenyl-4-[-2-[4-(bromomethyl)phenoxy]ethyl]oxazole (prepn. given) followed by protective group exchange and sapon. gave serine deriv. II (Q = CH<sub>2</sub>OCH<sub>2</sub>). Example hard gelatin capsule, tablet, suppository, suspension, i.v., and aerosol formulations are given. Prepd. compds. I were tested for hypoglycemic and hypolipidemic activities in male obese-diabetic viable yellow (Avy) mice.
- ST oxazolyylethyltyrosine oxazolylethoxyarylserine prepn antidiabetic agent; hypolipidemic agent oxazolylethyltyrosine oxazolylethoxyarylserine prepn
- IT Antidiabetic agents  
Hypolipemic agents  
(prepn. of oxazolylethyltyrosine and oxazolylethoxyarylserine derivs. as hypoglycemic and hypolipidemic compds.)
- IT 201659-90-7P 201659-92-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of oxazolylethyltyrosine and oxazolylethoxyarylserine derivs. as hypoglycemic and hypolipidemic compds.)
- IT 201659-91-8P 201659-93-0P 201659-94-1P  
201659-95-2P 201659-96-3P 201659-97-4P  
201659-98-5P 201659-99-6P 201660-00-6P  
201660-01-7P 201660-02-8P 201660-03-9P 201660-04-0P  
201660-05-1P 201660-06-2P 201660-07-3P  
201660-08-4P 201660-09-5P 201660-10-8P  
201660-11-9P 201660-12-0P 201660-13-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of oxazolylethyltyrosine and oxazolylethoxyarylserine derivs. as hypoglycemic and hypolipidemic compds.)
- IT 96-86-6 100-83-4 103-80-0, Benzeneacetyl chloride 105-13-5  
122-01-0 123-08-0 349-95-1 701-99-5 773-99-9, 1-Naphthaleneethanol  
873-75-6 874-60-2 1145-80-8 1164-16-5 1939-99-7,  
Benzenemethanesulfonyl chloride 3005-66-1 3173-56-6 4465-44-5  
60834-63-1 84446-03-7 103788-65-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of oxazolylethyltyrosine and oxazolylethoxyarylserine derivs. as hypoglycemic and hypolipidemic compds.)
- IT 25506-37-0P 38065-38-2P 132646-27-6P 172154-13-1P 173173-54-1P  
179170-38-8P 179170-56-0P 201660-15-3P 201660-16-4P 201660-17-5P  
201660-18-6P 201660-19-7P 201660-20-0P 201660-21-1P 201660-22-2P  
201660-23-3P 201660-24-4P 201660-25-5P 201660-26-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of oxazolylethyltyrosine and oxazolylethoxyarylserine derivs.  
as hypoglycemic and hypolipidemic compds.)

IT 201659-90-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); **THU (Therapeutic use)**;

**THU (Therapeutic use)**; BIOL (Biological study); PREP


(Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of oxazolylethyltyrosine and oxazolylethoxyarylserine derivs.  
as hypoglycemic and hypolipidemic compds.)

RN 201659-90-7 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-O-[2-(2-phenyl-4-oxazolyl)ethyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 23 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:809856 HCAPLUS

DN 128:48215

TI Preparation of propionic acid derivatives as blood sugar lowering agents

IN Shinkai, Hisashi; Shibata, Tsutomu; Orui, Satoshi

PA Japan Tobacco, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 44 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM C07D263-32

ICS A61K031-42; A61K031-44; C07D213-30; C07D413-04; C07D263-32;  
C07D333-54



CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09323982	A2	19971216	JP 1996-217548	19960819
	JP 3215048	B2	20011002		
	WO 9807699	A1	19980226	WO 1997-JP2873	19970819
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9738665	A1	19980306	AU 1997-38665	19970819
	AU 740444	B2	20011101		
	EP 930299	A1	19990721	EP 1997-935823	19970819
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI			
	BR 9711627	A	19990824	BR 1997-11627	19970819

CN 1233241	A	19991027	CN 1997-198837	19970819
RU 2174121	C2	20010927	RU 1999-105567	19970819
NO 9900700	A	19990419	NO 1999-700	19990215
US 6204277	B1	20010320	US 1999-242620	19990219
PRAI JP 1996-81744	A	19960403		
JP 1996-217548	A	19960819		
WO 1997-JP2873	W	19970819		
OS MARPAT 128:48215				
GI				



AB The title compds. (I; R = 2-phenyl-5-methyl-isoxazol-1-yl, 5-ethyl-2-pyridinyl, etc.; R4 = H, lower alkyl; R7 = CO2H, CONH2, etc.; R8 = acyl, alkoxycarbonyl; R9 = H, lower alkyl or alkoxy, etc.; R10 = OH, NH2, lower alkoxy) are prepd. I, possessing blood sugar lowering activity, are useful for treatment of hyperlipemia, diabetes mellitus, and related diseases. Thus, compd. (II; X = OMe) was treated with aq. NaOH to give 100% the title compd. II (X = OH), which showed EC50 of 0.45 nM when tested with 3T3-L1 cell.

ST propionate prepn blood sugar lowering agent; diabetes mellitus treatment propionic acid prepn; hyperlipemia treatment propionic acid prepn

IT Lipids, biological studies  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (hyperlipidemia; prepn. of propionic acid derivs. as blood sugar lowering agents)

IT Diabetes mellitus  
 (prepn. of propionic acid derivs. as blood sugar lowering agents)

IT 50-99-7, D-Glucose, biological studies  
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)  
 (blood; lowering agents; prepn. of propionic acid derivs. as blood sugar lowering agents)

IT 111025-46-8P 159018-02-7P 170861-69-5P 170861-70-8P 199794-28-0P  
 199794-29-1P 199794-30-4P 199794-31-5P **199794-32-6P**  
**199794-33-7P 199794-34-8P** 199794-35-9P 199794-36-0P  
 199794-37-1P 199794-38-2P 199794-39-3P 199794-40-6P 199794-41-7P  
 199794-42-8P 199794-43-9P **199794-44-0P 199794-45-1P**  
**199794-46-2P 199794-47-3P** 199794-48-4P 199794-49-5P

199794-50-8P 199794-51-9P 199794-52-0P 199794-53-1P  
 199794-54-2P 199794-55-3P 199794-56-4P  
 199794-57-5P 199794-58-6P 199794-59-7P  
 199794-60-0P 199794-61-1P 199794-62-2P 199794-63-3P 199794-64-4P  
 199794-65-5P 199794-66-6P 199794-67-7P 199794-68-8P 199794-69-9P  
 199794-70-2P 199794-71-3P 199794-72-4P 199794-73-5P 199794-74-6P  
 199794-75-7P 199794-76-8P 199794-77-9P 199794-78-0P 199794-79-1P  
 199794-80-4P 199794-81-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of propionic acid derivs. as blood sugar lowering agents)

IT 50-99-7, D-Glucose, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(prepn. of propionic acid derivs. as blood sugar lowering agents)

IT 67-63-0, Iso-propyl alcohol, reactions 74-88-4, Iodomethane, reactions  
 100-11-8, 4-Nitrobenzyl bromide 100-39-0, Benzyl bromide 105-36-2,  
 Ethyl bromoacetate 105-53-3, Diethyl malonate 108-59-8, Dimethyl  
 malonate 13195-64-7, Di-iso-propyl malonate 42726-73-8, tert-Butyl  
 methyl malonate 103788-59-6 170861-71-9 199794-82-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of propionic acid derivs. as blood sugar lowering agents)

IT 199794-83-7P 199794-84-8P 199794-85-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of propionic acid derivs. as blood sugar lowering agents)


IT 199794-32-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of propionic acid derivs. as blood sugar lowering agents)

RN 199794-32-6 HCAPLUS

CN Benzenepropanoic acid, .alpha.-[(dimethylamino)carbonyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:77060 HCAPLUS

DN 126:89361

TI Preparation of (oxazolyl)alkoxyphenylpropionic acid derivatives as hypoglycemics and hypolipemics

IN Takeno, Hidekazu; Ikemoto, Tomoyuki; Saitoh, Isao; Watanabe, Kazuhiro

PA Sumitomo Metal Industries, Ltd., Japan; Takeno, Hidekazu; Ikemoto, Tomoyuki; Saitoh, Isao; Watanabe, Kazuhiro


SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent  
 LA Japanese  
 IC ICM C07D213-55  
 ICS C07D263-32; C07D263-56; C07D277-22; C07D277-82; C07D413-12;  
 C07D417-12; A61K031-42; A61K031-425; A61K031-44  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9638415	A1	19961205	WO 1996-JP1380	19960524
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	JP 08325263	A2	19961210	JP 1995-133460	19950531
	AU 9657791	A1	19961218	AU 1996-57791	19960524
PRAI	JP 1995-133460		19950531		
	WO 1996-JP1380		19960524		
OS	MARPAT 126:89361				
GI					



AB The title compds. I [A represents a nitrogenous heterocycle; W represents oxygen or carbonyl; R1 represents hydroxy, an ester residue or a substituted imide group; and R2 and R3 represent each hydrogen, alkyl, aralkyl, alkanoyl, benzoyl, etc.; R4 = H, nitro, etc.; m = 0 - 2] are prepd. The title compds. at 10 mg/kg gave 32 to 54% decrease of blood glucose in diabetic mice.

ST oxazolylalkoxyphenylpropionic acid prepn hypoglycemic hypolipemic  
 IT Anticholesteremic agents  
 Antidiabetic agents

(prepn. of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

IT 153939-53-8P 185679-07-6P 185679-10-1P  
 185679-11-2P 185679-12-3P 185679-13-4P  
 185679-14-5P 185679-15-6P 185679-16-7P  
 185679-18-9P 185679-19-0P 185679-21-4P  
 185679-22-5P 185679-23-6P 185679-24-7P  
 185679-25-8P 185679-26-9P 185679-27-0P  
 185679-28-1P 185679-29-2P 185679-30-5P  
 185679-31-6P 185679-32-7P 185679-33-8P  
 185679-34-9P 185679-35-0P 185679-36-1P  
 185679-37-2P 185679-38-3P 185679-39-4P  
 185679-40-7P 185679-41-8P 185679-42-9P  
 185679-43-0P 185679-44-1P 185679-45-2P 185679-46-3P  
 185679-47-4P 185679-48-5P 185679-49-6P  
 185679-50-9P 185679-51-0P 185679-52-1P  
 185679-53-2P 185679-63-4P 185679-64-5P 185679-65-6P  
 185679-66-7P 185679-67-8P 185679-68-9P 185679-69-0P 185679-70-3P

185679-71-4P 185679-72-5P 185679-73-6P 185679-74-7P 185679-75-8P  
 185679-76-9P 185679-77-0P 185679-78-1P 185679-79-2P 185679-80-5P  
 185679-81-6P **185679-89-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

IT 50-00-0, Formaldehyde, reactions 64-18-6, Formic acid, reactions 74-88-4, Methyl iodide, reactions 75-03-6, Ethyl iodide 75-30-9, Isopropyl iodide 79-03-8, Propionyl chloride 79-04-9, Chloroacetyl chloride 100-39-0, Benzyl bromide 107-08-4, Propyl iodide 122-01-0, 4-Chlorobenzoyl chloride 122-04-3, 4-Nitrobenzoyl chloride 124-63-0, Methanesulfonyl chloride 141-75-3, Butyryl chloride 403-43-0, 4-Fluorobenzoyl chloride 407-25-0, Trifluoroacetic anhydride 421-83-0, Trifluoromethanesulfonyl chloride 542-69-8, Butyl iodide 628-17-1, Pentyl iodide 5223-06-3, 2-(5-Ethyl-2-pyridyl)ethanol 7664-41-7, Ammonia, reactions 22509-74-6, N-Ethoxycarbonylphthalimide 72594-77-5 103788-65-4 185679-62-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

IT 185679-54-3P 185679-55-4P 185679-56-5P 185679-57-6P 185679-58-7P  
 185679-59-8P 185679-60-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

IT **185679-04-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics and hypolipemics)


IT **185679-07-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

RN 185679-07-6 HCAPLUS

CN L-Tyrosine, N-methyl-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 25 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:1003033 HCAPLUS

DN 124:202231


TI N-[3-(2-Phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidation of low density lipoprotein

KATHLEEN FULLER EIC 1700/PARKER LAW 308-4290

IN Malamas, Michael S.; Nelson, James A.  
 PA American Home Products Corporation, USA  
 SO U.S., 13 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-42  
 NCL 514374000  
 CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5468760	A	19951121	US 1993-148474	19931108
PRAI	US 1993-148474		19931108		
OS	MARPAT 124:202231				
GI					



I

AB This invention relates to compds. useful in treating diseases mediated by one or more leukotrienes or oxidative modification of low d. lipoprotein such as inflammation, bronchoconstriction or atherosclerosis. The compds. of this invention have the formula I wherein R1 and R3 are independently hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 alkyl, trifluoromethyl, C1-C6 alkoxy, or C1-C6 trifluoroalkoxy; R2 and R4 are hydrogen or Me independently; R5 is hydrogen, Me or hydroxy; X and Z are independently oxygen or sulfur; and Y is CH2, CH(CH3), or CH:CHCH(CH3). Thus, e.g., carbamoylation of N-[3-(5-methyl-2-phenyloxazol-4-ylmethoxy)benzyl]hydroxylamine (prepn. given) with trimethylsilyl isocyanate afforded 69% 1-hydroxy-1-[3-(5-methyl-2-phenyloxazol-4-ylmethoxy)benzyl]urea (I; R1 = H, R2 = Me, R3 = H, Y = CH2, Z = O, NR4R5 = NH2) which exhibited 52% inhibition of LTB4 at 1.mu.M in human whole blood, and inhibition of Cu+2-mediated oxidn. of low d. lipoprotein with IC50 = 0.64 .mu.M.

ST phenyloxazolylmethoxyphenylalkylhydroxyurea lipooxygenase inhibitor; antioxidant low density lipoprotein phenyloxazolylmethoxyphenylalkylhydroxyurea; oxazolylmethoxyphenylalkylhydroxyurea phenyl lipooxygenase inhibitor; hydroxyurea phenyloxazolylmethoxyphenylalkyl lipooxygenase inhibitor; thiazolylmethoxyphenylalkylhydroxyurea phenyl lipooxygenase inhibitor

IT Antioxidants

Bronchodilators


Inflammation inhibitors

(N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)

IT Antiarteriosclerotics

(antiatherosclerotics, N-[3-(2-phenyloxa(thia)zol-4-

- ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- IT Lipoproteins  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(low-d., N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- IT 173173-39-2P 173173-40-5P 173173-41-6P  
173173-42-7P 173173-43-8P 173173-45-0P  
173173-47-2P 173173-48-3P 173173-49-4P  
173173-50-7P 173173-51-8P 173173-52-9P  
173173-53-0P 174258-03-8P 174258-04-9P  
174258-05-0P 174258-06-1P 174258-07-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- IT 80619-02-9, 5-Lipoxygenase  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- IT 67-64-1, Acetone, reactions 100-83-4, 3-Hydroxybenzaldehyde 121-71-1  
6723-30-4 103788-61-0, 4-Chloromethyl-5-methyl-2-phenyl-oxazole  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- IT 159017-85-3P 174258-08-3P 174258-09-4P 174258-10-7P 174258-11-8P  
174258-12-9P 174258-13-0P 174258-14-1P 174258-15-2P 174258-16-3P  
174258-17-4P 174258-18-5P 174258-19-6P 174258-20-9P 174258-21-0P  
174258-22-1P 174258-23-2P 174258-24-3P 174258-25-4P 174258-26-5P  
174258-27-6P 174258-28-7P 174258-29-8P 174258-30-1P 174258-31-2P  
174258-32-3P 174258-33-4P 174258-34-5P 174258-35-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- IT 173173-39-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(N-[3-(2-phenyloxa(thia)zol-4-ylmethoxy)phenylalkyl]-N-hydroxyureas as inhibitors of 5-lipoxygenase and oxidn. of low d. lipoprotein)
- RN 173173-39-2 HCAPLUS
- CN Urea, N-hydroxy-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AN 1995:983209 HCAPLUS  
 DN 124:105587  
 TI Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of  
 5-Lipoxygenase  
 AU Malamas, Michael S.; Carlson, Richard P.; Grimes, David; Howell, Ralph;  
 Glaser, Keith; Gunawan, Iwan; Nelson, James A.; Kanzelberger, Mira; Shah,  
 Uresh; Hartman, David A.  
 CS Wyeth-Ayerst Research Inc., Princeton, NJ, 08543-8000, USA  
 SO Journal of Medicinal Chemistry (1996), 39(1), 237-45  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 CC 1-3 (Pharmacology)  
 Section cross-reference(s): 28  
 AB Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO)  
 inhibitors. Structure-activity relations studies have demonstrated that  
 electroneg. substituents on the 2-Ph portion of the oxazole tail increased  
 the ex vivo potency of these inhibitors. Similar substitutions on the  
 thiazole analogs had only minor contribution to the ex vivo activity. The  
 trifluoromethyl-substituted oxazole was the best compd. of the oxazole  
 series in both the ex vivo (6-h pretreated rats) and in vivo (3-h  
 pretreated rats) RPAR assay with ED50 values of approx. 1 and 3.6 mg/kg,  
 resp., but was weakly active in the allergic guinea pig assay. An  
 unsubstituted thiazole was the best compd. of the thiazole series, by  
 inhibiting the leukotriene B4 biosynthesis in the RPAR assay (3-h  
 pretreated rats) by 99%, at an oral dose of 10 mg/kg, and the  
 bronchoconstriction in the allergic guinea pig by 50%, at an i.v. dose of  
 10 mg/kg. This activity was selective for 5-LO, as concns. up to 15 .mu.M  
 in mouse macrophages did not affect prostaglandin formation. One of the  
 oxazoles was the most active inhibitor in the human monocyte assay with an  
 IC50 value of 7 nM.  
 ST azole phenoxy hydroxyurea lipoxygenase inhibitor prepn; oxazole deriv  
 lipoxygenase inhibitor structure prepn; thiazole deriv lipoxygenase  
 inhibitor structure prepn  
 IT Monocyte  
 (azole phenoxy hydroxyureas as lipoxygenase inhibitors)  
 IT Molecular structure-biological activity relationship  
 (bronchoconstricting, azole phenoxy hydroxyureas as lipoxygenase  
 inhibitors)  
 IT Bronchi  
 (bronchoconstriction, azole phenoxy hydroxyureas as lipoxygenase  
 inhibitors)  
 IT Molecular structure-biological activity relationship  
 (lipoxygenase-inhibiting, of azole phenoxy hydroxyureas)  
 IT 166262-06-2P 166262-07-3P 166262-08-4P  
 166262-09-5P 166262-10-8P 166262-11-9P  
 166262-12-0P 166262-15-3P 166262-16-4P  
 166262-17-5P 166262-18-6P 166262-20-0P  
 166262-21-1P 166262-25-5P 173173-19-8P 173173-20-1P  
 173173-21-2P 173173-22-3P 173173-23-4P 173173-24-5P  
 173173-25-6P 173173-26-7P 173173-27-8P  
 173173-28-9P 173173-29-0P 173173-30-3P  
 173173-31-4P 173173-32-5P 173173-33-6P  
 173173-34-7P 173173-35-8P 173173-36-9P  
 173173-37-0P 173173-38-1P 173173-39-2P  
 173173-40-5P 173173-41-6P 173173-42-7P  
 173173-43-8P 173173-44-9P 173173-45-0P  
 173173-46-1P 173173-47-2P 173173-48-3P  
 173173-49-4P 173173-50-7P 173173-51-8P

173173-52-9P 173173-53-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(azole phenoxy hydroxyureas as lipoxygenase inhibitors)

IT 80619-02-9, 5-Lipoxygenase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(azole phenoxy hydroxyureas as lipoxygenase inhibitors)

IT 123-08-0, 4-Hydroxybenzaldehyde 53370-50-6 103788-61-0 173173-54-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(azole phenoxy hydroxyureas as lipoxygenase inhibitors)

IT 103788-59-6P 103789-66-8P 141820-05-5P 150301-88-5P 166262-31-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(azole phenoxy hydroxyureas as lipoxygenase inhibitors)

IT 150321-05-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(w; azole phenoxy hydroxyureas as lipoxygenase inhibitors)


IT 166262-06-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(azole phenoxy hydroxyureas as lipoxygenase inhibitors)

RN 166262-06-2 HCAPLUS

CN Urea, N-hydroxy-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:931621 HCAPLUS

DN 124:146141

TI N-Hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein

IN Malamas, Michael S.; Nelson, James A.

PA American Home Products Corp., USA

SO U.S., 15 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM C07D263-32

ICS C07D277-30; A61K031-425; A61K031-42



NCL 514374000

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI US 5459154 A 19951017 US 1993-148603 19931108  
 US 5504097 A 19960402 US 1995-423061 19950417  
 PRAI US 1993-148603 19931108  
 OS MARPAT 124:146141  
 GI



I

AB This invention relates to compds. having 5-lipoxygenase inhibiting properties and inhibition of oxidative modification of low d. lipoprotein which have the formula I wherein: R1 and R3 are independently hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, trifluoromethyl, or C1-C6 trifluoroalkoxy; R2 is hydrogen or methyl; R4 is hydrogen, Me or hydroxy; R5 is hydrogen, NH2, C1-C6 alkyl, C6-C10 aryl, C6-C10 aryl-C1-C6 alkylene, or N:CMe2; X and Y are independently O or S; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. Compds. which inhibit 5-lipoxygenase are useful in the treatment of diseases mediated by leukotrienes such as inflammation or bronchoconstriction. Compds. which inhibit oxidative metab. of low d. lipoprotein are useful in the inhibition of atherosclerotic plaque formation. Thus, e.g., carbamoylation of N-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)benzyl]hydroxylamine (prepn. given) with trimethylsilyl isocyanate afforded 1-hydroxy-1-[4-(5-methyl-2-phenyloxazol-4-ylmethoxy)benzyl]urea (I; R1 = R3 = R4 = R5 = H, R2 = Me, n = 0, Y = O) which exhibited 69% inhibition of LTB4 synthesis at 25 mg/kg p.o. in the reverse passive Arthus pleurisy assay in rats, 38% inhibition of bronchoconstriction (at 10 mg/kg i.v.) in guinea pigs induced by exogenous antigen, and inhibition of copper ion mediated oxidn. of low d. lipoprotein with IC50 = 1.1 .mu.M.

ST hydroxyurea phenyloxazolylmethoxybenzyl phenylthiazolylmethoxybenzyl lipoxygenase inhibitor; oxazolylmethoxybenzylhydroxyurea lipoxygenase inhibitor; thiazolylmethoxybenzylhydroxyurea lipoxygenase inhibitor; low density lipoprotein antioxidant oxazolylmethoxybenzylhydroxyurea thiazolylmethoxybenzylhydroxyurea; bronchodilator oxazolylmethoxybenzylhydroxyurea thiazolylmethoxybenzylhydroxyurea; antiinflammatory oxazolylmethoxybenzylhydroxyurea thiazolylmethoxybenzylhydroxyurea; antiatherosclerotic oxazolylmethoxybenzylhydroxyurea thiazolylmethoxybenzylhydroxyurea

IT Antioxidants

Bronchodilators

Inflammation inhibitors


(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)

IT Antiarteriosclerotics

(antiatherosclerotics, N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and


- inhibitors of oxidative modification of low d. lipoprotein)
- IT Lipoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(low-d., N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)
- IT 173191-85-0P 173191-87-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)
- IT 173173-26-7P 173173-27-8P 173173-28-9P  
173173-29-0P 173173-30-3P 173173-31-4P  
173173-32-5P 173173-33-6P 173173-34-7P  
173173-35-8P 173173-36-9P 173173-37-0P  
173173-38-1P 173191-80-5P 173191-81-6P  
173191-82-7P 173191-83-8P 173191-84-9P  
173191-86-1P 173191-88-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)
- IT 80619-02-9, 5-Lipoxygenase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)
- IT 67-64-1, Acetone, reactions 99-93-4, 4'-Hydroxyacetophenone 110-87-2, Dihydropyran 123-08-0, 4-Hydroxybenzaldehyde 1195-45-5, 4-Fluorophenylisocyanate 2525-62-4, N-Hexyl isocyanate 7198-10-9, DL-4-Hydroxymandelic acid 30494-97-4, 4-(Chloromethyl)-2-phenyloxazole 103788-61-0, 4-Chloromethyl-5-methyl-2-phenyloxazole 141580-65-6, N,O-Bis(carbo-phenoxy)hydroxylamine  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)
- IT 103789-66-8P 103789-67-9P 103789-68-0P 173191-89-4P 173191-90-7P  
173191-91-8P 173191-92-9P 173191-93-0P 173191-94-1P 173191-95-2P  
173191-96-3P 173191-97-4P 173191-98-5P 173191-99-6P 173192-00-2P  
173192-01-3P 173192-02-4P 173192-03-5P 173192-04-6P 173192-05-7P  
173192-06-8P 173192-07-9P 173192-08-0P 173192-09-1P 173192-10-4P  
173192-11-5P 173192-12-6P 173192-13-7P 173192-14-8P 173192-15-9P  
173192-16-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low d. lipoprotein)
- IT 173191-85-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(N-hydroxy-N-[4-(2-phenyloxazolyl- and -thiazolylmethoxy)benzyl]ureas

as 5-lipoxygenase inhibitors and inhibitors of oxidative modification  
of low d. lipoprotein)  
RN 173191-85-0 HCAPLUS  
CN Hydrazinecarboxamide, N-hydroxy-N-[[4-[[5-methyl-2-[4-  
(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA  
INDEX NAME)




L7 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2003 ACS  
AN 1995:705727 HCAPLUS  
DN 123:112070  
TI Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and  
anti-arteriosclerotic agents  
IN Malamas, Michael S.; Gunawan, Iwan  
PA American Home Products Corporation, USA  
SO U.S., 14 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
IC ICM A61K031-415  
ICS A61K031-42; A61K031-425; C07D263-32  
NCL 514364000  
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5428048	A	19950627	US 1993-148602	19931108
	US 5541205	A	19960730	US 1995-409781	19950324
PRAI	US 1993-148602		19931108		
OS	MARPAT 123:112070				
GI					




I



II



III



IV

- AB A method of inhibiting the biosynthesis of leukotrienes and the oxidative modification of lipids is claimed, which comprises administration to a mammal in need thereof a therapeutically effective amt. of aryl-N-hydroxyureaa I wherein: R2 is hydrogen, halogen or C1-C6 alkyl; one of R3 and R4 is H and the other is CHR5N(OH)C(:Y)R, Y is O or S; R5 is hydrogen or Me, R6 is NH2, CH3 or OCH3; and R1 is II, III, or IV wherein R7, R8 and R10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifluoromethanesulfonyl; R9 is hydrogen or methyl; and Z is O or S, or a pharmaceutically acceptable salt thereof. Thus, e.g., to a soln. of 4-(2'-hydroxyethyl)-5-methyl-2-phenyloxazole (III-CH2CH2OH, R8 = H, R9 = Me, Z = O) and 4-HOC6H4CHO in THF was added di-Et azodicarboxylate; workup afforded 4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde (78%); oximation (90%), followed by redn. to the hydroxylamine (85%) and carbamoylation with trimethylsilyl isocyanate afforded 1-hydroxy-1-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]urea I [R1 = III, R8 = H, R9 = Me, Z = O, R2 = R3 = H, R4 = CH2N(OH)CONH2; 69%] which demonstrated inhibition of 5-lipoxygenase in human whole blood with 55% inhibition of LTB4 at 1. $\mu$ M dose and inhibited Cu+2-mediated oxidn. of low d. lipoprotein with IC50 = 0.69  $\mu$ M.
- ST arylhydroxyurea leukotriene biosynthesis lipid peroxidn inhibitor; hydroxyurea aryl lipoxygenase lipid peroxidn inhibitor; urea arylhydroxy lipoxygenase lipid peroxidn inhibitor; antiarteriosclerotic arylhydroxyurea
- IT Antiarteriosclerotics  
(aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)
- IT Leukotrienes  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(biosynthesis inhibitors; aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)
- IT Antioxidants  
(lipid peroxidn. inhibitors; aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)
- IT Lipoproteins  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(low-d., antioxidants; aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)
- IT 150321-05-4P 166262-06-2P 166262-07-3P

166262-08-4P 166262-09-5P 166262-10-8P  
 166262-11-9P 166262-12-0P 166262-13-1P  
 166262-14-2P 166262-15-3P 166262-16-4P  
 166262-17-5P 166262-18-6P 166262-19-7P  
 166262-20-0P 166262-21-1P 166262-22-2P  
 166262-23-3P 166262-24-4P 166262-25-5P 166262-26-6P  
 166262-27-7P 166262-28-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)

IT 80619-02-9, 5-Lipoxygenase

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)

IT 99-93-4, 4'-Hydroxyacetophenone 100-83-4, 3-Hydroxybenzaldehyde  
 121-71-1, 3'-Hydroxyacetophenone 123-08-0 64483-96-1,  
 4-(2'-Hydroxyethyl)-2-phenylthiazole 103788-65-4 122320-77-8  
 166262-31-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)

IT 103788-59-6P 103789-56-6P 141820-05-5P 150301-88-5P 166262-29-9P  
 166262-30-2P 166262-32-4P 166262-33-5P 166262-34-6P 166262-35-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)

IT 150321-05-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anti-arteriosclerotic agents)

RN 150321-05-4 HCAPLUS

CN Urea, N-hydroxy-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

